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Small-molecule DNA interactive compounds are critical as both carcinogens and 
therapeutic agents. In this research, a synthetic precursor to a known carcinogen, 
(±)-Nʹ′-nitrosonornicotine-5ʹ′-acetate was synthesized, and its interactions with 
DNA were evaluated by polyacrylamide gel electrophoresis and electrospray-
ionization mass spectrometry. A library of skipped benzimidazolium aza-
enediynes which selectively target unmethylated cytosines in presence of 
unmethylated cytosines were synthesized, and their biological properties were 
evaluated in a nicking assay and cytotoxicity study. Finally, a series of structural 
analogs to a antineoplastic agent, UK-1, were synthesized via a biaryl coupling at 
C2 on the benzoxazole. 
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Small molecules that interact with DNA are important as potential 
pharmaceuticals and carcinogens. Understanding these DNA-small molecule interactions 
is critical to drug design, because DNA is responsible for all cellular functions. Small 
molecules that interact strongly with DNA can cause damage to the cell or organism.1 
Covalent or non-covalent DNA modification can cause errors in transcription and 
subsequent translation of DNA to proteins (Figure 1.1).2 Damage that prevents proper 
replication and cell division can lead to cell death, and damage that affects genetic 
function can have deleterious effects, such as cancer. Luckily, agents that damage DNA 
can also have positive effects, such as antineoplastic or antibacterial compounds, which 
also cause cell death, but for therapeutic purposes. In this dissertation, both carcinogenic 










Figure 1.1. DNA damage leading to cell death. 
In this introductory chapter, a brief overview of methods to quantify and 
determine the nature of DNA-small molecule interactions will be discussed. Following an 
introduction to the structure of B-form DNA and methods to determine the sequence of 
unmodified DNA, methods used to analyze small molecule covalent adducts of DNA will 
be described. Then, an overview of some common methods of analyzing non-covalent 
 2 
DNA-small molecule interactions will be provided. Finally, some examples of DNA-
interactive small molecules will illustrate common structural motifs that direct DNA 
binding mode and sequence selectivity. 
 








Figure 1.2. DNA's function in biological systems1 
Deoxyribonucleic acid (DNA) is the simple and robust genetic code for all living 
things. Through variation of four nucleotide bases, DNA encodes all the genetic 
information for entire organisms. A basic principle of molecular biology is the 
transcription of DNA to messenger RNA (mRNA), which then is translated into proteins 
(Figure 1.2).1 It is a polymeric structure consisting of a sugar-phosphate backbone with 
either a purine or pyrimidine ring system attached at the 1ʹ′-position on the ribose. 
Numbering of atoms on the nucleotides is shown in Figure 1.3. Nucleotides are linked 





































































Guanosine Adenosine Cytidine Thymidine  
Figure 1.3. Structure of Nucleotides 
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This single-stranded polymer assembles into a tertiary structure, commonly a 
duplex form in an antiparallel double-helix where the bases π stack internally and the 
phosphate backbones form a hydrophilic exterior (Figure 1.4). For the purposes of this 
discussion, only the most common tertiary structure, B-form DNA,3 will be discussed. 
The formation of a double-helix is driven by hydrogen-bonding interactions between 
purine and pyrimidine base pairs (with guanosine paired to cytidine and adenosine to 
thymidine) and hydrophobic interactions when the bases π stack. The free energy of an 
A-T base pair has been computationally estimated to be -4.3 kcal/mol, and a G-C base 
pair is estimated to be -5.8 kcal/mol.4 The distance from C1ʹ′ to C1ʹ′ in a G-C base pair is 
10.67 Å, and an A-U pair is 10.48 Å.5 The purine C1ʹ′-N9 base-sugar bonds or pyrimidine 
C1ʹ′-N1 base-sugar bonds are on the minor groove of the helix, and the C6/N7 (purine) or 
C4 (pyrimidine) atoms and their substituents are on the major groove (Figure 1.5).5 In B-
DNA, the right-handed helix contains ten base pairs per complete turn, with the base 
pairs nearly perpendicular to and stacking over the helical axis.5 The helical axis in B-
form DNA is not linear; it is distorted by approximately 19°.5 
 
Figure 1.4. Diagram of B-form DNA. 
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The major groove of B-DNA is 11.6 Å wide and 8.5 Å deep. The minor groove is, 
on average, 6.0 Å wide (ranging from 2.6-8.9 Å as determined for a series of decamers by 
X-ray crystallography6) and 8.2 Å deep.5 AT-rich DNA tends to have a wider major 
groove (and thus a more narrow minor groove) than GC-rich DNA.5,6 The repulsion 
between the anionic backone phosphates is the structural feature that limits minimum 
width of the helical grooves.6 Normal distance along the helical axis between the parallel 


































Figure 1.5. Watson-Crick Base Pairs 
 
1.2. DNA SEQUENCING 
Techniques to sequence DNA were initially developed nearly 15 years after the 
structure of DNA was elucidated. Since the development of sequencing, the number of 
reported DNA sequences has doubled every 16 months, increasing logarithmically by 
nine orders of magnitude between 1965 and 2005. 7 
The original method for chemically sequencing DNA was described by Maxam 
and Gilbert.7,8 This method has been supplanted by more efficient and high-throughput 
methods,7,9 but it is still widely used for sequencing short DNA fragments and in studies 
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of small-molecule DNA interactions. The Maxam-Gilbert sequencing technique relies 
upon chemical reactions that selectively modify either for purines (G+A) or pyrimidines 
(T+C), and reactions selective for G or C,8 followed by treatment with piperidine at 
elevated temperatures to cause DNA strand cleavage at the modified positions.  
The original series of chemical reactions involved selective reactions with either 
purines of pyrimidines.8 Guanosine residues are modified at the N7 position (located in 
the major groove), and adenosines are modified at N3 and N7 by dimethyl sulfate 
(Scheme 1.1).10 Alkylated adenosines and guanosine residues both undergo depurination 
in the presence of either acid or piperidine and heating.8,11 Thymidine and cytidine are 
both modified by incubation with hydrazine, but performing the same incubation in the 
presence of sodium chloride attenuates reactivity of the hydrazine with thymidines, 
allowing selective sequencing of cytosines.8,10 The hydrazine opens the pyrimidine ring, 
converting it to a good leaving group (Scheme 1.2).10  
After the base-selective reactions, the DNA is purified via ethanol precipitation 
(to remove both excess reagents and short fragments of DNA cleaved by frank strand 
cleavage during the selective reactions). The purified DNA is then subjected to 
piperidine-heat treatment, which causes quantitative cleavage of the DNA at its 
backbone.12,13 Upon heating the modified base leaves, assisted by electron donation from 
the oxygen in the furanose ring (Scheme 1.1). Piperidine attacks the resultant cyclic 
oxonium ion to generate the acyclic iminium ion, which then undergoes two elimination 
reactions (losing both phosphates) to give cleavage of the phosphate DNA backbone. The 
first elimination is likely a β-elimination, but the loss of the proton at C4' of the 
deoxyribose has not been shown experimentally, and the products of this proposed 
elimination have not been characterized.14 The resulting DNA fragments are separated by 
polyacrylamide gel electrophoresis (PAGE).8 Visualization of these fragments on the gel 
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often is accomplished by autoradiography, which requires that the original DNA be 

























































































































































Scheme 1.2. Maxam-Gilbert Sequencing on C 
1.3. SMALL MOLECULE-DNA INTERACTIONS 
Agents with the ability to disrupt DNA replication or transcription are potentially 
useful as antineoplastic agents. In this section, methods of analyzing small molecule-
DNA interactions will be discussed. Either covalent or non-covalent interactions can 
significantly alter DNA replication. When a DNA-small molecule interaction is analyzed, 
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two pieces of information are key to understanding the downstream effects: where the 
DNA-drug interaction occurs (sequence specificity and binding mode), and how strongly 
the two molecules interact (covalent modification, tight non-covalent binding, or weak 
noncovalent interaction). There are several types of both covalent and noncovalent 
interactions. Figure 1.6 illustrates the types of interactions that will be described in this 
introductory chapter. Alkylating agents with one reactive electrophilic site can modify 
nucleotide bases (alkylation), and alkylating agents with two reactive electrophilic sites 
can covalently link the two strands (crosslinking). Some small molecules modify DNA 
via oxidative damage, i.e. removal of a hydrogen atom from the ribose backbone. 
Intercalating agents, which typically contain a planar extended conjugated π system, 
noncovalently bind in between the π-stacked nucleotide bases. Minor groove binders, 
which are usually rigid, bent molecules, bind along the minor groove of DNA.  
 8 
 
Figure 1.6. DNA binding motifs 
 
1.3.1. DNA Alkylation 
DNA alkylation is a common mode of covalent modification. Alkylation can 
either lead to cytotoxicity (cell death), or mutagenicity.15 In the case of antineoplastic 
agents, cell death is therapeutic (rather than harmful). Examples of alkylating agents that 
react with a bimolecular rate as a neutral compound (SN2) include alkyl halides, alkyl 
sulfonates, and epoxides.15 Alkylating agents that react by an SN1 type mechanism 
typically generate cationic intermediates as the electrophile that covalently modifies 
DNA.16 Guanine contains three commonly modified nucleophilic sites, N2, N7, and O6 
(Scheme 1.3). Cytidine contains two nucleophilic sites that can react with these 
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electrophiles, the exocyclic amine (N3) and carbonyl (O1). Simple alkylating agents 
(mustard gases, chloroethyl-nitrosourea,17 and dimethylsulfonates18 – discussed in detail 
in a later section of this chapter) commonly modify guanosines.16 More complex 
alkylating reagents (i.e. CC-1065 or tallimustine, discussed in Section 1.4.1.1.) typically 
alkylate on N3 of adenosine (Scheme 1.4), which is located in the minor groove of 
duplex DNA.19 Alkylation at N3 of adenine is especially harmful because it creates a 
nucleoside that is incapable of forming a hydrogen-bonded base pair.1 This causes DNA 
replication to stall, which leads to cell death.1 Alkylations of guanine proceeding via an 
SN1-type mechanism show increased modification of N7 and O6; SN2-type alkylations 
occur at N7, which is located in the major groove of the double helix.15 The biological 
consequences of O-alkylation of guanine are typically severe, as this modification can 
result in more mutations than any other alkylation of DNA because of mis-pairing at the 
alkylated position during replication.15 Alkylation at O6 changes the tautomeric form of 
guanine so that it base pairs with thymine, not cytosine. 1 
 
Scheme 1.3. Alkylation of guanosine by electrophile 
Duplex DNA is less easily modified by alkylating agents than single-stranded 
DNA because Watson-Crick pairing increases steric bulk at nucleophilic sites and 
decreases nucleophilicity because of the hydrogen bonding.15 Although alkylations were 
once thought to have base selectivity but no sequence selectivity (for example, the G 
reaction in Maxam-Gilbert sequencing), it has been shown that even simple alkylating 
reagents such as diazomethane or acetoxymethylmethylnitrosamine have a sequence 
selectivity that depends on the 5ʹ′ neighboring base (G leads to more frequent 
 10 
modification) and slightly on the 3ʹ′ neighboring base (GG>GA>GC>GT).15 This data, in 
concert with theoretical calcuations,16 shows that sequence selectivity can be attributed to 
electrostatic interactions between charged alkylating agents and the nucleophilic 
guanosine.15  
 
Scheme 1.4. Covalent modification of adenosine 
 
1.3.2. Analysis of DNA Alkylation 
1.3.2.1. Electrophoretic mobility shift assays 
Possibly the simplest assay to probe for covalent modification of DNA is an 
electrophoretic mobility shift assay (EMSA, Figure 1.7). In this method, a short 
radiolabeled DNA oligomer is incubated with the potential alkylating agent, and the 
mixture is analyzed by gel electrophoresis.20 In the case of DNA modified by alkylating 
agents, this method can show singly and multiply adducted DNA, provided that the 
modification changes the electrophoretic mobility of the oligomer.21  
 
Figure 1.7. Electrophoretic mobility shift assay 
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A similar mobility shift assay can be used to measure effective concentrations of 
the small molecule, as well as to explore sequence selectivity of crosslinkers (Figure 
1.8).21 Crosslinkers are agents that chemically link two molecules, in this case two DNA 
strands, by a covalent bond. Although other methods are known to evaluate potentially 
crosslinked DNA22 a simple method for analyzing crosslinks is denaturing gel 
electrophoresis.22 Self-complementary double-stranded DNA is typically used because 
having identical upper and lower strands simplifies oligomer design; however, only one 
oligomer in the duplex must be labeled for quantification.21,22 Incorporating unnatural 
bases and determining whether they inhibit crosslinking can provide information 
regarding structure of the crosslinked site on the bases.21 The DNA is prepared by 
radiolabeling and annealing as described in Figure 1.9. Increasing concentrations of the 
compound of interest are incubated with the ds-DNA (Figure 1.8) then the DNA is 
denatured using either alkali (sodium hydroxide, pH 12-12.5) or heating followed by 
rapid cooling.22 The denatured DNA can then be analyzed using either gel electrophoresis 
(agarose or denaturing polyacrylamide gel) or chromatography (ion-exchange, size-
exclusion, or affinity).22 The crosslinked DNA will not denature to single-stranded DNA 
because the two strands are covalently linked, so lower mobility bands will be observed. 
Sequence information about the crosslinks can be obtained by subjecting the DNA to 
exonuclease III digestion.21 This digestion causes exolytic degradation from the unlabeled 
3’-end of the DNA (stopping 1-3 bases before the adduct), which provides information 
about the site of the crosslink based on the mobility of the covalently bound duplex.21  
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Figure 1.8. DNA crosslinking assay 
 
1.3.2.2. Chemical cleavage of covalent adducts 
While the gel-shift assays described above are useful for revealing the presence of 
covalent DNA modification, they do not provide information about which DNA residues 
are involved in these covalent adducts. Fortunately, in many cases this information can be 
obtained by simply treating the modified DNA with piperidine at elevated temperature. 
As in Maxam-Gilbert sequencing (Scheme 1.1), this causes DNA strand breaks at the 
position of the modified DNA base, allowing visualization of the positions of adduction 
(Figure 1.9) by polyacrylamide gel electrophoresis (PAGE). Piperidine-heat treatment 
can be used to map N7 guanine or adenosine adducts.12,23 The cationic alkylated base is 
cleaved (depurination), leaving an abasic site, which is labile to hydrolysis of the 
backbone.24 Depurination of methylated adenosines (N3 or N7) and guanosines (N7) can 
occur at room temperature under neutral pH, but the rate is very slow (half-life of 2.8 h-
155 h).17,25 Although N1 of cytosine is subject to alkylation, piperidine/heat treatment 
does not generate an abasic site and subsequent strand break.24  
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First reported in 1981 by Randerath,26 32P-postlabeling (Figure 1.10) rapidly 
became the most widely used and sensitive method for detecting DNA adducts in 
biological samples. In 32P-postlabeling the sample of DNA incubated with the small 
molecule is subjected to digestion with nucleases (typically micrococcal endonuclease 
and spleen exonuclease) to afford a mixture of unmodified and modified nucleotide 3ʹ′-
phosphates via cleavage of the glycosidic linkages.26-28 This mixture of modified and 
unmodified nucleotide monophosphates then can be analyzed in one of two ways. One 
way to analyze samples is to quantitate adduction by using a large excess of 32P-labeled 
adenosine triphosphate ([γ-32P]-ATP) in the presence of polynucleotide kinase to 
radiolabel the nucleotides.26,27 This mixture can then be analyzed by two-dimensional thin 
layer chromatography (2D-TLC) on cellulose paper to quantify adducts.29 Because a large 
excess of [γ-32P]-ATP is used to drive the reaction to completion, all the bases are 
assumed to be labeled with equal efficiency, regardless of covalent modification, and the 
method is considered quantitative.29 Alternatively, to intensify detection of the covalent 
adducts relative to the background signal of the unmodified bases, P1 nuclease can be 
used to selectively dephosphorylate the unmodified nucleotides to their deoxyribosides 
preferentially to the modified nucleotides.30,31 Because the unmodified bases do not have 
the required monophosphate or free hydroxyl group, only the modified adducts are 
enzymatically labeled at the 5ʹ′ position.31 This effectively amplifies the signal from 
modified bases, allowing greater sensitivity. These labeled nucleotides are then separated 
by 2D chromatography using cellulose paper. The P1 nuclease digestion leads to a 300-
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1000-fold increase in radioactivity at the modified bases.31 This technique works well, 
particularly for DNA adducts where the modified nucleotides are easily separated from 
unmodified nucleotides, e.g., in the case of polycyclic aromatic hydrocarbon adducts.30 
Another advantage is sensitivity. 32P-postlabeling can detect 0.5-5 adducts in 108 DNA 
bases employing samples as small as 10 µg of DNA.31 Also, because radiolabeling occurs 
post-exposure, it can be very practical for analyzing biological samples without requiring 
radiolabeled alkylating agents or oligomer. A disadvantage of this approach is that it does 
not provide information about the structure of the adduct, unless suitable authentic 
samples are available. Because of this limitation, particularly for DNA adducts which are 
difficult to resolve by TLC (because of lability or polarity), mass spectrometric methods 
(discussed in section 1.3.5.1) are beginning to supplant 32P-postlabeling as the method of 
choice for adduct detection and identification.  
 
Figure 1.10. 32P -Postlabeling to identify covalent modification 
1.3.3. DNA Footprinting 
1.3.3.1. Enzymatic and Chemical Footprinting 
Since its development in 1978, DNA footprinting (Figure 1.12) has been used to 
analyze sequence selectivity of both covalent and non-covalent interactions.32 For the 
purposes of this discussion, only techniques that analyze small-molecule-DNA 
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interactions will be reviewed. To analyze small-molecule-DNA interactions, a small 
(100-200bp) radiolabeled DNA oligomer of known sequence is combined with the DNA-
interactive compound (Figure 1.12).32 The DNA is then exposed to some agent that will 
cleave the DNA backbone at each base, except where the DNA-interactive compound is 
bound. Cleavage agents can be either chemical or enzymatic.32 Common enzymes used 
include DNAse I, DNAse II, micrococcal nuclease,33 and exonuclease III.32,34,35 DNAse I 
footprinting is extremely common36 and requires mild, physiologically relevant 
conditions, but it has the disadvantage that the enzymatic DNA cleavage exhibits a slight 
sequence selectivity.32,37 Also, enzymatic footprinting typically leaves a footprint that 
extends several bases beyond the actual modification.38-40 Chemical footprinting reactions 
have the advantage that the cleavage is typically less sequence selective and generates a 
smaller footprint. Chemical cleavage agents include copper/phenanthroline,41,42 Fe (II) 
methidium propyl-ethylene diamine tetraacetic acid (Fe(II)-MPE-EDTA, ),43 and uranyl 
photocleavage.42,44-46 The chemical cleavage agents operate by causing oxidative damage 



























Fe(II)-EDTA Fe(II)-MPE-EDTA  
Figure 1.11. Iron (II)-EDTA (l) and Iron (II)-MPE-EDTA (r) 
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If the bound compound prevents a DNA cleavage event from occurring, a 
characteristic “footprint” appears when the DNA fragments are separated by gel 
electrophoresis and visualized using autoradiography (Figure 1.12). The footprint 
consists of an area where cleavage does not occur, which is observed as an absence of 
bands on the gel. Because only one end of one complementary strand of the DNA is 
labeled, only the labeled fragments will appear.32 These observed fragments can be 
compared to sequencing lanes to determine the sequence selectivity of the DNA-
interactive agent.32 It is key to obtaining accurate results to ensure that each band is due to 
a single cleavage event (i.e. the DNA is cut only one time by the agent used).32 This is 
termed “single-hit kinetics.”37 In a typical experiment, to obtain a distinct footprint (under 
single-hit kinetics), the majority (60-90%) of the DNA is not cleaved.32 Also, footprinting 
can be used to estimate binding constants for certain areas of the DNA sequence, if it is 








DNA cleavage Gel Electrophoresis
 
Figure 1.12. DNA footprinting 
 
1.3.3.2. PCR-Based Footprinting 
A variety of DNA polymerase inhibition assays adapt the typical PCR process to 
map DNA adduct positions. They give information about the position of adduction, but 
unlike footprinting, they do not provide information about the size of the binding region. 
Typical polymerase chain reaction (PCR), first described in 1985,48 allows exponential 
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amplification of a DNA sequence (Figure 1.13). This process has been adapted to identify 
sequence selectivity of adduct formation. In routine PCR, duplex DNA containing the 
sequence of interest is denatured by heating in presence of a large excess of primers (12-
20 base) single-stranded fragments of DNA complementary to either the 3ʹ′ end of the 
lower strand or the 5ʹ′ end of the upper strand of interest), a mix of deoxynucleotide 
triphosphates, and a polymerase enzyme. Because a large excess of primer is used, the 
primers anneal at the start of the desired sequence of each long strand when the PCR 
reaction mixture is cooled to temperatures 5 °C below the melting temperature of the 
primer-DNA duplex. The reaction mixture is heated to the optimal temperature for the 
polymerase to perform DNA chain elongation. The polymerase synthesizes the DNA 
beginning at the primer until it reaches the end of the sequence. The cycle is repeated, i.e. 
the DNA is denatured with heat, then the primers anneal, and the DNA is incubated to 
synthesize duplex DNA. In each successive PCR cycle, the desired sequence is amplified, 
and the initial sequence used (which may contain a longer sequence than desired) 
represents a smaller and smaller proportion of the reaction mixture. After many cycles 




Figure 1.13. Polymerase chain reaction amplifies a DNA sequence 
A variety of DNA polymerase inhibition assays adapt the typical PCR process to 
map DNA adduct positions (Figure 1.14).49 They provide information about the position 
of adduction, but unlike footprinting, they do not provide information about the size of 


























Figure 1.14. DNA Polymerase Interruption Assay 
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Commonly used PCR-based footprinting techniques include quantitative PCR 
(QPCR), strand-specific PCR (ss-QPCR), and single-strand ligation PCR (ssligPCR).50 
QPCR uses PCR techniques to analyze damage to both strands of DNA in the duplex.51,52 
The duplex is incubated with the drug of interest, then PCR is performed. The covalent 
modification prevents the strand from being properly amplified, so the PCR terminates 
prematurely,52 which leads to failed amplification on covalently modified strands.52 These 
PCR products can be compared to PCR using unmodified DNA as its template to 
quantitate the extent of the damage.52 Ss-QPCR (Figure 1.15) measures lesions on either 
the transcribed or non-transcribed strand.51 Isolated DNA (from cells subjected to 
incubation with the drug of interest) is subjected to a single round of PCR, using a 
biotinylated primer (primer 1) complementary to the transcribed strand to yield a series of 
biotinylated sequences of varying lengths due to modification of the original DNA by the 
drug.51 This biotinylated DNA is bound to streptavidin-coated paramagnetic beads, using 
a strongly basic solution to wash away excess DNA.51 After neutralization, this DNA is 
used as a template for subsequent PCR cycles.51 The downstream primer (primer 2) for 
this PCR is complementary to the transcribed strand and binds a sequence inside the 
sequence bound by the first primer.51 The third primer is complementary to the 
nontranscribed strand and its binding site determines the size of the resulting amplified 
region.51 If the PCR is stopped during the exponential phase, the amount of product 
formed is proportional to the amount of unmodified template in the original genomic 
DNA.51 Sslig-PCR also begins with a single round of PCR using a 5ʹ′-biotinylated 
primer.52 Linear amplification generates ss-DNA of varying length for which the 5ʹ′-end is 
biotinylated and the 3ʹ′-end is limited by the position of the DNA modification.52 These 
products are isolated on streptavidin-coated magnetic beads.52 In order to amplify these 
sequences (because all the 3ʹ′ ends are different), a 5ʹ′-phosphorylated single-stranded 
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oligonucleotide is ligated to their 3ʹ′-OH ends using T4 RNA ligase.52 This ligated DNA 
can then undergo exponential amplification using a primer complementary to the ligated 
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Figure 1.15. ss-QPCR 
1.3.4. Assays for DNA cleavage  
1.3.4.1. Nicking Assay on Supercoiled DNA 
Supercoiled DNA can be used to determine the extent to which a small molecule 
creates single-stranded breaks.53 Supercoiled DNA is incubated with the compound of 
interest. If the compound causes DNA nicking, the supercoiled DNA relaxes to the 
circular form. If both strands are cleaved, or multiple proximal sites are nicked, the DNA 
can linearize. The three possible DNA structures (supercoiled, nicked (relaxed), or linear) 
can be separated by gel electrophoresis.54,55 Visualization of the DNA can be achieved 
either by incorporating a radiolabel into the supercoiled DNA (by using a radiolabeled 
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nucleotide and cellular machinery), or by ethidium bromide staining.53 Nicking assays of 
supercoiled DNA are extremely sensitive, as they can detect as little as a single break in a 
plasmid (e.g. 1 break per 3,000 bp).56 100 ng is sufficient DNA for a single experiment. 
The limit of detection is reported to be 4% nicking DNA in a sample for radiolabeled 
samples.53  
 
Figure 1.16. DNA nicking assay 
1.3.4.2. FRET-Based Assays 
Another type of assay is the “break light” assay (so named because a break in the 
DNA causes a light). In the “break-light” system, a stem-and-loop DNA structure is 
designed which has the appropriate cleavage sequence as part of its stem.57 A fluorescent 
resonance energy transfer (FRET) pair is used as the signal for cleavage. At the 5ʹ′ end of 
the DNA is a fluorescent tag, and at the 3ʹ′ end is a quencher (Figure 1.17).57 The assay is 
designed for continuous monitoring of cleavage by fluorimetry.57 As cleavage occurs, the 
quencher and the fluorescent tag are separated, which removes the FRET quenching of 
the fluorescent signal (Figure 1.17).58 The extent of cleavage is then proportional to the 
fluorescence signal. 57 “Break-lights” work for both enzyme restriction sites and small-
molecule cleavage agents. In the seminal publication by Biggins et al., the sequence used 
contained the recognition sequence 5ʹ′-TCCT-3ʹ′ for calicheamicin and used fluorescein 
(FAM) as the fluorophore and 4-(4ʹ′-dimethylaminophenylazo)benzoic acid (DABCYL) 
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as the quencher.57 The FRET is 99.9% complete between this pair because of large 
spectral overlap.57 Because this assay is continuous, kinetic parameters of cleavage can be 
calculated.  
 
Figure 1.17. "Break-Light" Assay 
 
1.3.5. Analysis of Non-Covalent DNA-Small Molecule Interactions 
1.3.5.1. Mass Spectrometry 
Electrospray ionization mass spectrometry (ESI-MS) is rapidly becoming the 
preferred method for analyzing covalent and non-covalent small-molecule-DNA 
interactions.59 Because this method uses a relatively gentle method of ionization, ESI-MS 
works well for analyzing large biomolecules without creating high levels of 
fragmentation, which allows this method to provide structural and sequence 
information.60 Interestingly, DNA containing alkylated nucleotides shows simplified 
fragmentation patterns compared to the unmodified DNA because alkylation of guanine 
weakens the glycosidic bond, which causes ready loss of the alkylated base and enhanced 
cleavage of the 3ʹ′ C-O bond.60 The cleavage pattern can then be used to analyze the 
position of modification, providing information about sequence selectivity of the 
alkylating agent.  One difficulty in effectively mapping DNA sequence selectivity is the 
sequence of the ds-DNA being examined. Unlike proteins, DNA contains subunits with 
highly similar molecular weight, making it difficult to differentiate between the upper or 
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lower strands of the duplex.60 This is typically addressed by designing non-self-
complementary sequences.60 ESI-MS typically uses oligomers similar in length to X-ray 
crystallography or NMR; however, methods exist for analyzing longer sequences.61,62 As 
in 32P-postlabeling, amplification of the signal from modified samples is key to good 
detection. Mass spectrometry can be coupled with a variety of separation techniques, 
including liquid chromatography,63 capillary electrophoresis, and capillary 
electrochromatography.64 Recent advances in ESI-MS analysis of DNA include the use of 
selective ion monitoring (SIM) and selective reaction monitoring (SRM).59 In selective 
ion monitoring, the quadrupole array is tuned to retain the predicted mass. For SRM, the 
first trap Q1, is tuned to trap the predicted mass, which then travels to q2, the collision 
chamber (Figure 1.18). In this chamber, the selected ions undergo collisions and pass 
through to Q3, a second mass analyzer. This mass analyzer is then used to look for the 
predicted product ion.59 SIM has been shown to detect DNA on picomole scale, whereas 
SRM is able to detect adducts on femtomole scale.59,63 Quantitation of DNA adducts by 
mass spectrometry is possible but requires an authentic sample of the adduct being 
analyzed, in order to calculate ionization potentials.59 Qualitative information about 
relative binding affinities, however, can be obtained. A key advantage to the use of mass 
spectrometry to analyze DNA adduction is that it gives information about the structure of 
the adducts, which is valuable when the structure is unknown.63 Also, it is easier to 







Figure 1.18. Cartoon of a triple quadrupole mass spectrometer.  
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Q1 is a mass analyzer, q2 is a collision cell filled with inert gas, and Q3 is a 
second mass analyzer. 
1.3.5.2. Competition Dialysis 
Competition dialysis (Figure 1.19) is a method used to assess DNA binding 
selectivity of small molecules. Multiple small dialysis tubes containing different 
sequences or structures of DNA (in equal volumes at identical concentrations) are stirred 
in a solution of the small molecule of interest (dialysate).65 After the system reaches 
equilibrium (usually in less than 24 h), the concentration of drug in each tube is compared 
to the concentration of the analyte in the large chamber using either fluorescence or 
absorbance. The dialysis tubes containing the highest concentration of the compound of 
interest represent the structures with the highest binding affinities.  
  
 
Figure 1.19. Competition Dialysis 
1.3.5.3. Melting Curves 
Thermal melting curves are a method of obtaining general information about 
drug-DNA interactions.66 “Melting” refers to denaturation of DNA from its secondary 
structure to its single-stranded form. Multiple factors create the underlying physical basis 
for DNA stabilization by a small molecule, including the ligand binding constant, binding 
enthalpy, and site size.65 When DNA melts, AT rich sequences denature first (because 
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they have only two hydrogen-bonding interactions per base pair), causing partial 
unwinding, then GC rich regions (which have three hydrogen bonds between the base 
pairs, leading to stronger association) dissociate.66 Changes in melting temperature, Tm, 
can be measured using a number of techniques, including UV absorbance, NMR, circular 
dichroism, viscosity, electrophoresis, or calorimetry. UV absorbance is most commonly 
used because it is sensitive (so only small amounts of material are required) and 
operationally simple.66 Tm values give only general binding information, not specific, and 
data acquisition requires elevated temperatures in buffers that are optically transparent. 
Melting curves are typically obtained at 260 nm.66 As the duplex melts, the absorbance 
increases (hyperchromicity) approaching the absorbance of single monomers because 
base-stacking is lessened.66 The inflection point on a plot of absorbance vs. temperature is 
the Tm.  
Drugs that bind (and stabilize) duplex DNA cause an increase in Tm.66 Also, a 
drug that binds tightly to the DNA can cause a broadened transition or even a biphasic 
transition (in a situation where the DNA polymer is more heterogeneous and the drug can 
bind multiple sites).66 Classical intercalators raise the Tm significantly and act similarly 
with regard to AT-rich vs. GC rich DNA sequences. Major and minor groove binders 
typically raise the Tm of the duplex. They have very low binding to ss-DNA because it 
exists as a random coil, without a structured groove with a specific electrostatic 
environment.  
 
1.3.5.4. Spectroscopic Titrations67 
Non-covalent complexation between DNA and small molecules can be monitored 
spectroscopically using several methods. Frequently, the fluorescence or electronic 
absorption spectrum of a small molecule will be altered by binding to DNA.68 For 
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example, ethidium bromide displays enhanced fluorescence upon DNA binding69 whereas 
some aminoacridines and anthracyclines (see section 1.4.4.2) show fluorescence 
quenching.68 In UV-Visible spectroscopy, the absorption spectrum of the drug changes to 
a longer wavelength (bathochromic shift) and the extinction coefficient (εmax) at the 
maximum absorbance (λmax) decreases (hypochromic effect).68 Although titrations have 
the advantage of being operationally simple, they do not distinguish binding modes (i.e. 
intercalation vs. minor groove binding).68 Quantification of DNA binding requires a 
linear relationship between absorption or fluorescence and concentration and an 
unchanging extinction coefficient or normalized fluorescence intensity over a wide range 
of concentrations. A nonlinear relationship implies polymerization, aggregation, or 
precipitation of the compound of interest.68 Equilibrium binding titrations are commonly 
used to analyze DNA-drug binding interactions. Aliquots of DNA solution are added 
serially to a drug solution of fixed concentration. Optical changes are measured and 
analyzed according to the concentration ratios of free drug and DNA-drug complex.68 
A = Af + Ab = εf·Cf + εb·Cb 
Equation 1.1. Determining binding of small molecules to DNA 
A represents Absorbance, C represents concentration, and ε is extinction coefficient. The 
subscripts f and b refer to free and bound small molecule. 
A complementary method varies the concentration of the drug while holding the 
DNA concentration constant. Using a wide range of concentrations is important, because 
the shape of the isotherm can vary as drug concentration increases.68 Continuous variation 
plots (or Job plots) of binding titrations provide the DNA:drug binding stoichiometry.70 A 
series of measurements are taken at independently varying DNA and drug concentrations, 
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and the signal (fluorescence or absorbance) is plotted against the mole fraction of drug to 
DNA.70 The inflection point of the plot gives the binding stoichiometry.70  
1.3.5.5. Displacement Assays 
An indirect method of determining binding constants uses ethidium bromide 
displacement from DNA (a discussion of ethidium bromide as a DNA-interactive 
compound follows in Section 1.4.4.1).68 Increasing concentrations of the compound of 
interest are added to a DNA-ethidium bromide complex while monitoring changes in 
fluorescence. The DNA-ethidium complex is highly fluorescent, whereas free ethidium 
bromide is only weakly fluorescent.68 This method works not only for intercalators but 
also for minor groove binders using an appropriate drug-DNA complex. Fluorescent 
compounds or compounds which do not bind strongly enough to displace ethidium 
bromide (Ka<104 M-1) do not work in this type of determination. The concentration at 
which 50% of the ethidium bromide is displaced (C50) is inversely proportional to the Ka 
for the DNA-drug association.  
1.3.5.6. NMR Binding Studies 
Both 1D and 2D NMR have been invaluable in characterizing solution-state 
DNA-small molecule interactions.71 Because of the complexity of the data obtained, it is 
easier to use self-complementary, short (6-12 bp) DNA oligomers and highly site-specific 
compounds.72 NMR is one of the least sensitive solution-state methods used for DNA 
characterization, with 2 mM in 600 µL solvent of the drug-DNA complex preferred for 
2D experiments.72 Exchangeable protons are of special interest, as DNA-drug interactions 
frequently involve hydrogen bonding.72 Small-molecule binding can induct characteristic 
spectral changes. For example, intercalators commonly cause a 1 ppm upfield shift in the 
imino protons near the drug-binding site, and minor groove binders shift protons H1ʹ′ and 
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H4ʹ′ on the deoxyribose units.72 2D NMR studies have similar features72 but will not be 
discussed here.  
1.3.5.7. X-ray Crystallography 
X-ray crystallography provides information about DNA-small molecule 
interactions in a solid state. Successful crystallization of samples is nontrivial,73 but X-ray 
crystallography provides detailed information about the relative positions of the bases 
compared to NMR, because the structures are rigid.74 Because of distortions due to crystal 
packing forces, the information obtained does not necessarily represent the solution-state 
or in vivo structure.6 For most X-ray methods, the absolute stereochemistry of the crystal 
cannot be determined, so models rely on a mathematical set of assumptions. Although 
multiple sets of refinement algorithms exist, at a nominal resolution of 2.0 Å or better, the 
refinement used does not affect the proposed structure.6 Different DNA-drug complexes 
have been characterized by this methods, leading to improved design of analogs or 
explanations of biological activities.74  
 
1.4. EXAMPLES OF SMALL MOLECULE DNA-INTERACTIVE COMPOUNDS 
This section will give examples of types of DNA modification and compounds 
associated with that modification pattern.  
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1.4.1. Alkylating Agents 
 
Figure 1.20. Cartoon depicting DNA alkylation 
Alkylating agents contain electrophilic moieties that can covalently modify 
nucleophilic sites on the nucleoside bases (Figure 1.20). Damage of this type can often be 
repaired by cellular repair machinery (such as base excision repair), depending on the 
size of the lesion.75 Alkylation most commonly occurs at the purine bases but can also 
occur at pyrimidines. 




Figure 1.21. CC-1065 (l) and Duocarmycin A (r) 
CC-1065 and Duocarmycin A (Figure 1.21) are known to alkylate N3 of 
adenine.76 CC-1065 binds double-stranded DNA at the sequence 5ʹ′-TTA-3ʹ′, and forms a 
covalent adduct at the adenosine.77 The structure of the covalent DNA adduct was 
determined by X-ray crystallography and NMR spectroscopy using a single base.76 The 
proposed mechanism of adduction for both compounds begins with a noncovalent 
association with DNA as minor groove binders followed by covalent modification by the 
nucleophilic N3 site at adenine (Scheme 1.5).78,79 The tetracyclic unit containing the 
cyclopropyl moiety is largely responsible for the sequence specificity and the ability of 
CC-1065 to bend duplex DNA.80 CC-1065 shows protection in hydroxyl radical 
footprinting at sequences of 5ʹ′-AAAAA-3ʹ′ and 5ʹ′-PuNTTA-3ʹ′ (Pu = purine). Alkylation 
occurs almost exclusively at the 3ʹ′-A of the sequence.80 These consensus sequences are 
bent by an angle of 17-22°.80 Covalent modification by CC-1065 does not change the 
angle of DNA bending, but it changes the center of the angle from the central A (A3) to 
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the A one base nearer the 3ʹ′ end (A4).80 Hurley et al. propose that in order to achieve the 
geometry required for alkylation, the duplex DNA must be flexible, as shown by its 
ability to bend, and once the desired geometry is achieved, alkylation at adenine holds the 
DNA at the angle of bending.81 CC-1065 is an extremely potent antineoplastic agent, 
requiring only 40 pg/mL to show 90% growth inhibition on mouse leukemia cells.82 
 
Scheme 1.5. Proposed mechanism for DNA modification by 
cyclopropyl-based alkylating agents 
 
1.4.1.2. Nitrosoureas 
Nitrosoureas have been used as antineoplastic agents.83 The mechanism by which 
they damage DNA is unclear, although most proposals agree that a diazonium ion is the 
intermediate responsible for alkylation.83,84 N-alkylnitrosoureas methylate DNA at several 
positions.85 As expected, N-methylnitrosourea preferentially alkylates the N7 position of 
guanine, but it also alkylates N7 of and N3 of adenine in a ratio of 1:0.03:0.15 
(N7MeGua:N7Ade:N3Ade).86 Adduct formation can be mapped using piperidine-heat 
treatment.86 Effective concentrations of NMU in incubations with DNA to see distinctive 
cleavage via PAGE analysis of radiolabeled DNA are in the µM range. 86 NMU appears 
to modify guanines without preference for flanking sequences. CNUs (Figure 1.22) are 
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bisfunctionalized, but the vast majority of adduct formation is monoalkylation, not 
crosslinking.83 BCNU modifies O6 of guanine.87,88 Streptozocin is an antibiotic 
nitrosourea formed by a streptomyces strain, which acts as a potent alkylating agent by 
modifying N7 of guanine, O6 of guanine, and N3 and N7 of adenine.89 A single dose to 



















R = CH2CH2Cl (BCNU)
   = CH2CH2OH (HECNU)
   = CH2CONH2 (acetamidoCNU)
   = Cy (CCNU)  
Figure 1.22. Nitrosoureas 
 
1.4.1.3. Polyaromatic hydrocarbon diol epoxides 
Commonly occurring polyaromatic hydrocarbons are metabolically activated to 
form a mixture of diastereomeric diol epoxides (Figure 1.23).90 Adducts arise from attack 
by the exocyclic amine of either guanine (N2) or adenine (N6) at the benzylic position of 
the epoxide to form a covalent adduct.90 Adduction can occur with either retention or 
inversion at the carbon stereocenter. Ratios of the stereochemical outcome for both DNA 
and single nucleosides have been determined for benzo[g]chrysene diol epoxide.91 In all 
cases, trans ring-opening is favored, but ratios vary from 51:2 in the case of 
deoxyadenosine in DNA to 37.5-15 in the case of deoxyguanosine as a nucleoside.91 
Benzochrysene epoxide at 10 ng/µg DNA shows a mutation rate of approximately 300-
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fold more than background.91 Out of 106 mutations, 2 were large deletions, and 104 were 
point mutations. 99 of the point mutations were single base mutations over the entire 
sequence, and 5 had two sites where bases were exchanged.91 The mutations observed 
were AT→TA, 41%, GC→CG, 12% (53% transversions, see section 2.1.1 for a 
discussion), GC→AT, 5%, AT→GC, 3% (8% transitions).91  
 




Figure 1.24. Cartoon depicting interstrand DNA crosslinking 
Crosslinkers are bifunctional alkylating agents. They can create either inter- or 
intrastrand links. Crosslinks are thought to have more severely damaging effects than 
simple alkylating agents, because they effectively cause two lesions, which foils most 
repair mechanisms.92 Interstrand crosslinks covalently join bases (or ribose units) on two 
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complementary strands and prevent DNA denaturation. Interstrand crosslinks occur 
between bases (or ribose units) along the same strand. 
1.4.2.1. Nitrogen Mustards 
Nitrogen mustards are some of the oldest chemotherapeutics.93 They contain 
bifunctional alkylating agents, containing two primary alkyl chloride moieties.93 
Mechlorethamine, registered by Merck as Mustargen for treatment of multiple tumor 
types, modifies DNA through both monoalkylation and crosslinking, but monoalkylation 
at N7 of guanine comprises 93-95% of DNA modification.93 The remainder of the 
modifications are G-G interstrand crosslinks.93 Instrastrand crosslinks can occur, but only 
in very limited sequence-specific cases. Mechlorethamine has been shown to crosslink 
DNA at 5’-GNC sites.22,94  
 
Figure 1.25. Nitrogen mustards chlorambucil (l), mechlorethamine (center), 
and cyclophosphamide (r) 
The proposed mechanism of DNA modification is displacement of a chloride by the 
amine to form an aziridinium ring, which then undergoes nucleophilic attack by the 
nucleoside base (Figure 1.26).95,96 The free amine then forms a second azridinium ring 
with the other electrophilic arm.93,95 This ring can then be opened by either water to form 
a mono-alkylated adduct or a second nucleoside base to form a cross-link. 93 
Chlorambucil is less base-selective, with 75% of adducts formed at guanosine and 25% at 




Figure 1.26. Proposed mechanism for reaction of nitrogen mustards with 
DNA.93 
Phosphamides modify N7 of guanine,87 but can also alkylate the phosphodiester 
backbone,97 which comprises 67% of DNA adducts formed.93 Cyclophosphamide, 
registered by Bristol-Myers Squibb as Cytoxan, for use against leukemia, requires 
metabolic activation to alkylate DNA. A cytochrome P450 adds a hydroxyl group a to the 
amide nitrogen.93 The cyclic product then spontaneously opens to generate acrolein and a 
phosphoramide mustard, which is the active alkylating agent.93 The activity of the 
independently synthesized phosphoramide mustard with DNA has been confirmed in 
cells studies98 and by mass spectrometric analysis.99  
 
 
Figure 1.27. Proposed activation of cyclophosphamide and subsequent 
DNA adduct formation. 
 
 
Figure 1.28. Cisplatin 
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Cisplatin (trade name Platinol, from Bristol-Myers Squibb, Figure 1.28) is an 
antineoplastic agent indicated for treatment of testicular, ovarian, and bladder cancer100 
that works as a DNA crosslinking agent. The mode of action is thought to be disruption 
of replication through formation of 1,2-intrastrand crosslinks of neighboring purines, 
which cause bending and partial unwinding of the duplex and widening of the minor 
groove, which can cause secondary effects enhancing the cytotoxicity.51,52,101 Cisplatin 
modifies DNA at guanine N7 as well as adenine N1 and N7.87 Although these lesions 
account for approximately 80% of the DNA modification caused by cisplatin, evidence 
also suggests that 1,2 GG interstrand links, although less common, might cause similar 
effects to the intrastrand crosslinks.102  
 
1.4.3. Oxidizers (via H-atom Abstraction) 
Oxidative Damage
 
Figure 1.29. Cartoon of oxidative damage of DNA 
 
1.4.3.1. Enediynes 
Enediynes are a well-known class of compounds that covalently modify DNA. 
Esperamicin and calicheamicin (Figure 1.30) can induce both double-stranded and single-
stranded DNA strand breaks.  
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Figure 1.30. Calicheamicin γ1 (l) and Esperamycin A1 (r) 
The mechanism of DNA damage by enediynes has been well-studied103,104 and is 
thought to proceed through reduction of the trisulfide (Scheme 1.6). The anionic sulfur 
can then perform conjugate addition to the α,β-unsaturated carbonyl to form a five-
membered ring, which has been characterized by NMR.105 Subsequent tautomerization re-
forms the carbonyl, and the ene-diyne moiety then relieves ring strain by undergoing a 
Bergman cyclization106 to form the p-benzyne diradical.  The activation energy, ΔG‡, of 
the Bergman cyclization of activated calicheamicin has been determined to be 20.1 
kcal/mol,105 significantly lower than the 28.8 kcal/mol barrier for Bergman cyclization of 
(Z)-hex-3-ene-1,4-diyne.107 Thus, this triggering reaction serves two purposes: it reduces 
the distance between C2 and C7 prior to the cyclization, which accounts for 
approximately one quarter of the reduction in activation energy, and it also reduces the 
strain at the bridgehead carbons by saturating the bridgehead alkene, which reduces the 
activation barrier to cyclization.108 This diradical then abstracts hydrogen atoms from the 
DNA.109 Depending on the structure of the enediyne and the DNA sequence of the 
cleavage site, DNA hydrogen atom abstraction occurs at C1ʹ′, C4ʹ′ or C5ʹ′ of the 
deoxyribose unit (Scheme 1.7).  
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Scheme 1.6. Triggering of esperamicin103,105 
A deuterium-exchange reaction with using deuterio-buffer and proteo-DNA 
showed that H-atom incorporation onto the cyclized enediyne comes exclusively from the 
DNA,103,109 although a subsequent experiment using a different oligomer sequence failed 
to observe such high selectivity (80% incorporation).110 The majority of DNA damage 
caused by esperamicin consists of single-stranded DNA breaks, as determined by a 
nicking assay.103 Hydroxyl radical footprinting on calicheamicin shows protection at 
pyrimidine-rich sites (i.e. TTTT, TTGT, CCCA, etc.) over seven bases, and footprints 
were consistent with positions of cleavage,111 which has been corroborated by NMR 
analysis.112 Esperamicin cleaves DNA selectively at repeated pyrimidines (CTC, TTC, or 




Figure 1.31. Reactive diradicals from enediynes114 
Neocarzinostatin (NCS) is a potent antitumor natural product that consists of a 
protein and a DNA-cleaving chromophore. Although the NCS chromophore lacks the 3-
ene-1,5-diyne core common to the ten-membered enediynes such as calicheamicin and 
esperamicin, thiol addition generates a reactive enyne cumulene system that cyclizes to 
afford a reactive diradical intermediate (Figure 1.31). Like calicheamicin and 
esperamycin, NCS chromophore cleaves DNA by hydrogen atom abstraction. However, 
under anaerobic conditions, neocarzinostatin does not exhibit DNA cleavage; rather, it 
forms covalent adducts with DNA.115,116 The mechanism of formation and structure of 
these adducts are not well-characterized, but they appear to involve hydrogen atom 
abstraction by NCS chromophore at the DNA 5ʹ′ position followed by addition of the 
resulting DNA-centered radical onto the reduced NCS chromophore.115,116 Calicheamicin 
γ11 also mainly produces DNA monoadducts under anaerobic conditions (Figure 1.31).114  
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Scheme 1.7. Different H-abstraction motifs on the ribose backbone of DNA114 
C1027, a metabolite isolated from Streptomyces globisporus C1027 strain, under 
aerobic conditions, shows C4ʹ′ hydrogen atom abstraction at A1 of the duplex 5ʹ′-GTTA1T-
3ʹ′/3ʹ′-CA3A2TA-5ʹ′, as evidenced by gel electrophoresis showing a phosphoglycolate 
fragment (running slightly faster than the Maxam-Gilbert 3ʹ′-phosphates).114 Under 
aerobic conditions, C5ʹ′ hydrogen atom abstraction at A3 leads to a strand break 
containing a 3ʹ′-phosphate, as well as C1ʹ′ hydrogen atom abstraction at A2, which forms 
the ribonolactone (Scheme 1.7).114 When the DNA is incubated under anaerobic 
conditions, the chromophore associated with C1027 remains associated with the DNA 
even after extensive extraction and precipitation.114 Additionally, under anaerobic 
conditions, low mobility bands were observed, suggesting that these compounds were 
also causing crosslinking. An additional experiment using oligonucleotides of differing 
length confirmed that the lower mobility bands were crosslinked DNA.114 Replacing the 
H at C1ʹ′ on the ribose unit of A2 with deuterium severely limits damage (kH/kD = 7.8) and 
shifts damage to A3.114 In this deuterated system, the crosslinking kH/kD is 1.8, 
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significantly lower than for H-atom abstraction, suggesting the crosslinking occurs 
mostly between A1 and A3.114 Fe(II)-EDTA/H2O2 footprinting showed that crosslinks are 
formed between A1 and A2 or A3.114  
1.4.3.2. Metal-Dependent Cleavage Agents 
One example of a DNA-interactive agent that displays metal-dependent oxidative 
DNA damage is bleomycin.  
 
Figure 1.32 Bleomycin A2 
Bleomycin (BLM, Figure 1.32) is an antineoplastic agent which causes single- 
and double-stranded DNA strand breaks in presence of several transition metals, 
including Ni(III),117 Cu(I) or Fe(II).118 BLM is registered by Bristol-Myers Squibb (trade 
name Blenoxane) as effective against squamous cell lymphomas and testicular cancer.100 
Bleomycin cleavage on DNA is selective for GC and GT sequences, but the extent and 
selectivity of the cleavage depends on the chelated metal.118 Sequence selectivity of the 
BLM-Ni(III) complex was analyzed by incubating short (100-200 bp) oligomers with the 
BLM-Ni(III) complex (generated by using BLM:Ni 1.0:1.2 in presence of an oxidizing 
agent, oxone or Ir(IV)) followed by piperidine-heat treatment and denaturing gel 
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electrophoresis.117 Additionally, addition of both Cu(I) and Fe(II) causes amplified 
cleavage, greater than what would be predicted by using each separately.118 Mechanistic 
studies suggest that DNA cleavage proceeds via H-atom abstraction at C4ʹ′ (Scheme 
1.8).119 The subsequent radical then traps molecular oxygen to form a peroxy radical. 119 
This radical is further reduced to the peroxide, possibly by the Fe(II) present (although 
the identity of the reductant has not been determined).119 The peroxide then rearranges to 
cleave the C3ʹ′-C4ʹ′ bond in the ribose unit, leaving a phosphate hemiacetal, which forms 
the open-chain aldehyde under basic conditions.119 Following loss of the phosphate, the 







































































































Scheme 1.8. Proposed mechanism of BLM-Fe(II)-induced DNA cleavage 
1.4.4. Intercalators 
Although no intercalating compounds will be described later in this dissertation, 
any overview of DNA-small molecule interactions would be remiss in not covering this 
common binding mode. Intercalators bind DNA via π stacking between nucleoside bases 
(Figure 1.33). The extend the distance between the π stacked bases from 3.4 Å to 6.8 Å.5 
This causes lengthening and unwinding of the DNA duplex. Crystal structures of 
intercalated duplex-DNA show little change in the backbone conformation of DNA 




Figure 1.33. Cartoon depicting DNA intercalation 
 
1.4.4.1. Synthetic Dyes 
 
Figure 1.34. Mitoxantrone 
Mitoxantrone (Figure 1.34) is an anthracenedione registered by Lederle as 
Novantrone for activity against acute leukemia.100 Mitoxantrone shows cytotoxicity 
against multiple types of cancer (in vitro against human lung adenocarcinoma, small cell 
lung carcinoma, melanoma, biliary tree cancer, and adenocarcinoma, with good activity 
against breast cancer,121 ovarian cancer, non-Hodgkin’s lymphoma, head and neck cancer, 
squamous cell lung cancer, soft tissue carcinoma, gastric cancer, and hepatoma. 
Mitoxantrone is extremely potent, showing effects in doses as small as 1 ng/mL in 
vitro.122 It arrests the cell cycle at the transition from G2 phase (the phase which follows 
DNA synthesis, when cells are tetraploid) to M phase, when mitosis occurs.123 Studies 
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show a synergistic effect with doxorubicin (see section 1.4.4.2), as well as other 
chemotherapeutic agents.123 Mitoxantrone induces the same type of DNA damage as 
doxorubicin, suggesting that its mechanism of action might be similar, acting by both 







Figure 1.35. Ethidium Bromide 
Ethidium bromide (Figure 1.35) is an intercalator selective for AT-rich DNA 
sequences.69 It causes unwinding of DNA from a 36° base turn angle for unmodified B-
DNA to 18°, shown in the crystal structure of ethidium bromide with 5-iodouridylyl (3ʹ′-
5ʹ′) adenosine and 5-iodouridylyl (3ʹ′-5ʹ′) guanosine reported in 1977.124,125 The heavy atom 
incorporation was for use in X-ray crystallography. Ethidium bromide shows enhanced 
fluorescence upon DNA binding, making it a useful stain for imaging gel work and as a 
probe for displacement assays. Ethidium bromide shows strongest binding with double-
stranded DNA, showing about 54% less enhancement in fluorescence when bound to 
denatured calf thymus DNA and 58% decrease in fluorescence enhancement when 






Figure 1.36. Daunorubicin, doxorubicin, and iremycin. 
Daunorubicin (Figure 1.36) is used to treat leukemia and is registered by Wyeth-
Ayerst as Cerubidine, and doxorubicin (trade name adriamyin) is indicated for multiple 
tumor types by Adria and Others.100 The anthracycline antibiotics are known to 
intercalate DNA and inhibit Topoisomerase II.127 The flat, conjugated π-system 
intercalates between nucleosides, and the sugar moiety extends into the major groove.127 
Binding of doxorubicin to DNA was determined to be 1.0x106 M-1bp-1 by fluorescence 
titration and 29±2 x 105 M-1 using equilibrium dialysis.128 Daunomycin binds DNA at 
6.9±2 x 105 M-1 as determined by equilibrium dialysis.128 Both binding constants for 
daunomycin and doxorubicin show a concentration-dependence on monovalent cations, 
which may be attributed to a change in distance between the phosphates upon 
intercalation.128 This shift causes a change in electrostatic interactions, with the small 
molecule intercalators having an overall favorable electrostatic effect.128 Daunomycin 
displays a DNA unwinding angle of 15.4±1.5° and iremycin unwinds DNA at an angle of 
15.0±1.5°.129 Circular dichroism has been used to determine the degree of DNA 
lengthening caused by intercalation of daunorubicin and iremycin. Daunomycin 
lengthens DNA by 0.31±0.02 nm per molecule intercalated.129 Iremycin lengthens DNA 
by 0.40±0.02 nm per molecule intercalated.129 The IC50 value for inhibition of DNA 
 47 
synthesis for iremycin is 29 µM, and daunomycin is 23 µM, as determined using 
radiolabeled monophosphate deoxyribosides.130 Inhibition constants were proportional to 
DNA binding affinity.130 In footprinting experiments, doxorubicin, daunomycin, and 
iremycin, protect the DNA from DNase I digestion and show site selectivity for 
intercalation between CG and CA intervals.131 DNase I footprinting was used to 
determine the binding site of daunomycin at 5ʹ′-A(T)GC or 5ʹ′-A(T)CG.47 Daunomycin 
and doxorubicin show increased protection compared to iremycin.131  


































Figure 1.37. Echinomycin 
Echinomycin (Figure 1.37) is a member of the quinoxaline antitumor antibiotics 
(effective against Gram-negative bacteria), a family of octapeptide macrocycles with 
sulfur-containing cross-bridges.132,133 The quinoxaline moieties are thought to intercalate 
DNA and sandwich two DNA bases, but DNase footprinting does not indicate whether 
the preferred two base sequence is ApT or TpA.132 Echinomycin is a member of the 
quinomycin family of this class of compounds, which contain a thioacetal cross-bridge. 
Echinomycin is thought to interact with DNA by intercalation of the two heteroaromatic 
rings with the bases. Unlike most intercalators, echinomycin exhibits a sequence 
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selectivity for GC-rich DNA.133 DNase I footprinting using a 160-base oligomer (from E. 
coli containing the tyr T promoter region) shows protection at sites that have a CpG step 
in common, but the footprints comprise six bases with no clear consensus sequence.133 
CpG steps, then, are a prerequisite but not the minimum requirement for binding.133 NMR 
modeling suggests that the intercalators sandwich four bases, which include a CpG 
interval. DNase I cleavage is significantly enhanced at AT-rich bases adjacent to the 
protected site.133 The intercalation may slightly unwind the DNA (or cause bulges), 
allowing the nuclease to more easily recognize and cleave the DNA.133  
Triostin A and TANDEM (Figure 1.38) are also examples of quinoxaline 
antitumor antibiotics belonging to the triostin family, which is defined by the disulfide 
bridge across the octapeptide. Triostin A, like echinomycin, binds GC-rich DNA, but has 
a slightly lower sequence selectivity. TANDEM is a des-N-tetramethyl synthetic analog 
of triostin A that shows the opposite sequence selectivity (5000-fold binding preference 
to poly(dA-dT) compared to poly(dG-dC).132 DNase I footprinting shows binding similar 
to echinomycin (six bases, two CpG steps) but with less pronounced footprints.132 
TANDEM, however, shows footprints centered around ATAT and ATAA sequences. Its 
protection of DNA from cleavage is nearly 20-fold lower than either triostin A or 
echinomycin, and it appears to be slightly more specific in its binding, since not all AT-
rich tracts are protected from DNase I cleavage.132  
 
 
Figure 1.38. Triostin A (l) and TANDEM (r) 
 49 
 
1.4.5. Minor Groove Binders 
Compounds that bind to the hydrophobic minor groove of DNA (Figure 1.39) 
have historically been used as models for DNA binding but have recently gained 
prominence as potential anticancer agents. There are several proposed mechanisms by 
which minor groove binding compounds can serve as antineoplastic agents. The ligand-
DNA interaction can distort the DNA structure, interfering with transcription or 
replication. These distortions can interfere with topoisomerases (which cleave and re-
attach parts of the phosphate backbone of DNA), helicases (which unwind DNA), and 
polymerases (involved in transcription of DNA). 134 Other effects can be classified as 
being global (selective binding to long AT repeat sequences critical to chromosome 
metabolism) or specific (lesions might interrupt a specific nuclear process such as 
transcription of a gene).134 
 
Figure 1.39. Cartoon of minor groove binding on DNA 
	  
1.4.5.1. Polypyrroles 
Polypyrroles are a class of minor groove binders that selectively bind AT-rich 
sequences, which are more electron-rich than GC rich sequences.134 Hairpin polyamides 
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generally bind specific sequences of bases. Their binding typically interferes with DNA 
binding of endogenous compounds (i.e. binding of transcription factors). Distamycin 
(Figure 1.40), a classical example of a minor groove binder, inhibits helicases associated 
with Werner and Bloom syndrome as well as topoisomerase I and II and inhibits RNA 
polymerase I and II.134 Distamycin inhibits RNA polymerase II by causing longer pauses 
at the enzyme’s natural pause sites, which inhibits transcription.134 Tight binding of 
distamycin directly to RNA polymerase I blocks chain elongation.134 Netropsin (Figure 
1.40), which binds DNA with a 1:1 stoichiometry inhibits the same helicase family as 
well as topoisomerases I and II.134  
	  
Figure 1.40. Netropsin (L) and Distamycin (R) 
Netropsin shows two footprints on a restriction enzyme digest (HaeIII/HindIII) of 
plasmid pBR322 consisting of 142 base pairs.135 Both sites contain more than 70% A+T 
residues, but one footprint is 7 base pairs in length, and the other includes 14 base pairs. 
Distamycin-DNA interactions have been extensively studied. Hydroxyl radical 
footprinting has been used to analyze the interactions of distamycin with 5S ribosomal 
RNA genes of Xenopus.136 Hydroxyl radical footprinting shows protection of three to four 
base pairs by distamycin at AT rich regions, with a minimum of two base pairs required 
for recognition.136 Distamycin has been subjected to DNAse I footprinting, but results 
using this technique are less specific than others because DNase I has a lower affinity for 
AT-rich sequences, to which distamycin binds preferentially.40 The footprint does, 
however, show enhanced cleavage at AT bases adjacent to the poorly defined footprint.40 
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The footprints are offset on the complementary strand by two to three bases, indicating 




Bis(benzimidazoles) are fluorescent dyes that induce DNA strand breaks.134 
Hoechst 33258 (Figure 1.41) inhibits topoisomerase and helicases and also elevates 
enoduplication and polyploidy in Chinese hamster ovary (CHO) cells.134 Additionally, 
this dye causes decondensation of heterochromatin and aneuploidy in mouse L cells.134 
Bis(benzimidazoles) have been conjugated to nitrogen mustards, which allows for 
alkyation.134 Short linkers lead to alkylation at N3 of adenine; longer linkers allow 
alkylation at N7 of guanine.134 These compounds are highly cytotoxic but display low 
rates of mutagenesis in bacterial assays.134 The combination of a groove-binding moiety 
with alkylating moeity allows these conjugates to bind DNA with greater affinity than the 
alkylating agents themselves, which correlates to the increased cytotoxicity observed 
with these conjugates. This increased cytotoxicity might also be related to topoisomerase 











Figure 1.41. Hoechst 33258 dye 
Bisquaternary ammonium heterocycles (Figure 1.42), which are structurally 
similar to polyamides, bind to AT tracts containing at least 4 base pairs, causing 
distortion of DNA structure and inhibiting DNA and RNA polymerases.134 
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Figure 1.42. Berenil (l), Pentamidine (center), and DAPI (r) 
 
1.4.5.3. Aureolic Acids 
The aureolic acids include the microbial secondary metabolites mithramycin137 
and chromomycin138 (Figure 1.43), which are antitumor antibiotics.  These natural 
products inhibit gene expression and appear to exert their biological activity by metal 
dependent DNA binding in the minor groove. The saccharide moieties on both 
mithramycin and chromomycin are important for sequence selectivity. NMR studies 
suggest a 2:1 aureolic acid to metal ion binding stoichiometry, and demonstrate that 
mithramycin selectively binds DNA at GpC steps.139,140 Mithramycin has traditionally 
been thought to act as a 2:1 complex of mithramycin to Mg2+, although recent studies 
suggest that other metal-complexes might also be biologically active.141,142 Two Mg2+ 
complexes have been characterized in solution, with different association constants. The 
2:1 drug:metal complex has a Ka of 1.6 x 103, and the 1:1 complex has a Ka of 1.8 x 104. 
Lower concentrations of drug and metal favor formation of a 1:1 complex (25 µM Mg2+ : 
50 µM mithramycin); higher concentrations favor 2:1 (100 µM Mg2+ : 200 µM 
mithramycin). Both complexes have been shown to be minor groove binders. 
Fluorescence titrations showed that both complexes bind calf thymus DNA with very 
similar binding constants (2.8±0.3 x 105 for 1:1 and 1.15±0.1 x 105) and ratios of 
drug:nucleoside (0.15 for 1:1 and 0.19 for 2:1). 107 Although the 2:1 complex appears to 
be slightly larger than the minor groove, NMR data for both mithramycin and 
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chromomycin, as well as diplacement assays, suggest that the minor groove becomes 
slightly distorted to accommodate the ligand.107,143 Chromomycin shows a binding 
selectivity for GC-rich DNA, preferring GpC to CpG intervals (determined by NMR 
titrations).144 Fe(II)-MPE footprinting for chromomycin A3 shows the strongest protecting 
effect at 5ʹ′-GGG-3ʹ′ and 5ʹ′-CGA-3ʹ′.138 
 
Figure 1.43. Chromomycin A3(l) and Mithramycin (r)145 
1.5. CONCLUSIONS 
This is only a brief overview of small-molecule DNA interactions. Covalent and 
non-covalent modification of DNA is an active field of research because of its effects on 
cell growth or death. Newer, more rapid and sensitive methods of analysis are under 
development. Additionally, although many of the drugs shown here are used 
therapeutically or are under development, much more can be done in this area to improve 
drug-like properties (i.e. selectivity, toxicity, etc.). Understanding both therapeutic and 
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2. Synthesis of (±)-Nʹ′-Nitrosonornicotine-5ʹ′-Acetate 
2.1. BACKGROUND 
This chapter will describe the biological damage caused by nicotine ingestion, and 
previous work characterizing DNA adducts from nicotine metabolites. A review of 
sulfininime chemistry follows, then the (±)-Nʹ′-nitrosonornicotine-5ʹ′-acetate (NNN-OAc) 
synthesis is described. Finally, biological studies on DNA interactions with NNN-5ʹ′-OAc 
are reported. 
2.1.1. Tobacco Carcinogens 
Cigarette smoking causes not only 87% of lung cancer deaths (the leading cause 
of cancer death for both men and women) but also 30% of all cancer deaths, including 
cancer of the larynx, oral cavity, pharynx, esophagus, stomach, renal body, liver, colon, 
and bladder.1,2 Furthermore, smoking has been linked to kidney, pancreatic, cervical, and 
stomach cancers, as well as acute myeloid leukemia.3,4 Nicotine, a constituent of cigarette 
smoke, also has been shown to induce angiogenesis and arteriogenesis, both of which are 
associated with not only cancer but also heart disease, macular degeneration, and diabetic 
retinopathy.5 Although the causal relationship between cigarette smoking and cancer has 
been known since 1957,6 relatively little is known about the mechanism by which 
carcinogens found in cigarette smoke cause DNA damage. A key component of the 
pathway appears to be nicotine carcinogen-associated damage of tumor supressor gene 
p53. A damaged p53 gene is found in at least half of all cancers,7 and an increased 
number of G→T transversions is found in about 60% of smokers who develop lung 
cancer.8,9 Transversions are unusual mutations because they substitute a purine for a 
pyrimidine or a pyrimidine for a purine,10 in contrast with more common transitions, in 
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which a purine (i.e. G) is exchanged for another purine (A) or one pyrimidine is 
substituted for the other.10  
Scheme 2.1. Possible DNA replication outcomes 
Although most work concerning DNA damage caused by smoking has focused on the 
role of polyaromatic hydrocarbons (i.e. benzopyrenes) on p53 mutations (Scheme 2.2), 
nicotine-based carcinogens may also play a significant role in DNA damage.  
	  
Scheme 2.2. DNA modification at guanosine by benzo[α]pyrene diol epoxide11 
Additionally, polyaromatic hydrocarbons are ubiquitous,12 whereas nicotine derivatives 
are specific to tobacco products and might leave a more unambiguous “fingerprint” as to 
the source of DNA damage. Two carcinogenic nicotine-derived components of cigarette 
smoke are 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and Nʹ′-
nitrosonornicotine (NNN) (Figure 2.1).13 
In tobacco plants, nornicotine is derived from N-demethylation of nicotine by 
nicotine N-demethylase (Scheme 2.3), which is a cytochrome P450 enzyme.14 Following 
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tobacco harvesting, depending on curing conditions, as much as 90% of the nicotine may 
be converted to nornicotine.15 During curing and storage of the tobacco from plants, 
nornicotine is then converted to the established carcinogen N-nitrosonornicotine in a 
microbe-mediated nitrosation.14-17  
 
 
Figure 2.1. Structures of NNK (l) and NNK (r) 
 
 
Scheme 2.3. Conversion of nicotine to NNN-5ʹ′-OH 
Upon ingestion, tobacco smoke carcinogens are oxidized by cytochrome P450 
enzymes,18 (Scheme 2.4) which hydroxylate alpha to the Nʹ′-nitrosoamine. In general, 
cytochrome P450 oxidation increases water solubility and rate of excretion of metabolites. 
These metabolites also sometimes form reactive intermediates containing electrophilic 
moieties that can covalently modify DNA.13 Prior to hydroxylation α to the Nʹ′-
nitrosamine, NNK can be reduced to its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL), which is the predominant species in vivo.19 Both NNAL-OH and 
NNK-OH have been shown to covalently modify DNA.19 These oxidized nicotine 
derivatives are unstable and cannot be synthesized or stored easily, which makes studying 
their in vitro interactions with DNA difficult. A solution to this problem is to synthesize 
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the more stable acetate-protected alcohol and to deprotect it in situ using pig liver 
esterase (PLE) (Scheme 2.4).  
 
 
Scheme 2.4. Metabolic activation of NNK; synthetic precursors for reactive metabolites 
Adducts of NNAL with DNA have been characterized by Hecht and coworkers, 
who incubated NNAL-OAc with calf thymus DNA or deoxyguanosine and compared the 
products to independently synthesized standards using high performance liquid 





Scheme 2.5. NNAL DNA adduct formation 
Additionally, O2 adducts of the pyrimidine bases have been identified and 
characterized (Figure 2.2).20 Incubation of single deoxyribonucleosides with the stable 
NNK-OAc and NNAL-OAc precursors yielded adducts in quantities large enough for 
characterization by standard techniques (NMR, UV-Vis, MS). Incubation of each 
carcinogen precursor with calf-thymus DNA and pig liver esterase followed by either 
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thermal or enzymatic hydrolysis, was compared using selective ion monitoring LC-MS to 
the single-base samples.20  
 
 
Figure 2.2. NNAL and NNK DNA adducts of pyrimidine bases 
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Scheme 2.6. NNN DNA adducts on guanosine 
During early stages of the work discussed here, characterization of adducts of 
NNN-5ʹ′-OH with guanosine had been reported (Scheme 2.6),21 but no other studies had 
been published regarding sequence selectivity or reactions of NNN-5ʹ′-OH with other 
nucleotide bases. Although NNN had been synthesized both racemically22 and 
asymmetrically (through use of chiral auxiliaries),23 a facile route to NNN-5ʹ′-OAc (and 
NNN-5ʹ′-OH) has remained unavailable. To access the 5ʹ′-hydroxylated NNN formed by 
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cytochrome P450 in vivo,13 NNN-5ʹ′-OAc can be deprotected using pig liver esterase 
(Scheme 2.7); so, it is an attractive synthetic precursor for examining DNA damage. The 
proposed mechanism of activation of NNN-5ʹ′-OAc as an electrophile is shown in 
Scheme 2.8. The acetate is deprotected to leave the free hydroxyl group, which can ring-
open to the acyclic aldehyde. Loss of water generates an alkyldiazonium species which 




Scheme 2.7. Using PLE to mimic biological oxidation of NNN 
 
Scheme 2.8. Proposed mechanism of enzymatic deprotection of NNN-5ʹ′-OAc 
 
2.2. NNN-5ʹ′-OAC SYNTHESIS BACKGROUND 
The only reported synthesis of NNN-5ʹ′-OAc is inefficient (Scheme 2.9), using a 
minor product from deprotonation and electrophilic trapping at the 5ʹ′ position of NNN.24 
Additionally, this synthesis is racemic, whereas in tobacco products, (S)-NNN is the 
predominant enantiomer (50% enantiomeric excess).25 The synthesis relies on 
electrophlilic trapping of an anion generated α to the cyclic nitrosamine. Using dimethyl 
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disulfide. Substitution at the 2ʹ′ position (the thermodynamic product) predominates, but 
the minor 5ʹ′ product was isolated and carried forward. Chlorine activates the thioether to 
undergo nucleophilic substitution with the acetate under buffered conditions. The final 
product is isolated in yields ranging from 0.01-0.04%.24  
 
 
Scheme 2.9. Previously reported route to NNN-5ʹ′-OAc 
Retrosynthetic analysis (Scheme 2.10) suggests that isomyosmine (3-(3,4-
dihydro-2H-pyrrol-2-yl)-pyridine) could provide the desired NNN-5ʹ′-OAc product. 
Isomyosmine poses an interesting synthetic challenge because the carbon-nitrogen π 
bond is not conjugated with the pyridine ring, suggesting that it might prove a difficult 
target because of possible isomerization and hydrolysis of the aliphatic imine.  
 
 
Scheme 2.10. Retrosynthetic analysis of NNN-5ʹ′-OH 
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2.2.2. Previous isomyosmine syntheses 
 
Scheme 2.11. Previous synthesis of isomyosmine using condensation to form pyrroline 
ring26 
Two syntheses of isomyosmine have been reported.26,27 In earlier reports regarding 
isomyosmine, the structural assignment was incorrect, assigning the double bond of the 
pyrroline ring as being conjugated with the pyridine ring (C4ʹ′-C5ʹ′) rather than out of 
conjugation (N1ʹ′-C2ʹ′).28 One previous route approaches isomyosmine through an 
intramolecular imine formation between an aldehyde and a primary amine (Scheme 
2.11). Deprotonation of the methyl oxime of 3-acetylpyridine yields a nucleophile 
suitable for 1,4 addition to the α,β-unsaturated sulfoxide to provide the carbon skeleton 
for the pyrroline ring in good yield. Reduction of the methoxime using diborane provides 
the primary amine as well as the diethylthioacetal, which closes to form the pyrroline 
upon oxidative deprotection of the thioacetal using iodine in aqueous acetonitrile. The 
overall yield ranges from 14-23%. The authors comment on the instability of 
isomyosmine, which they isolated by preparative “thick-layer” chromatography on silica 
using ammonium hydroxide in the eluent system.26  
 
Scheme 2.12. Thermal rearrangement of cyclopropylimine to give isomyosmine27 
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The second reported synthesis by Campos and coworkers proceeds via flash 
vacuum thermolysis of an N-cyclopropylimine, affording isomyosmine in 26% yield 
(Scheme 2.12).27 Campos et al. do not report the yield for the imine formation. Similar 
rearrangements using photochemistry have been previously reported, but no 
heteroaromatic substrates were used.29-31  
2.2.3. Sulfinimine Chemistry 
2.2.3.1. Synthesis of Sulfinimines 
Recently, Ellman et al. reported a novel cyclization to form 2-substituted 
pyrrolines from α-chiral amines using with tert-butyl sulfinamides as a chiral auxiliary.32 
They propose the deconjugated cyclic imine as an intermediate but isolate the product 
after silane reduction (Scheme 2.13).  
 
Scheme 2.13. Sulfinamide cyclization to generate pyrroline 
The chiral tert-butylsulfinamide is commercially available in both racemic and 
enantiomerically enriched form, and either enantiomer can be easily synthesized from di-
tert-butyl disulfide. Racemic synthesis commences with hydrogen peroxide oxidation of 
one of the sulfides is followed by sulfinyl chloride formation (Scheme 2.14). The 
sulfinamide is generated by treatment of this sulfinyl chloride with concentrated 




Scheme 2.14. Route to racemic tert-butylsulfinamide33 
 
Scheme 2.15. Organic Syntheses preparation for (R)-tert-butyl sulfinamide34 
The asymmetric synthesis of tert-butyl sulfinamide uses a vanadium catalyst with 
a tert-leucine-derived (Scheme 2.16) or indane-derived (Scheme 2.15) ligand in the 
oxidation step, followed by displacement of the sulfide using lithium amide (Scheme 
2.15, Scheme 2.16). The product could be crystallized to afford high optical purity.  
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Scheme 2.16. Asymmetric synthesis of tert-butyl sulfinamide33 
Condensation of the tert-butanesulfinamide with aldehydes to sulfinimines 
proceeds more slowly than imine formation between amines and aldehydes; however, the 
rates can be improved with addition of MgSO4 and pyridinium p-toluenesulfonate.35,36 
Although conditions which can racemize the chiral center at sulfur are known,37 
nucleophilic addition to sulfinimines does not cause racemization as judged by HPLC.35 
In fact, sulfinamide formation from amides using tert-butylsulfinyl chloride can be used 
to determine stereoselectivity of amine formations.37 The chiral tert-butylsulfinamide 
may also be recovered and recycled following deprotection of the amine.38  
 
2.2.3.2. Use of Sulfinamides as Chiral Auxiliaries 
 
Scheme 2.17. Nucleophilic Addition to Sulfinimines.35 
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These sulfinimines have been shown to be versatile building blocks for a variety 
of transformations. They undergo nucleophilic addition by Grignard reagents to yield 
protected α-branched amines (Scheme 2.17).35,39,40 Stereoselectivity depends most on the 
group attached to the sulfur of the sulfinimine. p-Toluenesulfonyl (tosyl) sulfinimines 
typically provide moderate diastereoselectivities, typically~4:1, and moderate yields.39 
Other, more sterically demanding chiral auxiliaries improve diastereoselectivities.40 With 
p-tosylsulfinimines, diastereoselectivities were modest to poor until chiral auxiliaries (i.e. 
menthyloxy, bornyloxy) were appended to the metal, which improved ratios to a 
minimum of ~9:1.41 Trialkylaluminum reagents also mediate 1,2-additions of 
organolithium reagents to sulfinimines, showing good yields and good to excellent 
diastereoselectivities.42 Metal-hydrides can perform similar 1,2-addition chemistry, with 
varying degrees of diastereoselectivity.41 Both open (acyclic) and closed (cyclic) 
transition states (Scheme 2.18) have been proposed to explain the diastereoselectivity of 
the additions. 
 




Scheme 2.19. Addition of α-phosphonate anions43 and phosphites43,44 to chiral 
sulfinimines. 
Phosphonates can be deprotonated with strong base and added to sulfimines to 
generate precursors to β-aminophosphonic acids (Scheme 2.19).43 Diastereoselectivities 
range from ~5:1 to ~10:1, and yields are moderate.43 Phosphite anions can also attack 




Scheme 2.20. Asymmetric Rh(I)-catalyzed addition to t-butyl sulfinimine.45 
An alternative to Grignard additions to add aromatic substituents at the imine 
carbon employs rhodium-catalyzed arylboronic acid (Scheme 2.20).45 This transformation 
is more functional-group tolerant than using a strongly nucleophilic organometallic 
reagent. The transformation proceeds in 70-96% yield, with good diastereomeric ratios. 




Scheme 2.21. Sulfinimine three-component coupling with allene and aryl iodide46 
Sulfinimines participate in a palladium-catalyzed 3-component coupling using an 
allene and an aryl iodide to generate a 2-aryl palladium π-allyl species, which then 
undergoes an indium-mediated nucleophilic addition to the sulfinimine in a closed, six-
membered transition state, to generate the allylated sulfinimide (Scheme 2.21)46 These 
transformations yield products in moderate yields (46-56%) as a single diastereomer as 
determined by 1H and 13C NMR.46 Only electron-poor aryl groups on the sulfinimine (Ar1 
in Scheme 2.21) were reported.  
 
 
Scheme 2.22. Enolate addition to sulfininimes. 
Sulfinimines can also undergo attack by metal enolates47,48 or Lewis-activated 
trimethylsilyl enol ethers (Scheme 2.22).49 The use of Lewis acids to activate the silyl 
ketene acetal proceeds in moderate to good yield, with diastereomeric ratios typically 
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near 9:1.49 The authors propose that the addition proceeds via an open transition state. 
The scope of the reaction remains largely unexplored.  Early reports of the addition of 
ester enolates to p-tosyl sulfinimines exhibited modest diastereoselectivities, until HMPA 
was added to the reaction, leading to excellent diastereoselectivity with a reverse in 
selectivity. This switch was attributed to a change from a closed six-membered transition 
state to an open transition state.48 The addition of metal enolates to the sulfimines 
tolerates both aldimines and methyl ketimines with good yields and good to excellent 
diastereoselectivities with tert-butanesulfinimines as electrophilic partners.47 Ellman et al. 
used this template to synthesize hexameric peptides containing β-amino acids using tert-
butane sulfinamide as the source for chirality.47 
 
Scheme 2.23. Aziridinations using sulfinimines50-52 
Sulfinimines can be used for asymmetric aziridine formation, either via an aza-
Darzen condensation50,52 or sulfur ylides (Scheme 2.23).51 The aza-Darzen condensations 
proceed in good yield with diastereoselectivities typically greater than 9:1, thought to be 
caused by a closed, cyclic transition state.50,52 The aziridine formations using sulfur ylides 
proceed in generally good yields, but diastereoselectivities depend largely on the identity 
of the R group on the sulfur, with tert-butyl groups providing the best selectivities.51 
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Scheme 2.24. Sulfinimines as electrophilic trap in 1,4-conjugate addition-electrophilic 
trapping53 
In addition to serving as electrophilic traps for enolates generated by α-
deprotonation of a carbonyl compound, sulfinimines also serve as electrophilic partners 
in 1,4-conjugate addition-electrophilic trapping reactions on α,β-unsaturated carbonyl 
compounds (Scheme 2.24).53 The dialkyl zinc adds to the β position to generate a 
metallo-enolate, which then attacks the sulfinimine. The authors propose an open 
transition state, but do not discount a closed six-membered cyclic transition state. Yields 
are moderate to good for dimethyl, dibutyl, and diethyl zinc, as well as a range of 
aromatic and aliphatic substituents for R2.53 A single diastereomer was observed by 1H 
NMR in the crude reaction mixtures under the optimized conditions.53 
 
Scheme 2.25. N-sulfinyliminoacetates undergo C-C bond formation under reductive 
conditions.54 
Tert-butylsulfinamide may also be used to form N-sulfinyliminoacetates, which 
can undergo vinylation under reductive conditions to generate precursors to unnatural α-
amino acids (Scheme 2.25). These reactions proceed in good to excellent yields with 
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excellent diastereoselectivity (>95:5 in all reported cases).54 Krische et al. suggest that the 
mode of stereoinduction comes from a coordination or rhodium by the nitrogen lone pair, 
which directs delivery of the vinylrhodium species to the less hindered π face of the 
imine.54 
 
Scheme 2.26. Reductive asymmetric coupling of sulfinimines with aldehydes.55 
 Another reductive asymmetric coupling using the tert-butylsulfinimine as a chiral 
auxiliary is an aza-pinacol coupling using samarium diiodide (Scheme 2.26).55 Typical 
yields for a range of substrates ranged from 70-90%, with drs after chromatographic 
purification ranging from 10:1 to >25:1.55 Although the coupling appears general for a 
range of aldehydes, ketones do not readily participate.55 
 
Scheme 2.27. Formation of α-fluoroamines using chiral sulfinamines.55 
Sulfinimines undergo nucleophilic attack by sulfone-stabilized carbon 
nucleophiles to generate precursors to α-fluoroamines (Scheme 2.27).56 The π-facial 
selectivity is reported as 99:1 in most examples, where R2 can be either aromatic or 
aliphatic with varying electronic properties.56 Yields on the nucleophilic addition are also 
excellent and do not appear to be very sensitive to either sterics or electronics at R2. 
Overall yields for the ammonium salts range from 70-80%.56 
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Scheme 2.28. Use of TMS-alkanes as pro-nucleophiles to alkylate sulfinimines 
In addition to forming mono-α-fluorinated chiral amines, sulfinimines have been 
used to form α-trifluoromethyl amines (Scheme 2.28).57 Olah et al. report the use of 
tetrabutylammonium difluorotriphenylsilicate (TBAT) in presence of 
(trifluoromethyl)trimethylsilane (Ruppert’s reagent).57 The fluoride forms an “ate” 
complex with silicon to activate the trifluoromethyl group as a nucleophile which adds to 
the electrophilic carbon of the sulfinimine. Yields were good to excellent, with electron-
poor aromatic R2 groups having the best yields.57 Diastereoselectivities were excellent 
(>95:5) in all reported cases.57 The diastereoselectivity was rationalized by invoking an 
open transition state.57 In a similar system, benzyltrimethylsilane is used in conjunction 
with tetrabutylammonium fluoride to benzylate the sulfinimine.58 Yields and 
diastereoselectivities in these benzylations were moderate.58 
Most recently, chiral sulfininimes have been shown to undergo vinylation 
reactions (Scheme 2.29).59 Using a variety of potassium trifluoroborate salts similar to 
those first reported by Vedejs60,61 and popularized for transition metal-catalyzed couplings 
by Molander,62 Ellman et al. were able to perform vinylations with good to excellent 
yields on both aliphatic and aromatic sulfinimines. The diastereoselectivity in all reported 
cases was >95:5.59  
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Scheme 2.29. Vinylation using rhodium catalyst and potassium trifluoroborate salt. 
Sulfinimine chemistry can generate structurally diverse α-chiral amines with a 
variety of nucleophiles. Yields and diastereoselectivities are typically good, so we were 
interested in applying this chemistry to the synthesis of NNN-5ʹ′-OAc, as it affords the 
possibility of an enantioselective variant. 
 
2.3. SYNTHESIS OF NNN-5ʹ′-OAC 
The original planned route to NNN-5ʹ′-OAc was to synthesize isomyosmine using 
a photochemical rearrangement of the cyclopropylimine, as reported by Sampedro et al.27 
Condensation of cyclopropylamine to pyridine-3-carboxaldehyde yielded MIS090 in 
55% yield (Scheme 2.30). This imine was stable to silica gel chromatography. Although 
imine formation proceeded smoothly, the photorearrangement was unsuccessful in our 
hands (Table 2.1). Because the rearrangement has not been reported using heteroaromatic 
groups,31 MIS089, derived from benzaldehyde, was synthesized. This attempt at 
photorearrangement was also unsuccessful under the reported conditions.29 It is possible 
that the Hg lamp and photoreactor were sufficiently different as to prevent excitation.63 
Given our inability to reproduce the reported photochemical isomerization, no conclusion 
concerning the viability of this route to isomyosmine can be made. However, because this 
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route required very dilute conditions, it was less attractive for gram-scale synthesis of 
isomyosmine en route to NNN-5ʹ′-OAc.  
 
Scheme 2.30. Attempts to perform photocyclization to generate isomyosmine. 
Table 2.1. Attempts to effect photorearrangement of MIS090 
Entry Solvent Sensitizer (mol%) Outcome 
1 Hexanes  No conversion 
2 Hexanes Rose Bengal Sensitizer insoluble; no conversion 
3 Hexanes Benzophenone No conversion 
4 MeCN  No conversion 
5 MeCN Rose Bengal No conversion 
 
At this point, we turned our attention to using sulfinimine chemistry to generate 
isomyosmine. This route would require one more step but afforded the advantage of a 
possible asymmetric synthesis of NNN-5ʹ′-OAc.  
 
Scheme 2.31. Grignard addition to sulfinimine 
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Generating the racemic sulfinamide MIS086 was straightforward (Scheme 
2.31).64 Using catalytic pyridinium p-toluenesulfonate and magnesium sulfate as a 
dehydrating agent, imine formation from pyridine-3-carboxaldehyde proceeded in 
quantitative yield at room temperature overnight, or until judged complete by TLC. 
Grignard addition at low temperature overnight to the sulfinimine gave the desired 
sulfinamide MIS087 in good yield. The product was isolated after column 
chromatography as a single diastereomer as determined by 1H and 13C NMR. X-ray 
crystallography on a single crystal showed either (R,R) or (S,S) stereochemical 
configuration (Figure 2.3).  
 
Figure 2.3. X-ray structue of MIS087 showing the atom labeling scheme. 
Displacement ellipsoids are scaled to the 50% probability level. 
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Scheme 2.32. Deprotection of MIS087 to generate isomyosmine 
Deprotection of MIS087 using trifluoroacetic acid yielded isomyosmine in 
quantitative yield. The isomyosmine was not stable to silica gel chromatography unless 
the silica was neutralized by washing the column with 0.5% triethylamine in the column 
eluent. A preferred method for purification used Fluorisil as the solid support for 
chromatography, which gave better separation than neutralized silica. Basic alumina also 
did not cause decomposition but did not provide good separation. Upon obtaining 
characterization data for the isomyosmine, we noticed a discrepancy between our 13C 
NMR data and the previously reported spectral data. 1H NMR data was identical in the 
prepared compound to both previous reports.26,27 The only previous 13C NMR 
characterization by Campos et al. reported the following 13C NMR (75 MHz, CDCl3): δ 
168.2, 154.8, 149.6, 148.2, 136.4, 130.1, 73.5, 37.5, 30.1.27 Our 13C NMR data was 
similar, but not identical: (75 MHz, CDCl3) δ 168.3, 148.2, 139.3, 133.9, 123.4, 73.5, 
61.5, 37.5, 30.1. Our compound lacked peaks at 154.8, 149.6, 136.4, and 130.1 but had 
peaks at 139.3, 133.9, 123.4, and 61.5. The pyrroline contains 9 carbons; so first we 
acquired 13C NMR in different solvents, as the peak at 148.2 was twice the height of other 
peaks. The peak resolved in both d6-benzene (148.8 and 148.5) and d2-DCM (148.6 and 
148.4). Along our synthetic route, the aromatic carbons of each intermediate had similar 
chemical shifts. In an e-mail communication to clarify the ambiguity, Soldevilla suggests 
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that because limited quantities were prepared in the vacuum thermolysis, the data 
presented here is likely the correct 13C NMR spectrum.65 
The nitro-acylation of isomyosmine gave the desired product in somewhat low 
yields, which were dependent on the reaction temperature. The maximum yields were 
obtained between 5 °C and 15 °C (Table 2.2). 
 
 
Scheme 2.33. Optimization of temperature for nitroso-acylation of isomyosmine 
Table 2.2. Optimization of temperature for nitroso-acylation. 








Scheme 2.34. Deprotection of MIS087 followed by nitroso-acylation. 
To our pleasure, the isomyosmine could be subjected without purification to 
nitroso-acylation to generate the NNN-5ʹ′-OAc in four steps in a 30% overall yield 
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(Scheme 2.34). Purification of isomyosmine did not improve the combined yield of the 
two steps. The 1H NMR was consistent with the literature data, but it showed a mixture of 
what we believe to be rotamers and diastereomers (Figure 2.4). 
 
Figure 2.4. Possible isomers and conformers of NNN-5ʹ′-OAc. 
In order to confirm that the isolated NNN-5ʹ′-OAc was in fact a mixture of 
isomers, we first tried to use VT-NMR to cause the proposed rotamers to converge. 
Unfortunately, NNN-5ʹ′-OAc is not thermally stable, decomposing at room temperature 
over extended periods. A sample in deuterio-chloroform was heated to 50 °C, but no 
convergence was observed. In a second attempt to establish that the mixture was 
isomeric, liquid chromatography-mass spectrometry (LC-MS) was obtained. The mass 
spectrum shows that the major component, which comprises 93% of the sample as 
determined by UV-Vis detection on the LC, has m/z of 236, which corresponds to the 
mass of NNN-5ʹ′-OAc (Figure 2.6). Neither this reverse-phase column nor C8 or SiO2 
HPLC columns showed resolution into multiple peaks. Although the proposed 
diastereomers and rotamers could not be resolved, the sample showed a single peak with 
uniform m/z at all timepoints examined.  
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Figure 2.5. LC-MS analysis of NNN-5ʹ′-OAc. 
Top: Total ion current; middle: MS on major component (93%; m/z 236); bottom: 
MS on minor component (7%, m/z 211). 
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Figure 2.6. LC chromatogram of NNN-5ʹ′-OAc using 254 nm UV detection showing ratio 
of 93:7 NNN-OAc isomers to minor component. 
Overall, this synthesis of (±)-NNN-5ʹ′-OAc proceeded in good yield and was 
amenable to medium scale synthesis. No significant loss in yield was noted upon 
increasing the scale of the first three steps to >1 g. For the final step increasing the scale 
to 600 mg led to a decreased yield of 17%, but this is likely because of the increased 
exothermicity of the NaNO2 addition. Portionwise addition of the sodium nitrite would 
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likely lead to more consistent internal temperature and increased yields. The route is four 
steps, with three chromatographic purifications, and proceeds in >30% overall yield.  
 
 
Scheme 2.35. Total synthesis of NNN-5ʹ′-OAc. 
2.4. INTERACTION OF NNN-5ʹ′-OAC WITH DNA IN PRESENCE OF PIG LIVER 
ESTERASE 
2.4.1. Simple enzymatic hydrolysis in absence of nucleosides 
With ready access to multigram quantities of NNN-5ʹ′-OAc, preliminary studies 
on its interactions with DNA and single nucleosides were performed. First, NNN-5ʹ′-OAc 
was subjected to hydrolysis in neutral (pH 7) sodium phosphate with pig liver esterase in 
the absence of DNA or nucleosides, which provided conversion to a new compound, 
observable by TLC as a new spot. We theorized that this compound resulted from 
trapping the tetrahydrofuranyl cation with water to deliver a 2-hydroxytetrahydrofuran. 
During the hydrolysis, gas evolution was observed, supporting the idea that N2 was 
evolved. 
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Unambiguous characterization of the proposed hydrolysis product was difficult 
due to its high water solubility and poor stability to chromatography; so, the proposed 
intermediate was independently synthesized. Grignard addition to 3-pyridine 
carboxaldehyde generates the alcohol, which can be deprotected in aqueous acid to 
generate the cyclic hemiacetal (Scheme 2.36). Interestingly, MIS096 and MIS 097 have 
the same Rf, so the reaction appears not to work as judged by TLC analysis.  
 
 
Scheme 2.36. Independent synthesis of hydrolyzed NNN-5ʹ′-OAc 
The synthetic product was identical to the product of NNN-5ʹ′-OAc hydrolysis by 
1H NMR, TLC, and LRMS. 
 
Scheme 2.37. Proposed mechanism for hydrolysis of NNN-5ʹ′-OAc in presence of PLE. 
2.4.2. Incubations of NNN-5ʹ′-OAc and PLE with single nucleosides 
Adducts of deoxyguanosine and NNN-5ʹ′-OAc formed via incubation of the NNN-
5ʹ′-OAc with 2-deoxyguanosine or calf thymus DNA in presence of PLE have been 
reported by Hecht et al.21 Following incubation with the NNN-5ʹ′-OAc and PLE, calf 
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thymus DNA was then digested either thermally or enzymatically, and the products were 
compared to independently synthesized authentic samples using LC-MS with selective 
ion monitoring (SIM).  
 
Scheme 2.38. Adduction of 2-deoxyguanosine by NNN-5ʹ′-OAc.21 
We performed similar incubations of NNN-5ʹ′-OAc with single bases (guanosine, 
adenosine, thymidine, cytidine) in neutral sodium phosphate in presence of pig liver 
esterase, which were analyzed by electrospray impact mass spectrometry (ESI-MS) by 
Ms. Suncerae Smith in the Brodbelt group at the University of Texas at Austin.1 Mass 
spectrometric analysis of the incubation of guanosine with NNN-5ʹ′-OAc in the presence 
of pig liver esterase shows significant adduct formation (Figure 2.7). Preliminary ESI-MS 
shows m/z commensurate with the previously reported guanosine adduct.66  
                                                
1 All ESI-MS spectra were provided by Ms. Suncerae Smith, Brodbelt Research Group, UT-Austin 
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Figure 2.7. ESI-MS of incubation of guanosine with NNN-5ʹ′-OAc in presence of PLE. 
 
 
Figure 2.8. ESI-MS of incubation of adenosine with NNN-5ʹ′-OAc in the presence of PLE 
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Figure 2.9. ESI-MS of incubation of cytidine with NNN-5ʹ′-OAc in the presence of PLE. 
 
 
Figure 2.10. ESI-MS of incubation of NNN-5ʹ′-OAc with thymidine in presence of PLE 
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Incubation of NNN-5ʹ′-OAc with adenosine affords a product whose ESI-MS 
displays a peak having the mass of the proposed NNN-adduct, albeit at a low intensity 
with respect to the peak corresponding to unmodified adenosine (Figure 2.8).67 Mass 
spectrometric analysis of the incubation of cytidine with NNN-5ʹ′-OAc also shows a peak 
that might represent a covalent modification (Figure 2.9).67 ESI-MS analysis of 
incubation of thymidine in presence of NNN-5ʹ′-OAc and pig liver esterase did not show 
any peaks corresponding to proposed adducts (Figure 2.10). In summary, the ESI-MS 
suggests formation of covalent DNA adducts not only at guanosines but also at 
adenosines and cytidines. Subsequent to this work, Hecht et al. published further 
investigations on the interaction of NNN-5ʹ′-OAc with single bases.66 They reported 
adducts with guanosine, adenosine, and thymidine, and characterized them by 
comparison with independently synthesized authentic samples (Figure 2.11). 
 
 
Figure 2.11. Adducts of NNN-5ʹ′-OAc with G, A, and T characterized by Hecht et al.66 
2.4.3. Incubations of NNN-5ʹ′-OAc and PLE with short oligomer 
To study sequence selectivity of the DNA adduct formation NNN-5ʹ′-OAc, the 
compound was incubated with short synthetic deoxyribonucleotides (5ʹ′-
CCGCGTCCGCG-3ʹ′ duplex with complement, 11 base pairs).67 Incubations were 
performed in 0.1 M sodium phosphate at pH 7, using 10 µM DNA duplex (110 µM base 
pair) with 11 mM NNN-5ʹ′-OAc (100 equivalents per base pair).67 The reaction mixture 
was analyzed by ESI-MS, which showed ion peaks corresponding to predicted m/z of 
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mono, bis, and tris-adducted DNA (Figure 2.12). Collision-activated dissociation on an 
ion corresponding to adducted DNA showed that loss of associated NNN occurred more 
readily than loss of a nucleoside or cleavage of the phosphate backbone.  
 
Figure 2.12. ESI-MS on an incubation of 11-mer (10 µM duplex) with NNN-5ʹ′-OAc (11 
mM) in presence of pig liver esterase shows multiple adduction. 
 
Figure 2.13. CAD experiment on parent ion (*) from Figure 2.12. 
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In order to elucidate the sequence preference (if any) of the NNN-5ʹ′-OAc with 
this short oligomer, infrared multiphoton dissociation (IRMPD) experiments were 
performed by our collaborator, Ms. Smith. CAD and IRMPD on an ion corresponding to 
a 1:1 complex of the DNA oligomer and NNN at the (-5) charge state results in 
dissociation of the duplex-NNN ions into single strands. Both the upper and lower strands 
appear to be modified by NNN at the (-2) and (-3) charge states. Trapping and further 
fragmentation (MS3) of these ions results in the sequence information shown in Figure 
2.14. The fragmentation pattern shows that adduction occurs preferentially at guanosine, 
specifically the guanosines at the end of the oligomer. This might be due to poorly 
annealed ends of the duplex (“end effects”). A typical helical turn is comprised of 10 
bases, and proper annealing relies on hydrophobic stacking of the bases. An 11-mer lacks 
the length to have hydrophobic interactions reinforcing duplex formation, leading to 
slight fraying of the duplex structure. Single-stranded DNA is less sterically hindered 
than duplex DNA, which means that it is more susceptible to alkylation. 
 
Figure 2.14. Sequence information about the "upper" strand in the 11-mer duplex 
Table 2.3 shows a summary of the fragments containing the mass of the proposed 
organic NNN fragment.  The notation on Figure 2.14 is as follows: “a#” signifies 
fragments that begin at the 5ʹ′-position and include the specified number of bases. “w#” 
represents fragments that include the specified number of bases from the 3ʹ′ end of the 
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sequence. Fragments labeled “+NNN” include the proposed mass of the NNN addition. “-
B” indicates loss of the base but not the 2ʹ′-deoxyribose. Not every possible fragmentation 
is observed. The “a” fragments are consistent with modification at the 3ʹ′-terminal 
guanine position. The “w” fragments are consistent with modification at G or C within 
the 5ʹ′-CCGCG- portion of the sequence. Fragment 5 suggests that if modification is, in 
fact, occurring selectively at G, that the modification is occurring at the first 5ʹ′ G, 
because the “-B” indicates loss of the guanine at the 3ʹ′ end of that fragment, but the mass 
corresponding to NNN is retained.  
 












Figure 2.15. CAD and IRMPD spectra of the (-4) charge state of DNA singly adducted 
with NNN. 
Figure 2.15 shows the mass spectra of a singly modified oligomer and the NNN-
5ʹ′-OAc for the (-4) charge state.67 Again, the CAD spectrum (a) shows dissociation of the 
complex by loss of the NNN adduct, leaving the intact duplex. The IRMPD spectrum (b) 
of the same parent ion shows a variety of sequence ions, with two fragments retaining the 
adduct. Unfortunately, this fragmentation is insufficient to determine the position of 
adduction. 
With these encouraging ESI-MS results, we were interested in quantifying DNA 
adduction. In order to view adducts by the complementary technique, polyacrylamide gel 
electrophoreses (PAGE), a mobility shift assay was performed. This assay uses short 5ʹ′-
radiolabeled DNA to analyze whether adduct formation is occurring as evidenced by a 
decrease in electrophoretic mobility due to increased mass and/or charge of the modified 
DNA. A single-stranded 11-mer, 5ʹ′-CCGCGTCCGCG-3ʹ′ (one of the strands comprising 
the duplex used for the ESI-MS analysis), showed no change in mobility after a 16 h 
incubation with NNN-5ʹ′-OAc in the presence of pig liver esterase, indicating that either 
no covalent modification was occurring or that the modification does not cause a change 
 103 
in mobility. This was disappointing but not unexpected, as the reported adduct on 
guanosine was neutral, not charged.21  
 
Figure 2.16. EMSA on incubations of NNN-5ʹ′-OAc in presence of 11-mer and PLE. 
 Lane 1: ds-DNA; Lane 2: 10 mM NNN-OAc in presence of PLE; Lane 3: 100 
mM NNN-OAc in presence of PLE; Lane 4: 500 mM NNN-OAc in presence of PLE; 
Lane 5: 500 mM NNN-OAc without PLE; Lane 6: 500 mM NNN-OAc in presence of 
PLE with ss-DNA. 
The DNA was also assayed for cleavage following piperidine-heat treatment. In 
this experiment, a longer 5ʹ′-radiolabeled oligomer (227 bp, derived from PCR on a 
pUC19 plasmid) was incubated with the NNN-5ʹ′-OAc in presence of PLE, purified 
through ethanol precipitation to remove excess small molecule, and subjected to 
piperidine-heat treatment to cause cleavage. The lanes with NNN-OAc (Figure 2.17, left) 
do not show increased cleavage above background (Figure 2.17, right), whereas acrolein 




Figure 2.17. PAGE analysis of incubations of 227 bp DNA with acrolein or NNN-5ʹ′-OAc 
in presence of PLE. 
Lane 1: Maxam-Gilbert G; Lane 2: Maxam-Gilbert G+A; Lane 3: Maxam-Gilbert 
T+C; Lane 4: 100 mM NNN-OAc with PLE, no cleavage treatment; Lane 5: 100 mM 
NNN-OAc with PLE, then 10% aq. piperidine, 90 °C, 30 min.; Lane 6: 100 mM NNN-
OAc with PLE, then 20% aq. piperidine, 90 °C, 30 min.; Lane 7: 100 mM NNN-OAc 
with PLE, then 10% aq. piperidine, 90 °C, 3 h; Lane 8: 100 mM acrolein, no cleavage 
treatment; Lane 9: 100 mM acrolein, then 10% aq. piperidine, 90 °C, 30 min.; Lane 10: 
100 mM acrolein, then 20% aq. piperidine, 90 °C, 30 min.; Lane 11: 100 mM acrolein, 
then 10% aq. piperidine, 90 °C, 3 h; Lane 12: 100 mM acrolein with PLE, then 10% aq. 
piperidine, 90 °C, 30 min.; Lane 13: No drug, no cleavage treatment; Lane 14: No drug, 
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then 10% aq. piperidine, 90 °C, 30 min.; Lane 15: No drug, then 20% aq. piperidine, 90 
°C, 30 min.; Lane 16: No drug, then 10% aq. piperidine, 90 °C, 3 h. 
The proposed adduct might not be observed by gel electrophoresis for several 
reasons. First, N2 modification of guanosines does not usually lead to increased cleavage 
when the DNA is subjected to piperidine-heat treatment.69 This means that although the 
DNA is being adducted, no increased cleavage is observed by PAGE analysis. Second, 
the proposed adducts might be forming reversibly, so exposure to the piperidine-heat 
treatment or subsequent denaturing gel could cause reversion to unmodified DNA. Third, 
no adducts might be forming (which is unlikely, given the ESI-MS results). The first 
possibility is the most likely of the three, as the reported adduct is an N2-guanosine 
adduct, which is not usually susceptible to cleavage when subjected to piperidine/heat 
treatment.  
 
Scheme 2.39. Reversibility of NNN-5ʹ′-OAc adduct formation with guanosine 
In order to test the second possibility (adducts forming reversibly), we treated 
reaction mixtures with NaBH3CN to reduce the adducts, which has been shown to “fix” 
the reversible modification into an irreversible modification in the case of the known 





Figure 2.18. EMSA on 11-mer with NNN-5’-OAc in presence of PLE using various post-
incubation techniques to try to visualize adduct formation. 
Lane 1: 0 mM NNN-OAc with PLE; Lane 2: 10 mM NNN-OAc, 100 mM NNN-
OAc with PLE; Lane 4: 500 mM NNN-OAc with PLE; Lane 5: 500 mM NNN-OAc 
without PLE; Lane 6: 500 mM NNN-OAc with PLE and ss-DNA; Lane 7: 0 mM NNN-
OAc with PLE; Lane 8: 10 mM NNN-OAc, 100 mM NNN-OAc with PLE; Lane 9: 500 
mM NNN-OAc with PLE; Lane 10: 500 mM NNN-OAc without PLE; Lane 11: 500 mM 
NNN-OAc with PLE and ss-DNA; Lane 12: 500 mM NNN-OAc with PLE; Lane 13: 0 
mM NNN-OAc with PLE; Lane 14: 10 mM NNN-OAc, 100 mM NNN-OAc with PLE; 
Lane 15: 500 mM NNN-OAc with PLE; Lane 16: 500 mM NNN-OAc without PLE; 
Lane 17: 500 mM NNN-OAc with PLE and ss-DNA; Lane 18: 500 mM NNN-OAc with 
PLE. Lanes 1-6: EtOH precipitation. Lanes 7-12: EtOH precipitation, NaCH3CN 




In conclusion, a new method to synthesize NNN-OAc in a concise manner was 
developed. This method could be modified to enable asymmetric synthesis of NNN-OAc. 
Covalent modification of DNA by NNN-OAc was analyzed by ESI-MS, leading to the 
suggestion of previously unreported adenosine and cytidine adducts. Unfortunately, the 
preliminary PAGE analysis did not show any evidence of adduct formation. More 
complex techniques of analysis such as assays using repair enzymes or interrupted PCR 





THF was distilled over sodium/benzophenone, and CH2Cl2 and toluene were 
distilled from CaH2 immediately prior to use. All reactions were run in oven- dried, 
argon-flushed round bottom flasks under an argon atmosphere. Solvent ratios are 
expressed as % by volume. Flash chromatography (FCC) was performed according to the 
method of Still.70 NMR was performed using a VARIAN Mercury spectrometer. 1H NMR 
was run at 400 MHz; 13C NMR was run at 100 MHz with broadband proton decoupling 
unless otherwise specified. Solvent chemical shifts are reported in ppm (δ) and 
referenced to solvent.71 IR was obtained on a Nicolet IR100 FT-IR spectrometer. Melting 
points were obtained in open capillary tubes on a Büchi Melting Pont B-540 and are 
uncorrected. 
 
MIS089. Nicotinaldehyde (Pyridine-3-carboxaldehyde) (515 mg, 4.8 mmol, 1 eq) 
was combined with cyclopropylamine (1 mL, 14.4 mmol, 3 eq) in dry toluene (0.5 M) 
and stirred at 80 °C in the presence of 4 Å molecular sieves for 48 h. The reaction wass 
filtered and concentrated to give a pale yellow oil (550 mg, 2.6 mmol, 55%). 1H NMR 
(CDCl3): δ 8.80 (1H, d, J = 1.4); 8.60 (1H, dd, J = 4.8, 1.7); 8.46 (1H, s); 8.04 (1H, dt, J 
= 7.9, 1.0); 7.31 (1H, dd, J = 7.8, 4.8); 3.06 (1H, septet, J = 0.4); 1.02-0.96 (4H, m). 13C 
NMR (CDCl3): δ 155.2, 150.9, 149.6, 133.9, 132.0, 123.5, 42.2, 9.1. LRMS (CI+): 147 
(M++1). IR (thin film, CDCl3): 3442, 3012, 2965, 1634, 1421, 1387, 1320, 1024, 954, 
888, 809, 708 cm-1.27 
MIS090 was prepared in accordance with literature procedure (in the same 
manner as MIS089). Spectral data were consistent with the structure assigned.29  
(±)-tert-Butylsulfinamide9 
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A variation on the published route to the racemic sulfinamide was followed: 
oxidation of di-tert-butyldisulfide by hydrogen peroxide in AcOH10 afforded the tert-
butylthiosulfinate, which was then transformed to the tert-butyl sulfinyl chloride with 
SO2Cl2.  Subsequent reaction with NH4OH as reported9 gave the desired product. 1H, 13C, 








Butyl sulfinamide (400 mg, 3.3 mmol, 1 eq) was dissolved in dry CH2Cl2 (6.6 mL) in a 
10 mL round bottom flask.  MgSO4 (2.0 mg, 16.5 mmol, 5 eq) was added, followed by 
pyridinium p-toluenesulfonate (42 mg, 0.17 mmol, 0.05 eq).  3-Nicotinaldehyde (354 mg, 
3.3 mmol, 1 eq) was added neat. This cloudy colorless solution was stirred at room 
temperature for 16 h. The reaction mixture was filtered through Celite, washed with 
CH2Cl2, and concentrated to yield a yellow oil that was purified by flash chromatography 
(SiO2, 10–50% EtOAc/Hex) to yield the sulfinimine MIS086 as a yellow oil (680 mg, 3.2 
mmol, 98%). 1H NMR (400 MHz, CDCl3) δ 8.96 (1H, br s); 8.69 (1H, d, J = 4.8 Hz); 
8.59 (1H, s); 8.11 (1H, d, J = 8.2 Hz); 7.37 (1H, dd, J = 7.9, 5.2 Hz); 1.19 (9H, s). 13C 
NMR (75 MHz, CDCl3) δ 160.32, 152.79, 150.86, 135.60, 129.54, 123.83, 57.99, 22.48. 
LRMS (CI+): 211 (M++1), 155 (M-tBu). HRMS (CI+) calc. for C10H15N2OS 211.0905, 










(MIS087). Freshly ground magnesium turnings (1.56 g, 64.2 mmol, 15 eq) were placed 
in a 50 mL round bottom flask.  THF (7.1 mL, 3 M) was added. A solution of 2-(2’-
bromoethyl)-1,3-dioxane (1.62 mL, 21.4 mmol, 5 eq) in THF (21.4 mL, 3 M) was added 
dropwise. With intermittent heating and catalytic iodine (1 small crystal) to initiate the 
reaction, the mixture was stirred at room temperature for 1h. The Grignard reagent was 
then transferred via syringe to a clean oven-dried, Ar-flushed 100 mL round bottom flask 
to remove the excess Mg metal. This solution was cooled to -48 °C. The sulfinimine 
MIS086 (900 mg, 4.3 mmol, 1 eq) was added as a solution in THF (4.3 mL, 1 M) at -48 
°C. This mixture was stirred at this temperature overnight. After 16 h, the reaction was 
warmed to room temperature and quenched with satd NH4Cl. The reaction mixture was 
partitioned between satd NH4Cl and EtOAc. The aq. layer was extracted (2 x EtOAc), 
and the combined organic layers were washed with satd NaCl, and dried (Na2SO4).  After 
evaporation of the solvent, the product was purified by flash chromatography (SiO2, 10% 
MeOH in CH2Cl2) to yield MIS087 as a yellow oil (930 mg, 3.6 mmol, 85%). 
Crystallization from EtOAc/Hex yielded an analytical sample as a white crystalline solid. 
1H NMR (400 MHz, CDCl3): δ 8.55 (1H, br s); 8.51 (1H, d, J = 4.5 Hz), 7.65 (1H, d, J = 
7.9 Hz); 7.26 (1H, dd, J = 7.7, 5.5 Hz); 4.48 (1H, t, J = 5.0 Hz); 4.38 (1H, q, J = 6.8 Hz); 
4.04 (2H, dd, J = 11.7, 4.8 Hz); 3.70 (2H, t, J = 11.7 Hz); 3.57 (1H, d, J = 4.8 Hz), 2.05-
2.15 (2H, m); 1.95-2.05 (1H, m); 1.81-1.92 (1H, m); 1.53-1.63 (1H, m); 1.31 (1H, d of m, 
J = 13.3 Hz), 1.20 (9H, s). 13C NMR (75 MHz, CDCl3): δ 149.1, 148.7, 137.8, 134.8, 
123.6, 101.4, 66.8, 57.1, 56.0, 31.2, 30.9, 30.7, 25.6, 22.5. LRMS (CI+): 327 (M++1), 231 
(M+–pyr). HRMS (CI+) calc. for C16H27N2O3S: 327.1742, found: 327.1746. IR (thin film; 






(±)-5-(3-Pyridyl)-1-pyrroline ((±)-Isomyosmine)10. The sulfinamide MIS087 
(4.34 g , 13.3 mmol, 1 eq) was dissolved in 95% aq. TFA (67 mL, 0.2 M) and stirred at 
room temperature for 1 h. The reaction was quenched by pouring over saturated NaHCO3 
then extracted (4 x CHCl3).  The organic layers were combined, dried over Na2SO4, and 
concentrated by rotary evaporation. Chromatography on basic alumina (100% EtOAc) or 
Fluorisil (5% MeOH/CHCl3) yielded a brown oil (1.87 g, 13.9 mmol, quant.) whose 1H 
NMR spectral data were in accordance with literature values.12 13C NMR (CDCl3): 
δ 168.3, 148.2, 139.3, 133.9, 123.4, 73.5, 61.5, 37.5, 30.1. LRMS (CI+) 147 (M++1). 
HRMS (CI+) calc. for C9H11N2: 147.0922, found: 147.0923. IR (thin film): 3019, 2968, 







Isomyosmine (87 mg, 0.60 mmol, 1 eq) was dissolved in glacial acetic acid (1 
mL, 0.6 M) and cooled to 5 °C. NaNO2 (53 mg, 0.77 mmol, 1.3 eq) was added, and 
reaction mixture was allowed to warm to room temperature for 1 h (until complete as 
judged by TLC). The reaction was quenched by pouring over saturated NaHCO3 then 
extracted (3 x CHCl3), dried (Na2SO4), and conc. The resulting brown oil was passed 
immediately through a Fluorisil column using EtOAc as the eluent.  The resultant yellow 
oil was purified by flash chromatography (SiO2, 50–75% EtOAc/Hex) to yield a light 
yellow oil (48.2 mg, 0.22 mmol, 37%) whose 1H NMR, IR, and MS spectral data were in 
accordance with the literature values.5 Subsequent chromatography (SiO2, 75% 
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EtOAc/Hex) yielded an inseparable mixture of four diastereomers as a pale yellow solid, 
13C NMR (CDCl3): δ 169.5, 169.4, 148.8, 148.7, 147.8, 147.1, 135.0, 133.9, 133.5, 132.7, 
123.5, 123.4, 85.0, 83.8, 59.3, 58.5, 31.1, 30.5, 29.6, 29.5, 21.1, 21.0. mp 57.4-64.1 °C. 
 
3-[1,3]-dioxan-2-yl-1-pyridin-3-ylpropan-2-ol. MIS096. Freshly ground 
magnesium turnings (1.36 g, 56.0 mmol, 15 eq) were placed in a 100 mL oven-dried, Ar-
flushed round bottom flask.  THF (18.7 mL, 3 M) was added. A solution of 2-(2’-
bromoethyl)-1,3-dioxane (3.03 mL, 22.4 mmol, 1.2 eq) in THF (7.5 mL, 3 M) was added 
dropwise. With intermittent heating and catalytic iodine (1 small crystal) to initiate the 
reaction, the mixture was stirred at room temperature for 1 h. The Grignard reagent was 
then transferred via syringe to a clean oven-dried, Ar-flushed 100 mL round bottom flask 
to remove the excess Mg metal. This solution was cooled to -78 °C. The pyridine-3-
carboxaldehyde (2 g, 18.7 mmol, 1 eq) was added as a solution in THF (18.7 mL, 1 M) at 
-78 °C. This mixture was warmed to room temperature over 3 h then quenched with satd 
NH4Cl. The reaction mixture was partitioned between satd NH4Cl and EtOAc. The aq. 
layer was extracted (2 x EtOAc), and the combined organic layers were washed with satd 
NaCl, and dried (Na2SO4).  After evaporation of the solvent, the product was purified by 
flash chromatography (SiO2, 10% MeOH in CH2Cl2) to yield the product as a yellow oil 
(3.62 g, 16.2 mmol, 87%). 1H NMR (CDCl3): δ 8.52 (1H, s); 8.44 (1H, s); 7.70 (1H, d, J = 
8.0 Hz); 7.24 (1H, dd, J = 7.5, 4.9 Hz); 4.75 (1H, dd, J = 7.0, 5.7 Hz); 4.58 (1H, t, J = 4.7 
Hz); 4.10 (2H, ddd, J = 11.3, 3.5, 1.5 Hz); 3.76 (2H, tt, J = 12.1, 2.3 Hz); 2.06 (1H, m); 
1.87 (2H, m); 1.75 (2H, m); 1.34 (1H, d of quint, J = 13.5, 1.4 Hz). 13C NMR (CDCl3): 
δ 148.4, 147.7, 133.6, 124.0, 123.8, 101.7, 71.6, 66.9, 33.32, 31.3, 25.7. LRMS (CI+): 224 
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(M++1), 206 (M+-H2O). HRMS (CI+): calcd. for C12H17NO3: 224.1827, found 224.1827. 
IR (thin film from DCM): 3342 (br s), 2958, 2852, 2733 (m), 1655 (m), 1594, 1580, 
1471, 1428, 1379, 1287, 1143, 1088, 999. 
 
5-Pyridin-3-yltetrahydrofuran-2-ol.72 MIS 097. Acetal MIS 096 (110 mg, 0.49 
mmol, 1 eq) was stirred in 1 M H2SO4 (0.1 M with respect to acetal) overnight at room 
temperature. The reaction was neutralized to pH 7-8 using satd NaHCO3 (15 mL), then 
extracted with DCM (3x10 mL).  The combined organic layers were dried (Na2SO4) and 
concentrated. FCC yielded the desired product as a yellow oil comprised of a 1:1 mixture 
of diastereomers (58 mg, 0.35 mmol, 71%) 1H NMR (CDCl3): δ 8.67 (1H, d, J = 2.0 Hz); 
8.59 (1H, d, J = 2.3 Hz); 8.51 (2H, dt, J = 4.7, 1.8 Hz); 7.79 (1H, dt, J = 7.8, 1.7 Hz); 
7.64 (1H, dtd, J = 7.8, 2.1, 0.6 Hz); 7.27 (2H, m); 5.79 (1H, dd, J = 5.1, 2.2 Hz); 5.67 
(1H, dd, J = 4.1, 1.0 Hz); 5.27 (1H, t, J = 7.0 Hz); 5.03 (1H, m); 2.53 (1H, ddt, J = 12.3, 
8.2, 6.9 Hz); 2.35 (1H, m); 2.19 (1H, m); 2.09 (1H, m); 2.05 (1H, m); 1.78 (1H, m). 13C 
NMR (CDCl3): δ148.7, 148.6, 148.0, 147.6, 138.7, 138.0, 134.2, 133.4, 123.42, 123.35, 
99.0, 98.7, 80.3, 34.5, 33.1, 32.7, 32.6.  LRMS (CI+): 166 (M++1), 148 (M+-H2O) HRMS 
(CI+): calcd. for C9H11NO2: 166.0868, found 166.0869. IR (thin film from DCM): 3269 
(br s), 2951, 1686 (m), 1583 (m), 1430 (m), 1352 (m), 1042 (m), 982 (m).  
2.5.1. Chemical DNA Synthesis 
Synthesis was performed on an Expedite 8909 DNA synthesizer from PerSeptive 
Biosystems. Phosphoramidites, columns, and other related reagents were purchased from 
Glen Research. Syntheses were performed on a 1 µM scale using the “trityl on” method 
followed by purification on Poly-Pak II columns using the standard protocol. 












2.5.2. Preparation of Duplex DNA for ESI-MS 
Duplex DNA was formed by heating equimolar amounts (typically ~200 nmol 
scale) of the ss-DNA to 90 °C in 0.1 M sodium phosphate buffer (pH 7) for 5 min, then 
cooling slowly (over ~8 h) to 4 °C and held for at least 10 h at 4 °C.  
Duplexes were analyzed for purity by ESI-MS (Brodbelt group) and found to be 
sufficiently pure for further use. 
 
2.5.3. DNA synthesis by PCR 
T4 polynucleotide kinase was obtained from New England Biolabs. Taq 
polymerase and the nucleotide mix were purchased from Roche. [32P]- γ-ATP was 
purchased from GE Healthcare. Primers were synthesized (as above) and purified by 
native polyacrylamide gel (20%) using UV shadowing to visualize the DNA and 1X TE 
buffer to elute the DNA. P-6 spin columns were purchased from Bio-Rad. 
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Primer L151 was radiolabelled by combining L151 stock solution (1µL , 40 µM 
in TE buffer) with PNK buffer (3 µL), sterile H2O (19 µL), [32P]- γ-ATP (6 µL), and T4 
kinase (1 µL). This mixture was incubated at 37 °C for 1 h, at which time an additional 
T4 kinase (1 µL) was added and the reaction was incubated an additional 1 h at 37 °C. 
After incubation, the enzyme was inactivated by heating the reaction mixture to 65 °C for 
10 min. The DNA was isolated using P-6 spin columns according to the enclosed 
protocol.  
 
The volume of eluent was measured, and the radiolabelled primer was combined 
with R378 primer (1 µL, 40 µM), dNTP mix (1 µL), pUC 19 template (1 µL, 10 µg/µL), 
PCR buffer (5 µL), water (to 50 µL total reaction volume), and 0.5 µL Taq polymerase. 
This mixture was subjected to PCR (13 cycles) followed by purification using a 6% 
native polyacrylamide gel. DNA was visualized using film, and desired bands were 
eluted using 1X TE buffer.  
DNA was sequenced according to standard protocols.73 
 
2.5.4. DNA-Drug Incubations for ESI-MS 
DNA was synthesized and annealed as described above. Pig liver esterase was 
purchased from Biocatalytics Inc. as a solution in 1 M ammonium sulfate and used 
without further alteration.  
Duplex DNA in 0.1 M sodium phosphate was combined with sterile water and 
sodium phosphate (0.5 M, pH 7), then treated with the desired drug (vide supra) and 
(when required) pig liver esterase (stock solutions were prepared by dilution with 0.1 M 
sodium phosphate). NNN-OAc stock solution was prepared by dilution of a 5 M stock in 
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DMSO with 0.1 M sodium phosphate pH 7. Acrolein stock solutions were prepared by 
dissolving the acrolein in 0.1 M sodium phosphate. For incubations less than 50 µM total 
volume, 100 µL PCR tubes were used for the incubations. Samples were incubated 12-16 
h at 37 °C, then given to the Brodbelt group for analysis.  
 
2.5.5. DNA-Drug Incubations with Radiolabelled DNA 
DNA was prepared as described above. DNA (150,000 cpm per sample) was 
diluted with water and 0.5 M sodium phosphate (pH 7), then treated with the desired drug 
(vide supra) and pig liver esterase (where required; stock solutions were prepared by 
dilution with 0.1 M sodium phosphate). NNN-OAc stock solutions was prepared by 
dilution of a 5 M stock in DMSO with 0.1 M sodium phosphate. Acrolein stock solutions 
were prepared by dissolving the acrolein in 0.1 M sodium phosphate. Samples were 
incubated for 16 h at 37 °C in 1.5 mL Eppendorf tubes.  
Following incubation, samples were extracted 2x using CHCl3. The DNA was 
then precipitated by adding cold (-20 °C) EtOH (700 µL) to the aqueous phase. Samples 
were cooled at -20 °C for approx. 60 min. Samples were centrifuged at 15,000 x g for 5 
min. in the microcentrifuge. The supernatant was removed, and samples were rinsed 
twice with cold EtOH (200 µL). Samples were then redissolved in water (200 µL) with 3 
M sodium acetate (pH 5, 20 µL). Cold (-20 °C) EtOH (500 µL) was added, and the DNA 
was cooled to –20 °C for approx. 60 min. Samples were centrifuged at 15,000 x g for 5 
min. in the microcentrifuge. The supernatant was removed, and samples were rinsed 
twice with cold 70% aqueous EtOH (200 µL). Samples were then redissolved in water 
(200 µL) with 3 M sodium acetate (pH 5, 20 µL). Cold (-20 °C) EtOH (500 µL) was 
added, and the DNA was cooled to –20 °C for approx. 60 min. Samples were centrifuged 
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at 15,000 x g for 5 min. in the microcentrifuge. The supernatant was removed, and 
samples were rinsed twice with cold 70% aqueous EtOH (200 µL). 
The DNA samples were then subjected to piperidine/heat treatment. Each sample 
was dissolved in 10% aq. piperidine (10 µL) and heated to 90 °C for 30 min. Samples 
were concentrated by centrifuging in vacuo. To remove residual piperidine, samples were 
redissolved in water (30 µL), transferred to clean tubes, and concentrated by centrifuging 
in vacuo. Samples were again redissolved in water (20 µL) and concentrated. Cleavage 
was assayed by running 7% denaturing acrylamide gels using formamide loading buffer.  
 
2.5.6. Mobility Shift Assays 
Single-stranded DNA (synthesized as described above) was radiolabeled using T4 
polynucleotide kinase following the protocol described above. Following isolation using 
P6 spin columns, the DNA was concentrated by centrifuging in vacuo, then redissolved 
in 10% aq. piperidine. Samples were heated to 90 °C for 30 min, then concentrated on the 
Speedvac. Samples were transferred to clean tubes by washing twice with water (20 µL, 
then 10 µL) and were concentrated by centrifuging in vacuo. DNA was purified using a 
20% denaturing acrylamide gel. Film was used to visualize the DNA, and the desired 
band was eluted with 1X TE buffer. The DNA was then concentrated to a volume of 
~100 µL, treated with EtOH and cooled to –80 °C. Samples were centrifuged at 15,000 x 
g for 5 min, and the supernatant was removed. Samples were dissolved in 0.1 M sodium 
phosphate (pH 7) and an excess (2-3 fold) of the complementary strand was added. These 
samples were heated to 90 °C for 5 min, then cooled slowly to 4 °C and held at 4 °C for 
~12 h.  
 118 
For experiments using long, double-stranded DNA, a 227 bp DNA duplex was 
obtained by PCR on a pUC19 plasmid using 32P-labelled 5ʹ′ primer according to a 
previously reported procedure.74  
Incubations were performed in 0.1 M sodium phosphate at pH 7 using 50,000 
cpm per sample. NNN-OAc with PLE and acrolein were used in varying concentrations. 
Samples were incubated at 37 °C for 16 h. Samples were extracted with CHCl3 (50 µL), 
then precipitated twice with cold EtOH (as previously described). Samples were analyzed 
using a 20% denaturing gel and visualized using the phosphorimager.  
Acrolein shows cleavage at 100 mM concentration when 16 h incubation is 
followed by isolation of the DNA by ethanol precipitation and treatment with aqueous 
piperidine at 90 °C.  In the literature, in vivo cell experiments were performed using 30 
µM acrolein to induce DNA damage.68  
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3. Structure-Activity Relationships of a Series of Propargylic 
Alkynylbenzimizadolium Salts on Cytosine and 5-Methylcytosine 
3.1. BACKGROUND 
3.1.1. Aza-Enediynes 
 Much effort has been spent to improve upon the promising anticancer activity of 
enediyne natural products (see Section 1.4.3.1)1. One approach to improving the 
cytotoxicity and selectivity of aza-enediynes is to explore alternative diradical-generating 
cyclizations that may be triggered more selectively or give rise to diradical intermediates 
which are more selective in their interactions with DNA than the enediynes natural 
products. In the Kerwin group, the general approach to improved drug-like enediyne 
compounds has been to synthesize analogs in which a nitrogen atom replaces one of the 
sp2-hybridized carbons (aza-enediynes). In this chapter, a brief background of the 
previously reported chemistry and biology of aza-enediynes and related systems will be 
presented. This will be followed by a discussion of DNA methylation and the possible 
significance of DNA methylation status in the biological effects of a specific class of aza-
enediynes. After this introduction, studies of the interaction of a variety of DNA-
interactive agents with DNA, including aza-enediynes, will be described. The preparation 
and evaluation of a small library of benzimidazole-based “skipped” aza-enediynes will be 
provided. A final conclusion section will describe the significance of the DNA selectivity 
and structure-activity studies of benzimidazole “skipped” aza-enediynes presented here 
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3.1.2. Diradical-generating cyclizations 
There are several possible mechanisms for modification of DNA by the aza-
enediyne (Scheme 3.1). The first possibility is simple electrophilic modification. The 
ynamine portion of the molecule can serve as an electrophile and undergo 1,4 conjugate 
addition by a nucleoside base. The second possibility is that the azaenediyne can undergo 
a diradical-denerating cyclization and subsequently perform a hydrogen atom abstraction 
from the DNA.  
 
Scheme 3.1. Possible mechanisms for DNA modification by aza-enediyne 
Several diradical cyclizations are possible in azaenediyne and skipped 
azaenediyne systems. One potential cyclization motif for the azaenediynes is an aza-
Bergman cyclization (Scheme 3.2). The Bergman cyclization is a thermal rearrangement 
of a 1,2-dialkynyl olefin to a diradical p-benzyne, which can then be trapped with a H-
atom donor (Scheme 3.2).2 Extensive studies have been performed regarding synthetic 
enediynes and their requirements for Bergman cyclization.1 Computational analysis has 
also been used model of the energetics of the reaction. The initial estimated ΔH‡ for the 
transformation is 32 kcal/mol2, with later calculations suggesting that it was near 28 
kcal/mol.3,4 In 1998, calculations comparing the Bergman cyclization to the aza-Bergman 
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(and aza-Bergman with protonated imine nitrogen) found the results summarized in Table 
3.1.3,4 The authors note that the CASMP calculation places the diradical intermediate too 
low in energy, whereas the CASSF does better at estimating the energy of the diradical 
but overestimates the activation energy by approximately 10 kcal/mol.4 Both 
computational models suggest that protonation of the aza-enediyne raises the activation 
energy for the retro-aza-Bergman and, for the CASMP model, lowers the energy of the 
diradical intermediate significantly.  More recently, in 2008, Shields et al. performed 
extensive computational analysis of the activation energy for Bergman and aza-Bergman 
cyclizations on a wide variety of enediynes and azaenediynes.5 
 
Scheme 3.2. Bergman and aza-Bergman cyclization 
In 1997, Kerwin et al. published a study on the aza-Bergman cyclization of an 
aza-enediyne.6 Instead of forming the substituted pyridine ring, the aza-enediyne at 
elevated temperatures (benzene at reflux) yielded a β-alkynyl-acrylonitrile (Scheme 3.3) 
in 88% isolated yield.6 The authors propose that the cyclized diradical intermediate 
rapidly undergoes an intramoleular cycloreversion to form the rearranged product.6 The 
first-order rate constant of this transformation at 100 °C in acetonitrile was 2.43x10-4, a 
t1/2 of 47 min. a more rapid reaction that the Bergman cyclization, which has a half-life of 
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71 min at 280 °C in acetonitrile, indicating that the aza-enediyne has a lower activation 
energy.  
 
Scheme 3.3. Aza-Bergman followed by retro-aza-Bergman6 
In an attempt to trap the proposed diradical, a hydrogen atom donor, 
cyclohexadiene, was added to the reaction mixture (Scheme 3.4).6 No trapped product is 
observed, indicating that the expected trapping is approximately 1000x slower than the 
cycloreversion.6 In an attempt to use an intramolecular trap for the predicted diradical, an 
appendant styrene was added. The exclusive product was the rearranged product rather 
than the cyclized ring system.6 This study supports the idea that adding a heteroatom to 
an enediyne system could lower the activation energy of the cyclization reaction, but the 
retro-Bergman might proceed too rapidly for trapping reactions. Other substitution 
patterns on these dialkynylimine systems led to more complex mixtures thought to arise 




Scheme 3.4. Unsuccessful attempts to trap proposed 2,5-didehydropyridine intermediate 
of aza-Bergman cyclization6 
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Figure 3.1. Calculated energy for aza-Bergman and retro-aza-Bergmana BCCD(T)/cc-
pVTZ//(U)BLYP/cc-pVTZ level of theory bCCSD(T)/cc-pVTZ//(U)BLYP/cc-pVTZ level 
of theory c(U)BLYP/cc-pVTZ)T level of theory8 
	  
Table 3.1. Computational estimates for energies of Bergman cyclization3 








CASSCF(6x6) /6-31G* 39.8 10.0 39.8 - 
Bergman 
CASMP2(6x6)/6-31G* 34.8 -0.7 34.8 - 
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CASSCF(6x6) /6-31G* 33.2 0.5 7.3 -49.0 Aza-
Bergman CASMP2(6x6)/6-31G* 27.7 12.1 10.7 -32.6 
CASSCF(6x6) /6-31G* 32.5 2.1 22.5 -28.3 Protonated 
Aza-
Bergman 
CASMP2(6x6)/6-31G* 29.1 -11.8 28.6 -16.9 
 
Interestingly, calculations suggest that an aza-Bergman cyclization where the 
nitrogen of the ene-diyne is protonated would have a similar activation barrier to form the 
diradical but a much higher activation barrier for the retro-Bergman (Table 3.1). In the 
case of the Bergman cyclization, the cyclization and retro-cyclization are degenerate 
cases, so the overall ΔH and activation barriers are equal. In the case of the aza-Bergman 
cyclizations, the β-alkynylacrylonitrile is significantly lower in energy, so raising the 
activation energy for the cyclization should slow the reaction, possibly allowing trapping 
of the diradical intermediate. 
There are two possible sites of protonation on an aza-enediyne. The computations 
shown in Table 3.1 place the position of protonation of the enediyne at the nitrogen, not 
at the ynamine carbon, which is the more thermodynamically favored position (Scheme 
3.5). The energy required for protonation is determined computationally to be +2.5 
kcal/mol as compared to the neutral imine of formaldehyde as a reference molecule.9 
Also, protonation at N is predicted to perturb bond lengths, shortening the N-C single 
bond by 0.036 Å and lengthening the C-C triple bond α,β to the imine by 0.021 Å.9 This 
perturbation of bond lengths implies that conjugation of the system increases upon 
protonation at N.9 Cremer et al. also note that the positive charge on N resulting from 
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protonation can be localized through the conjugated π system, which contributes to its 
stabilization. 9,10 
 
Scheme 3.5. Position of protonation of aza-enediyne 
Kerwin et al. subsequently reported attempts to perform an aza-Bergman 
cyclization of a dialkynylimidazole.11 This system had two advantages compared to the 
original acyclic system. First, the imidazole ring should prevent the retro-aza-Bergman 
cyclization, because the β-alkynyl acrylonitrile cannot form. Second, this system might 
act as a protonated aza-enediyne, which would lower the energy of the proposed diradical 
intermediate, extending its lifetime to allow efficient trapping (Scheme 3.6).  
 
Scheme 3.6. Attempt to mimic a protonated aza-Bergman cyclization. 
Unfortunately, this system led to many isolated products under differing reaction 
conditions.12,13 It is possible that the aza-Bergman cyclization does occur, but the 
mechanism for formation of the observed products could not be unambiguously 
determined. The authors propose the pathways outlined in Scheme 3.7 as possible routes 
to the observed products.12  
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Scheme 3.7. Proposed mechanistic pathway for products observed in thermolysis of 
dialkynylimidazoles.12 
Kerwin and coworkers also explored an alternative diradical-generating 
cyclization by which “skipped” azaenediynes might modify DNA. Myers and Saito 
contemporaneously reported a cyclization of enyne-allenes to generate α,3-
dehydrotoluene (Scheme 3.8).14,15 The trapping of the purported intermediate has been 
interpreted to imply presence of either a diradical or zwitterionic intermediate.16,17 In a 
similar manner to the aza-enediyne cyclizations, Kerwin et al. used a propargylic imine 
(termed a “skipped aza-enydiyne” because of the methylene that disrupts conjugation), 18 
which they theorized could generate an enyne-allene under appropriate reaction 
conditions. They hoped that this aza-enyne-allene could undergo an aza-Myers-Saito 
cyclization to generate a α,3-diradical dehydrotoluene. 
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Scheme 3.8. Myers-Saito cyclization 
Experimental data show that the activation energy from the reactive conformer to 
the α,3-dehydrotoluene diradical is 21.8±0.5 kcal/mol.19 The overall ΔG for the 
transformation from the reactive conformer is -19 kcal/mol. Computations at varying 
levels of theory show activation energies (ΔG‡) ranging from 20-29 kcal/mol and the 
overall ΔG from 4 to -60 kcal/mol, with most results falling between -8 to -15.19  
Schmittel et al. report a variation on the Myers-Saito cyclization where a fulvene 
diradical is formed from the enyne-allene in a 2,6-diradical cyclization (Scheme 3.9).20 
Evidence for diradical generation has been observed in studies on electronic effects of 
substituents,20 kinetic isotope effect experiments,21 and use of radical clocks.22  
 
Scheme 3.9. Schmittel cyclization 
Computations at the (U)B3LYP/6-31G* level of theory suggest that the aza-
Myers cyclization has a lower activation energy and is slightly more exothermic than the 
corresponding Schmittel cyclization (Scheme 3.10).18 Kerwin et al. synthesized a skipped 
aza-enediyne that they envisioned isomerizing to the aza-enyneallene and undergoing 
either an aza-Schmittel or an aza-Myers Saito cyclization 18 Experimentally, the synthetic 
skipped aza-enediyne generate products that likely derive from trapping of a 2,6-
didehydropicoline diradical (Scheme 3.11).18  
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Scheme 3.10. Aza-Schmittel and Aza-Myers-Saito 
The resonances for the proposed allene intermediate were observed by 1H and 13C 
NMR.18 Products of trapping were observed at low temperatures. The half-life for a 
traditional Myers-Saito cyclization is 20.5 h at 39 °C,14 whereas the aza-variant readily 
proceeds at low temperatures, which correlates with the computed values suggesting that 
this cyclization should have lowered activation energy.18  
 
Scheme 3.11. Trapping products of an aza-Myers-Saito cyclization18 
3.1.3. Biological Activity of Azaenediynes 
Research in the Kerwin group has focused on synthesizing and evaluating 
compounds designed to undergo aza-variants of these diradical-generating reactions 
using both acyclic6,7,18 and cyclic11,23,24 backbones to induce DNA damage.24-26 Possible 
mechanisms for DNA damage (Scheme 3.12) include isomerization of a propargylic 
benzimidazole to the imine-allene followed by aza-Bergman or aza-Schmittel cyclization 
to generate the diradical. Alternatively, it is possible that simple electrophilic covalent 
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adduction might occur. One series that showed promise for its ability to induce DNA 
damage consistent with a radical process is a series of skipped dialkynyl pyridinium 
compounds (Figure 3.2).23The effective concentrations (Table 3.2) were determined by 
the nicking assay described in Section 1.3.4.1.  
 
Figure 3.2. Pyridinium skipped aza-enediyne library27 
Table 3.2. EC25 for pyridinium skipped aza-enediynes27 
Compound Number EC25 (µM) at pH 7 EC25 (µM) at pH 8 
AZB032 4.6±1.5 9.8±2.3 
AZB034 23.0±5.2 23.5±6.5 
AZB009 15.5±1.5 10.5±1.5 
AZB035 21.5±8.5 11.5±1.5 
AZB037 6.8±1.7 1.8±1.0 
AZB039 28.0±3.0 16.1±1.2 
AZB059 16.5±0.5 6.5±0.2 
AZB073 37.8±5.2 39.0±3.0 
AZB008 >100 >100 
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AZB072 >100 >100 
AZB071 nda >100 
AZB070 39.5±3.5 44.3±7.3 
AZB038 >100 >100 
AZB059 39.5±3.5 44.3±7.3 
a nd = not determined 
Comparison of AZB009, 035, and 037 shows a small electronic effect on nicking 
(Table 3.2), but the effect is not continued through compound AZB039, which has 3,4,5-
trimethyoxy substitution.23 The most electron-poor pyridinium (AZB035) appears to 
display the least DNA nicking ability. Compounds with both alkyne arms perform better 
at nicking than compounds where one arm is missing, although the N-propargyl appears 
to be more important for activity than the 2-alkynyl substituent. Adding a reductant, 
dithiothreitol, to the nicking reactions, inhibited DNA nicking by AZB037.23 This 
dialkynyl pyridinium also showed pH dependence, with cleavage increasing as pH 
increased.23 Changing the reaction pH from 7 to 8 (in 10 mM Tris buffer) caused a 3.8-
fold increase in nicking. The authors propose that the reactive species involves 
isomerization to the aza-enyneallene, which can be facilitated by base.23 More detailed 
studies showed that AZB037 causes DNA damage by two modes of reactivity.23 First, the 
dialkynylpyridinium was oxidizing guanosines to cause base-selective cleavage.23 
Second, AZB037 was causing frank strand breaks by abstraction of hydrogen atoms from 
the ribose units at either C4ʹ′ or C5ʹ′.  
Another system of skipped aza-enediynes reported by Kerwin et al. that showed 
promising biological activity is a series of benzimidazolium and benzothiazolium 
compounds. These compounds might cause damage via generation of a reactive diradical 
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species, but they could also simply serve as an electrophilic trap for a nucleotide base 
(Scheme 3.12). 
 
Scheme 3.12. Possible modes of DNA modification by propargyl 
alkynylbenzimidazolium AZB017 
The DNA cleavage ability of the propargyl alkynylbenzothiazolium triflate and 
tetrafluoroborate compounds (Figure 3.3) was evaluated in a nicking assay on supercoiled 
DNA, φX174. The supercoiled DNA showed varying degrees of cleavage to the relaxed 
form (Form II) at 100 µM concentrations of the compounds.24  
 
 
Figure 3.3. Propargyl alkynyl benzothiazolium salts and relevant control compounds 
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Table 3.3. Nicking ability of benzothiazolium salts at 100 µM24 
Compound % nicking at pH 8 % nicking at pH 9 
AZB007 30±19 40±13 
AZB014 33±18 42±1 
AZB010 20±4 33±5 
AZB012 7±4 7±1 
AZB004 39±15 48±15 
AZB014 2.7±0.7 Not determined 
AZB022 16±0.2 Not determined 
 
Neutral benzimidazole AZB001 did not show DNA cleavage, nor did AZB006, 
which contains only one alkyne; however, AZB002 showed complete DNA nicking 
(exclusively Form I) at 1 mM (Table 3.3).26 The benzimidazolium triflate and 
tetrafluoroborate compounds showed similar DNA nicking ability (Table 3.4), implying 
that changing the noncoordinating counterion does not change the activity of the 
compound.  
 
Figure 3.4. Benzimidazole compounds used in nicking assay 
Table 3.4. Nicking ability of benzimidazolium salts 
Compound % Nicking at 100 µM % Nicking at 1 mM 
AZB001 0 0 
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AZB002 30 96 
AZB017 33 100 
AZB006 0 4.5 
In order to determine what sort of DNA modification might be occurring (a 
radical process leading to H-atom abstraction, or simple electrophilic trapping), AZB017 
was combined with various nucleophiles (Scheme 3.13).26,28 A deuterium-exchange 
reaction shows that to deprotonate the propargylic position and facilitate isomerization to 
the aza-enyneallene, stronger bases (i.e. K2CO3) are required, whereas NaHCO3 in MeOH 
shows no nucleophilic addition and only trace conversion to the neutral benzimidazole.26 
Methanol over basica alumina was the only nucleophile that showed nucleophilic 
trapping.26 The fact that higher pH is required for deuterium-exchange to form the 
proposed allene and that simple 1,4-addition does not require high pH is consistent with 
both proposed mechanisms for DNA adduction. 
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Scheme 3.13. Possible outcomes of benzimidazolium with various nucleophiles 
Kerwin and Brodbelt et al. performed ESI-MS analysis on incubations of 
AZB017 with short oligomers.29 They report that AZB017 covalently modifies cytosines, 
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as evidenced by observation of a DNA+AZB017 peak for the oligomer dCT5 at pH 6 or 
8.29 It appeared that C-adduction occurrs more readily at pH 6 than at pH 8. When an 
oligomer without cytosine (dT6) was used, loss of mass corresponding to AZB017 was 
observed when the oligomer was subjected to CAD (collision-activated dissociation), 
implying that there was no covalent interaction, merely an association.29 This interaction 
might be due to electrostatic attraction between the anionic phosphate backbone and the 
cationic benzimidazolium ring. 
These skipped dialkynyl heteroaryl compounds have shown an interesting ability 
to modify DNA in a range of mechanisms with varying sequence selectivity. We hoped 
to harness this novel reactivity to target a post-transcriptional DNA modification, 
methylated cytosines. 
3.1.4. DNA Methylation 
3.1.4.1. Occurrence of Cytosine Methylation in Biological Systems 
More than 50 years after the elucidation of the structure of DNA, the epigenome 
is becoming a focus of research. The epigenome consists of chromatin and its 
modifications, both to its associated proteins and the DNA bases themselves.30,31 The 
epigenome is responsible for regulation of the genome and has been found to be variable 
in an organism both throughout cell types and over time.32 While chromatin protein 
modifications are common, modifications to DNA bases are relatively rare. One such 
modification of the bases of DNA, found in vertebrates,33 is the covalent modification of 
cytosine by addition of a methyl group at the 5 position of cytosines at CpG intervals.34 In 
mammalian cells, 3% to 5% of cytosines are methylated, depending on the cell type and 
growth stage.35  
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Figure 3.5. G-C base pair with unmodified cytosine (left) and 5-methylcytosine 
Until the recent discovery of a DNA demethylase,36 DNA methylation had been 
considered to be an irreversible process, whereby DNA is methylated according to a 
pattern predetermined during development and maintained through life. Newer research 
suggests that DNA methylation is dynamic, with DNA methyl transferase enzymes 
catalyzing transfer of a methyl group from a methyl donor, S-adenosyl methionine, to the 
5-position of cytosine35,37,38 and demethylases catalyzing removal of methyl groups from 
cytosine residues.36 While primary DNA sequence fidelity in mammals is over 99.999%, 
methylation patterns are reproduced with only 96-99% fidelity.39 DNA methylation 
occurs following transcription at CpG sites. In addition to being likely promoters of 
mutagenesis, methylated bases can also influence adduct formation by exogenous 
carcinogens.40 Mutations, permanent changes in the nucleotide sequence of DNA, lead to 
lowered fidelity in DNA replication and can be classified as either silent (having little or 
no observed effect on gene function), advantageous (which is rare), or deleterious.41 
 
Figure 3.6. DNA methylation following replication41 
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DNA methylation patterns are linked to cancer in two ways: hypermethylation of 
tumor suppressor genes and global hypomethylation of cancer cells.42,43 DNA 
hypermethylation at tumor suppressor genes silences genes in the same way as deletions 
or mutations, changing their expression or function.44 CpG methylation profiles are 
correlated not only with different types of cancer45-47 but also with staging of cancers and 
response to chemotherapy.42,45,48-50  
 
3.1.4.2. Effects of 5-Methylcytosine on Adduct Formation 
It is well-established that cytosine methylation affects position and frequency of 
adduct formation (mutations).51 This effect appears to depend on the size of the 
carcinogen and mechanism of adduction. Studies by Waring et al. show that methylation 
has a dramatic effect on DNA binding by intercalators.52 DNAse footprints of 
daunomycin and other known intercalators were compared using DNA containing 
methylated cytosines to DNA containing unmodified cytosines, uracils, or methylated 
uracils were compared. The methylated cytosines and uracils showed a previously 
unobserved footprint, or region of decreased cleavage, indicating that a new binding site 
was created (See Section 1.3.3).52 They propose that the change can be explained by 
changes in local structure, possibly a narrowing of the minor groove or a change in 
curvature. It has been shown by X-ray crystallography that the minor groove of DNA rich 
in 5-methyl cytosine has geometry resembling AT-rich DNA, not GC-rich.53 
Additionally, Waring et al. note that the methylation at cytosine should reduce the dipole 
moment of the GC base pair.52  
Effects of cytosine methylation have been studied on covalent DNA-drug 
interactions as well. Flanking methyl cytosines (MeCs) at CpG mutational hotspots on 
tumor suppressor gene p53 enhance the reactivity of guanine with benzo[α]pyrenediol 
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epoxides (BDPEs).54 In unmethylated regions of p53, the BDPE acts as a minor groove 
binder, whereas in methylated systems, the conformational changes caused by the 
additional methyl group cause BDPE to act as an intercalator, affecting covalent 
modification of the DNA. It has been shown that BDPEs preferentially form covalent 
adducts at methylated CpG sites corresponding to mutational hotspots on p53.55 In 
smoking-related lung cancers, p53 mutations are concentrated at methylated CpG sites, 
including codons 157, 158, 175, 245, 248, 273, and 282.56 Lung cancer shows a 
characteristic and unusual mutation where 40% of the total mutations are G→T 
transversions (commonly found at codon 157).40 Such a mutation is unusual because 
unlike G→A mutations (transitions), transversions involve replacement of a purine base 
with a pyrimidine base, but only 9% of mutations in lung cancer involve a transition.40 N-
Hydroxyl-4-aminobiphenyl has been shown to preferentially bind two hotspots on p53 at 
codons 175 and 248 only after the CpG sites are methylated.57 Additionally, acrolein 
exhibits enhanced adduct formation at guanosines complementary to methylated sites on 
exons 5 and 7 of p53 in a way that mimics mutational hotspots.51 In a similar study, 
Shank and coworkers used aflatoxin B1-8,9-epoxide as a probe to analyze effects of 
cytosine methylation on adduct formation.58 They did not observe increased adduct 
formation at guanines next to a MeC (either 5ʹ′ or 3ʹ′) in either a short 11-mer which 
contained one MeC site or a longer oligomer (a restriction fragment of the regulatory 
HRPT gene).58  
In non-small cell lung carcinoma, an unusually high number of non-CpG residues 
in GC rich regions are methylated.59 However, a report from Tretyakova et al. shows that 
methylation at cytosine has a protective effect on adduct formation at both the N7 or O6 
position of neighboring guanines, showing a 17-27% reduction on N7 adducts and a 65-
75% reduction on O6 adducts.60 The overall effects of methylation on DNA damage 
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remain unclear; some carcinogens form adducts with greater facility adjacent to 
methylated cytosines and some do not.  
In summary, the overall effects of methylation on adduct formation are unclear. 
Research involving adduct formation at these sites might be able to resolve issues 
involving carcinogenesis (e.g. genetic predisposition) and develop new therapeutic 
regimens which target these genes with unusual methylation status.  
 
3.2. PROPOSED RESEARCH: SELECTIVE TARGETING OF UNMETHYLATED 
CYTOSINES IN PRESENCE OF METHYLATED CYTOSINES 
Selectively targeting cytosines in presence of methylated cytosines might provide 
a more selective class of antineoplastic agents, given the hypomethylation found in 
cancer cells. We hoped to design compounds that would selectively modify unmethylated 
cytosines in presense of methylated cytosines. We planned to screen compounds that 
might exploit this difference by assaying their adduction to synthetic DNA, which allows 
incorporation of a methylated cytosine consistently at each CpG position. If any 
compounds showed promising selectivity, we planned to synthesize a small library to try 
to improve selectivity and activity. 
3.2.1. Kinetics 
Reaction of the radiolabeled DNA with the substituted electrophile should follow 
pseudo-first order kinetics. The concentration of labeled DNA will be very low (mid nM 
range) compared to the electrophile (mM range). Bimolecular (SN2) reactions proceed 
with second order kinetics, with the following rate equation:61 
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For this work, the DNA serves as the nucleophile, and a small molecule (“Drug”) 




But if the relative concentration of drug is unchanging with respect to DNA 




Also, for this experiment, “single-hit kinetics” is required. Because adduct 
formation is being analyzed using cleavage of radiolabeled DNA, multiple adductions 
will not be observed; only cleavage caused by adducts formed nearest to the 5ʹ′ 32P label 
can be observed and quantified.  
 
3.2.2. DNA Sequence Selection 
The DNA sequence we wanted to examine was a part of exon5 (codons 150-160) 
of the p53 tumor suppressor gene. Damage at codons 154, 157, and 158 (bold) are 
correlated with lung cancer.56,63 The sequence is as follows (underlined Cs are 
methylation sites):  
 5ʹ′-CAC-CCC-CGC-CCG-GCA-CCC-GCG-TCC-GCG-CCA-3ʹ′ 
 3ʹ′-GTG-GGG-GCG-GGC-CGT-GGG-CGC-AGG-CGC-GGT-5ʹ′ 
3.2.2.1. 11-mer Sequence  
We planned to generate the desired sequence, with appropriate methylation status, 
using an automated DNA synthesizer. In designing an oligomer to use as a model system, 
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a segment of exon 5 of the p53 gene was used. The first oligomers synthesized were a G-
C rich 11 base oligomer and its complement.  
5ʹ′-CCGCGTCCGCG-3ʹ′ 
3ʹ′-GGCGCAGGCGC-5ʹ′ 
This oligomer contains 8 CpG intervals (underlined), each of which would be 
methylated in vivo. For ease of ESI-MS analysis, multiple oligomers were synthesized, 
each with a single methyl cytosine (MeC) at a different CpG step. The cytosines close to 
the end of each strand were not modified because of concerns about “end effects,” in 
which the ends of each strand are not properly annealed. Each helical turn contains about 
10 bases, so the ends of such a short oligomer might show significant denaturation 
(fraying).  
The radiolabelled DNA and its unlabelled complement were annealed in 0.1 M 
sodium phosphate and analyzed by ESI-MS and non-denaturing gel. ESI-MS showed 
fully annealed duplex, but the gel showed no annealed DNA. The working concentrations 
(5 mM for ESI-MS, low nM for radiolabelling work) are very different, which may 
explain the problems annealing. Figure 3.7 shows a non-denaturing gel that shows no 
difference between single-stranded labeled DNA and DNA that had been heated and 
cooled with its complement. The predicted melting temperature of this oligomer was 91.1 
°C at 5 mM (in presence of 0.5 M Na+) and 50.5 °C at 1 nM (with 0.5 M Na+). Under 
conditions similar to the DNA-drug incubations, 1 nM DNA and 10 mM Na+, the 
predicted Tm is 31.1 °C. For incubations at 37 °C, the DNA would not be properly 
annealed.2 Because the initial ESI-MS work showed complete duplex formation, the 
annealing was analyzed by gel electrophoresis using non-denaturing PAGE (Figure 3.7). 
                                                
2 Tm estimated using OligoAnalyzer 3.1 from IDT (Integrated DNA Technologies), available online at 
www.idtdna.com. Error is ±1.4 °C. 
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Unfortunately, complete annealing was not observed under any conditions, and the 
duration of the electrophoresis did not appear to affect the outcome (Figure 3.7).  
 
 
Figure 3.7. Non-denaturing PAGE analysis of annealing of 12-mer. 
Lane 1: ss-oligomer, run 6 h; Lane 2: Attempt at annealing, run 6 h; Lane 3: ss-oligomer, 
run 3 h; Lane 4: Attempt at annealing, run 3 h; Lane 5: ss-oligomer, run 1.5 h; Lane 6: 
Attempt at annealing, run 1.5 h. 
3.2.2.2. Second DNA Sequence 
To improve annealing by raising temperature at which the oligomer denatures 
(Tm), a 22-mer was synthesized. It includes a repeat of the original 11-mer sequence. Two 
upper strands were synthesized, one that was unmethylated at both the 5ʹ′ repeat and the 3ʹ′ 
repeat, and one where the 5ʹ′ repeat was methylated at all CpG steps. The complement 
was unmethylated at the 5ʹ′ end and permethylated at the 3ʹ′ end (at CpG steps as read 5ʹ′ to 
3ʹ′). An advantage to this system is that it is possible to have both an internal control (the 
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unmethylated half of the sequence) and both hemimethylated and bismethylated duplexes 
at the 5ʹ′ end of the sequence (with respect to the upper strand).  
Unmethylated upper sequence 
5ʹ′-CCGCGTCCGCGCCGCGTCCGCG-3ʹ′ 
3ʹ′-GGCMeGMeCAGGMeCGMeC  GGCGCAGGCGC-5ʹ′ 




The predicted Tm of this duplex is 73.6 °C at 1 nM DNA in the presence of 0.1 
mM Na+, and it increases to 79.9 °C in the presence of 1 M Na+.3 This DNA, which 
contains 90.9% by mass GC content, annealed fully using 1X TE (10 mM Tris, 1 mM 
EDTA) with 0.5 M NaCl (Figure 3.8).  
 
Figure 3.8. Annealing of 22-mer. 
                                                
3 Tm estimated using OligoAnalyzer 3.1 from IDT (Integrated DNA Technologies), available online at 
www.idtdna.com. Error is ±1.4 °C. 
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 Lane 1: Annealed methylated 22-mer using 1X TE, 0.5 M NaCl; Lane 2: 
Annealed 22-mer using 1X TE; 0.5 M NaCl; Lane 3: Annealed methylated 22-mer using 
1X TE; Lane 4: Partially annealed unmethylated 22-mer using 1X TE; Lane 5: Single-
stranded methylated 22-mer; Lane 6: single-stranded unmethylated 22-mer. 
3.2.3. Small Molecule-DNA Interactions 
With a suitable duplex in hand, we began to screen small molecules for their 
potential to modify methylated DNA differently than unmethylated DNA. The DNA was 
labeled at the 5ʹ′ end by polynucleotide kinase, which removes the labeled phosphate from 
[γ-32P]-ATP (adenosine triphosphate) and adds it to the 5ʹ′-hydroxyl group of the synthetic 
oligomer.64 This labeled oligomer was then PAGE-purified to remove excess 32P-ATP 
and short, labeled oligomers (fail sequences from DNA synthesis). The purified oligomer 
was then annealed to its complement and incubated with an electrophile. There are 
several ways to analyze the position of adduct formation (See Section 1.3), but 
piperidine/heat treatment was chosen because it is operationally the most simple. It 
cleaves the phosphate backbone of the DNA, allowing mapping of modification based on 
the fragmentation pattern. The pattern of fragmentation can then be compared to results 
from Maxam-Gilbert sequencing, a series of base-specific reactions (Section 1.2).65 
Radiolabeling uses very small quantities of DNA (pmols) and affords excellent 
sensitivity.  
3.2.3.1. Guanosine-Selective Alkylating Agents 
N7 modifications on guanosines lead to enhanced cleavage under piperidine-heat 
treatment (Scheme 3.14, also Section 1.3.1). Other modifications may or may not lead to 
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Scheme 3.14. Modification of guanosine N7, followed by piperidine/heat treatment 
After optimizing a model oligomer system, we began our search for compounds 
that would differentially modify DNA containing methylated and unmethylated cytosines 
using compounds that could easily be modified electronically. Styrene oxide is known to 
modify guanosines at N7 (as well as other positions depending on conditions and 
substituents on the aromatic ring).66,67 Benzyl bromide is an effective alkylating agent, 
with many analogs commercially available. Acrolein was used as a positive control, 
because it has recently been reported not only to modify guanosines, but to show a 2-4-
fold increase in adduct formation at guanosines complementary to MeC.51 Cleavage was 
normalized according to Equation 3.1. 
Equation 3.1. Normalization of % cleavage 
€ 







Benzyl bromide Styrene oxide
 
Figure 3.9. Benzyl bromide and styrene oxide 
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Figure 3.10. Incubation of acrolein, styrene oxide, and benzyl bromide with 22-mer in 50 
mM sodium phosphate, pH 6. 
Lane 1: Maxam-Gilbert G; Lane 2: Maxam-Gilbert C; Lane 3: no drug; Lane 4: 1 
mM acrolein; Lane 5: 10 mM acrolein; Lane 6: 100 mM acrolein; Lane 7: 1 mM styrene 
oxide; Lane 8: 10 mM styrene oxide; Lane 9: 100 mM styrene oxide; Lane 10: 1 mM 
benzyl bromide; Lane 11: 10 mM benzyl bromide; Lane 12: 100 mM styrene oxide. 
Lower arrow denotes modification across from and adjacent to MeC; Upper arrow is 
same local sequence with no methylation 
 
Table 3.5. Quantitation of DNA cleavage following incubation and piperidine/heat 
treatment with various alkylating agents. 




100 mM benzyl 
bromide 
1 mM benzyl 
bromide 
 153 
Unmethylated 2.5 19.5 2.1 12.6 
Methylated 1.9 31.4 2.2 18.0 
 
Unfortunately, little difference was observed in adduct formation at guanosines 
complementary to MeCs when compared to Cs (Figure 3.10) for benzyl bromide. The blue 
arrows show two sites with the same surrounding sequence in each repeat unit. At high 
concentrations, adduct formation occurs at multiple sites, leading to higher concentrations 
of small fragments. Acrolein has been reported to form adducts 2-4 times more frequently 
at methylated positions.18 A similar phenomenon is observed here, but the structure of 
acrolein is not easily modified to allow a systematic study. In order to find a suitable 
probe, several compounds previously synthesized by the Kerwin group were analyzed, 
including CRW054 and AZB004 (Figure 3.13). AZB004 had been shown to be active in 
the nicking assay, and while it did show modification at guanosines, there was only a 
small appreciable difference in modification of guanosines on the methylated half of the 
oligomer vs. the unmethylated portion. However, a larger difference in cleavage at 














Figure 3.12. AZB004 with 22-mer DNA in 50 mM sodium phosphate, pH 6. 
Lane 1: Maxam-Gilbert G; Lane 2: Maxam-Gilbert C; Lane 3: No drug; Lane 4: 
10 µM drug; Lane 5: 100 µM AZB004; Lane 6: 1 mM AZB004; Lane 7: 10 mM 
AZB004. Lower arrow denotes modification across from and adjacent to MeC; Upper 
arrow is same local sequence with no methylation 
Table 3.6. Quantitation of cleavage induced by piperidine/heat treatment of DNA 
incubated with AZB004 
Position Modified 100 µM 1 mM  
G on unmethylated portion of DNA 12 21 
C on unmethylated portion of DNA 6 14 
G on methylated portion of DNA 14 30 
C on unmethylated portion of DNA 4 8 
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The apparent difference in adduct formation for CRW054 can be attributed to the 
unusually high level of cleavage at G3, which raises the average cleavage from 14% to 
21%.  
 
Figure 3.13. CRW054 incubated with 22-mer in 50 mM sodium phosphate at pH 8.  
Lane 1: No drug; Lane 2: 10 µM CRW054; Lane 3: 100 µM CRW054; Lane 4: 1 
mM CRW054; Lane 5: 10 mM CRW054; Lane 6 Maxam-Gilbert G; Lane 7 Maxam-
Gilbert C. Lower arrow denotes modification across from and adjacent to MeC; Upper 
arrow is same local sequence with no methylation 
Table 3.7. Quantitation of DNA cleavage induced by piperidine/heat treatment following 
incubation of DNA with CRW054 
Position Modified pH 8, 100 µM pH 8, 1 mM  
G on unmethylated DNA 1 11 
G on methylated DNA 0 21 
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While these results were encouraging, the differences in methylated and unmethylated 
DNA were less pronounced than we hoped. We theorized that effects at complementary 
and adjacent guanosines were smaller than if DNA modification were occurring at 
cytosine itself.  
3.2.3.2. Cytosine-Selective DNA Modification 
AZB017 (Figure 3.14) was previously reported to modify DNA at Cs, so this 
compound appeared a likely candidate for showing a difference in adduct formation with 
varying methylation status.68 DNA modification occurs on G at pH 8, and C (with some 







Figure 3.14. AZB017 
  
Figure 3.15. Incubations of AZB017 with unmethylated or methylated DNA in 50 mM 
sodium phosphate at pH 6 or pH 8. 
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Lanes 1-7, unmethylated DNA. Lanes 12-18, methylated DNA. Lane 1: no drug, 
pH 6; Lane 2: 10 µM AZB017 pH 6; Lane 3: 100 µM AZB017 pH 6; Lane 4: 1 mM 
AZB017 pH 6; Lane 5: 10 µM AZB017 pH 8; Lane 6: 100 µM AZB017 pH 8; Lane 7: 1 
mM AZB017, pH 8; Lane 12: no drug, pH 6; Lane 13: 10 µM AZB017 pH 6; Lane14: 
100 µM AZB017 pH 6; Lane 15: 1 mM AZB017 pH 6; Lane 16: 10 µM AZB017 pH 8; 
Lane 17: 100 µM AZB017 pH 8; Lane 18: 1 mM AZB017, pH 8. 
 
Encouragingly, AZB017 does show a marked difference in adduct formation at 
MeCs compared to Cs (Figure 3.15). The extent of guanosine modification shows no 
appreciable difference. At the highest concentration shown, 1 mM AZB017 at pH 6, we 
observe a 10-fold increase in the level of DNA cleavage at methylated cytosines 




Synthesis of several AZB017 analogs would allow us to explore structure-activity 
relationships of cytosine adduction. This will allow a second generation of compounds 
that could effectively target unmethylated cytosines preferentially. Also, this set of 
analogs might show some electronic effects of cytosine methylation on DNA adduction. 
 
Scheme 3.15. Proposed AZB017 analog synthesis 
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Substituents 4-OMe, 4-Me, 4-F, and 4-CF3 were chosen for their range of 
electronic properties. Although this route (Scheme 3.15) is limited to benzimidazoles 
with identical alkynyl substituents, it allows rapid synthesis of the compounds of interest.  
The propargyl aldehydes were synthesized according to literature procedure 
(Scheme 3.16),70 using deprotonation of the appropriate terminal acetylene with n-BuLi at 
-40 °C, followed by immediate addition of N,N-dimethylformamide (DMF) at -40 °C. 
The resultant mixture was then warmed to room temperature and quenched by pouring 
the reaction over aqueous monobasic potassium phosphate at 0 °C. This method worked 
best for electron-rich phenylacetylenes but gave only moderate yields for the electron-
poor substrates (yields are an average of two trials). These propargyl aldehydes were then 
condensed onto 1,2-phenylenediamine with formic acid in toluene at reflux for 3 days 
(Scheme 3.16).28 This transformation proceeded in modest yield, giving the desired 
benzimidazoles in yields from 24-34%.  
 
Scheme 3.16. Synthesis of benzimidazoles 
Previous work in the Kerwin lab suggested that using methyl triflate might be 
incompatible with the p-MeO skipped dialkynyl benzimidazole;28 so, methylation was 
attempted using trimethyloxonium tetrafluoroborate (Scheme 3.17). These 
transformations appeared to generate the desired product (as determined based on TLC 
and 1H NMR), but methylation of AZB244, AZB344 or AZB345 proved difficult to 
purify by either recrystallization or chromatography.  
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Scheme 3.17. Initial methylation strategy 
 Methylation of the dialkynylbenzimidazoles using methyl triflate proceeded 
smoothly in all cases, albeit with diminished yield for the p-MeO substrate (Scheme 
3.18).28 The products were isolated by filtration from the reaction mixture and were 
purified by recrystallization from 1,2-dichloroethane (DCE) and diethyl ether, followed 
by recrystallization (with hot filtration) from DCM and hexanes to give analytically pure 
compounds. Compound AZB349 proved to be somewhat unstable in solution unless 
oxygen was rigorously excluded, so solvents were deoxygenated by sparging with argon 
prior to use.  
 
Scheme 3.18. Synthesis of methylated benzimidazolium salts 
Interestingly, compound AZB380 underwent spontaneous cyclization during either 
methylation or recrystallization. NMR, MS, and IR were consistent with the structure 
shown in Scheme 3.19. 
 160 
 
Scheme 3.19. Cyclization of AZB380. 
3.4. BIOLOGICAL EVALUATION OF AZB LIBRARY 
We had originally hoped to use ESI-MS to sequence the position and frequency of 



















AZB348AZB349 AZB347AZB017  
Figure 3.16. Benzimidazolium library 
Nicking assays were performed to ascertain the extent of DNA damage by the 
skipped azaenediyne benzimidazolium salts. Each compound was incubated with 
supercoiled plasmid φX174 DNA (50 µM bp) in 50 mM Tris (pH 8) with the compound 
added as 10X solution in DMSO. The control reaction included DMSO in the same 
proportion, 10% by volume, as the other incubations. The final incubation volume as 30 
µL, as that volume was shown to be the minimum required volume to have consistent 
results despite water evaporation over the time of the incubation.28 Cleavage was 
calculated according to Equation 3.2. 
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Equation 3.2. Determination of % Nicking 
€ 
%Nicking =100 × 2(FormIII) + FormII
2(FormIII) + FormII + FormI  
 
In order to account for nicking not caused by the compounds of interest, 
normalized percent nicking was determined according to Equation 3.3. 
 
Equation 3.3. Normalization of % Nicking 
€ 
Normalized% Nicking =100 ×
% cleavagedrug −% cleavagecontrol
100 −% cleavagecontrol  
 
 
Figure 3.17. Nicking assay on φX174 using skipped benzimidazolium triflates at 0.1 mM 
in 50 mM Tris, pH 8. 




Figure 3.18. Nicking assay on φX174 using skipped benzimidazolium triflates at 1.0 mM 
in 50 mM Tris, pH 8. 
Lane 1: No drug, Lane 2: AZB349; Lane 3: AZB348; Lane 4: AZB017; Lane 5: 
AZB347.
 
Results are summarized in Table 3.8. At 1 mM, in presence of the electron-rich 
compounds AZB349 and AZB348, no DNA could be observed using ethidium bromide 
stain. The compounds themselves appeared to migrate towards the anode of the gel and 
could be seen fluorescing above the well. The results for AZB017 are consistent with the 
previous report.26 At 0.1 mM of each compound, nicking could be observed. There does 
appear to be a trend in electronics that correlated to nicking ability. The benzimidazolium 
compounds containing electron-rich substituents are generally more able to cleave 
supercoiled DNA then electron-poor substituents. Compounds AZB017, AZB348, and 
AZB349 cause 11-24% normalized cleavage. The poor nicking ability of AZB349 might 
be attributable to its poor stability in DMSO. Upon dissolution, a color change is 
observed immediately from a pale orange solid to a neon-yellow solution. After 1 h at 
room temperature, the solution has degraded significantly, as judged by both 1H NMR 
and TLC (the product becomes at least three spots, which are poorly resolved). 
Deoxygenating the DMSO appears to slow decomposition, but not significantly. The 
error presented is the standard deviation calculated from three “no drug” control 
reactions. 
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Table 3.8. Nicking assay to determine extent of DNA cleavage 
Compound 
Normalized% Nicking  
at 0.1 mM drug 
Normalized% Nicking  
at 1 mM 
AZB349 11 NAa 
AZB348 19±5 NAa 
AZB017 24±5 71±5 
AZB347 4±5 42±5 
aNA = not applicable, i.e. the DNA could not be analyzed in this lane. bAverage of 
two trials 
We were interested to see whether the library had a similar trend in cytotoxicity as 
it did for DNA damage. The compounds (Figure 3.16) were analyzed for their 
cytotoxicity, which ranged from high nanomolar to low micromolar (Table 3.9). Ms. Jing 
Li in the Kerwin group performed cytotoxicity assays using A549 non-small cell 
carcinoma cells. Interestingly, the results are similar to the nicking assay in terms of the 
electron-poor AZB347. Interestingly, the electron-rich compounds (AZB349, AZB348) 
in this case show somewhat improved cytotoxicity compared to AZB017.  
 
Table 3.9. Cytotoxicity data on electronically varied benzimidazolium library 
Compound IC50 (µM) Std. Dev. 
MCC (Control 1) 0.05 ±0.02 
MCC (Control 2) 0.05 ±0.01	  
MCC (Control 3) 0.05 ±0.02	  
AZB348 1.0 ±0.1 
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AZB349 0.9 ±0.4 
AZB017 2.3 ±0.9 
AZB347 5.0 ±1.0 
AZB384 2.6 ±0.9 
AZB383 3.2 ±0.9 
 
3.5. CONCLUSIONS 
A small library of dialkynyl benzimidazolium salts was synthesized and evaluated 
for biological activity. It appears that electronics to play a role in determining DNA 
nicking ability, as well as cytotoxicity. DNA nicking ability appears to be the highest for 
AZB017. It is difficult to draw any conclusions about the mechanism by which these 
compounds cause nicking from these data. The slightly improved cytotoxicity could be 
the result of a number of factors; however, not enough is known about the mechanism by 
which these compounds case cell death to draw parallels between cytotoxicity and DNA 
damage. 
3.6. FUTURE DIRECTIONS 
Much work remains in the area of developing compounds that can selectively 
target unmethylated cytosines. We hope in the future to use the synthetic methylated 
oligomers to gain information at the level of single bases about electronic effects of the 
skipped aza-enediynes on adduct formation. Also, the mechanism of cytotoxicity should 
be explored in order to improve design of these compounds. ESI-MS with an appropriate 
small DNA oligomer might be of use in rapidly determining sequence selectivity and the 
structure of the adducts being formed. 
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3.7. EXPERIMENTAL SECTION 
3.7.1. Chemistry 
General Notes 
THF was distilled over sodium/benzophenone, and DCE, CH2Cl2, and toluene 
were distilled from CaH2 immediately prior to use. DMF was purchased from Aldrich as 
“anhydrous” and used without further drying. All reactions were run in oven-dried, 
argon-flushed round bottom flasks under an argon atmosphere. Solvent ratios are 
expressed as % by volume. Flash chromatography (FCC) was performed according to the 
method of Still.71 NMR was performed using a VARIAN Mercury spectrometer. 1H NMR 
was run at 400 MHz; 13C NMR was run at 100 MHz with broadband proton decoupling 
unless otherwise specified. Solvent chemical shifts are reported in ppm (δ) and 
referenced to solvent.72 IR was obtained on a Nicolet IR100 FT-IR spectrometer. Melting 




AZB376. p-Tolylpropynal. p-ethynyltoluene (2.0 mL, 15.8 mmol, 1 eq) was 
dissolved in THF (40 mL, 0.4 M). The solution was cooled to -40 °C, and n-BuLi (6.9 
mL, 15.8 mmol, 1 eq) was added slowly. Upon completion of the addition, DMF (2.44 
mL, 31.5 mmol, 2 eq) was added, and the reaction was allowed to warm to room 
temperature over 2 h. The reaction mixture was then slowly poured onto a solution (86 
mL) of 10% w/v aqueous KH2PO4 (8.59 g, 63.1 mmol, 4 eq KH2PO4). This solution was 
extracted 3x with MTBE (40 mL). Combined organic layers were washed with brine (75 
mL), dried (Na2SO4), and conc. The resultant dark yellow oil was purified by FCC (SiO2) 
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using a gradient of Hex-10% EtOAc/Hex as eluant to give the product as a pale yellow 
oil (2.01 g, 13.9 mmol, 89% yield). 1H, 13C NMR, and LRMS were in accordance with 
literature data.73 
 
AZB377. (4-Fluorophenyl)-propynal. 1-ethynyl-4-fluorobenzene (0.50 g, 477 
µL, 4.2 mmol, 1 eq) was dissolved in THF (10.4 mL, 0.4 M). The solution was cooled to 
-40 °C, and n-BuLi (1.66 mL, 4.16 mmol, 1 eq) was added slowly. Upon completion of 
the addition, DMF (644 µL, 8.33 mmol, 2 eq) was added, and the reaction was allowed to 
warm to room temperature over 2 h. The reaction mixture was then slowly poured onto a 
solution (23 mL) of 10% w/v aqueous KH2PO4 (2.27 g, 16.7 mmol, 4 eq KH2PO4). This 
solution was extracted 3x with MTBE (25 mL). Combined organic layers were washed 
with brine (50 mL), dried (Na2SO4), and conc. The resultant dark yellow oil was purified 
by FCC (SiO2) using a gradient of Hex-10% EtOAc/Hex as eluant to give the product as 
a pale yellow oil (485 mg, 3.27 mmol, 78% yield). 1H, 13C NMR and LRMS were in 
accordance with literature data.74 
 
AZB 378. (4-Methoxyphenyl)-propynal. p-ethynylanisole (1.23 g, 9.3 mmol, 1 
eq) was dissolved in THF (23 mL, 0.4M). The solution was cooled to -40 °C, and n-BuLi 
(4.53 mL, 9.3 mmol, 1 eq) was added slowly. Upon completion of the addition, DMF 
(1.44 mL, 18.6 mmol, 2 eq) was added, and the reaction was allowed to warm to room 
temperature over 2 h. The reaction mixture was then slowly poured onto a solution (51 
mL) of 10% w/v aqueous KH2PO4 (5.07 g, 37.2 mmol, 4 eq KH2PO4). This solution was 
extracted 3x with MTBE (25 mL). Combined organic layers were washed with brine (50 
mL), dried (Na2SO4), and concentrated in vacuo. The resultant dark yellow oil was 
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purified by FCC (SiO2) using a gradient of Hex-10% EtOAc/Hex as eluant to give the 
product as a pale yellow solid (1.17g, 7.3 mmol, 78% yield). Characterization (1H, 13C 
NMR, LRMS) was in accordance with literature data28,74  
 
 
AZB 379. (4-Trifluoromethylphenyl)-propynal. 1-ethynyl-α,α,α-
trifluorotoluene (2 g, 1.92 mL, 11.8 mmol, 1 eq) was dissolved in THF (0.4 M, 29.5 mL) 
and cooled to -78 °C. n-BuLi (5.7 mL, 11.8 mmol, 1 eq) was added slowly over 30 min. 
DMF (1.82 mL, 23.5 mmol, 1 eq) was added immediately at -78 °C to the dark red-
orange solution, and the reaction was warmed to room temperature, after which time it 
was a dark yellow solution. The reaction mixture was quenched by pouring it over a 10% 
aqueous solution of KH2PO4 (64 mL, 47.0 mmol, 4 eq) at 5 °C with stirring. The aqueous 
mixture was extracted 3x with 40 mL MTBE. The organic extracts were washed with 
satd NaCl, dried over Na2SO4, and concentrated in vacuo. The compound was isolated by 
FCC in Hexanes-5% EtOAc/Hexanes to give an off-white solid (1.09 g, 5.5 mmol, 47%). 
1H NMR (CDCl3): δ 9.44 (1H, s); 7.70 (4H, AA’BB’, J = 18.6, 9.2 Hz). 13C NMR 
(CDCl3): δ 176.4, 133.4, 132.6 (d, JC-F = 23 Hz), 125.7 (d, JC-F = 3.0 Hz), 123.4 (d, JC-F = 
272 Hz), 123.2, 92.2, 89.2. LRMS(CI+): 149 (M++1) HRMS calcd for C9H5FO 149.0402, 
found 149.0403. IR (thin film from CDCl3): 3075, 2962, 2204, 1664, 1580, 1485, 1431, 
1286, 1173, 1153, 1008, 884, 789, 719, 679 cm-1. mp 30.2-31.8 °C. 
 
AZB 380. (3-Fluorophenyl)-propynal. 1-Ethynyl-3-fluorobenzene (2 g, 1.92 
mL, 16.6 mmol, 1 eq) was dissolved in THF (0.4 M with respect to alkyne) and cooled to 
-40 °C (MeCN/CO2 bath). n-BuLi (8.1 mL, 16.6 mmol, 1 eq) was added slowly over 
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approx. 30 min. Upon completion of this addition, DMF (2.58 mL, 33.3 mmol, 2 eq) was 
added to the dark orange solution to give a pale yellow solution. The reaction was 
warmed to room temperature, then poured onto a solution of 10% w/v aqueous KH2PO4 
(91 mL, 66.6 mmol, 4 eq.) at 5 °C with stirring. The solution was extracted 3x with 
MTBE (40 mL), and the combined organic extracts were washed with brine (60 mL), 
dried (Na2SO4) and concentrated in vacuo. The residue was purified by FCC in Hexanes-
5% EtOAc/Hex to give the product as a pale yellow oil (1.06 g, 7.16 mmol, 43%). 1H 
NMR (CDCl3): δ 9.33 (1H, s), 7.30-7.28 (2H, m); 7.21-7.18 (1H, m); 7.13-7.08 (1H, m). 
13C NMR (CDCl3): δ 176.5, 162.2 (JC-F = 298 Hz), 129.8 (d, JC-F = 44 Hz), 129.7 (d, JC-F  
= 26 Hz), 121.1 (d, JC-F = 9 Hz), 119.7 (d, JC-F = 13 Hz), 118.7 (d, JC-F = 21 Hz), 92.8 (d, 
JC-F = 3 Hz), 88.4. LRMS(CI+): 199 (M++1), 179 (M+-F). HRMS calcd for C9H6FO: 
149.0403, found: 149.0402. IR (thin film from CDCl3): 2193, 1664, 1614, 1404, 1332, 




benzoimidazole. (4-Fluorophenyl)-propynal (800 mg, 5.4 mmol, 2 eq) was dissolved 
into toluene (14 mL, 0.2 M). 1,2-phenylenediamine (292 mg, 2.7 mmol, 1 eq) was added, 
and the solution was deoxygenated by bubbling with Ar. Formic acid was added (95 µL, 
2.5 mmol, 0.93 eq), and the resulting dark red mixture was refluxed for 3 d. After 3 d, the 
reaction mixture was cooled to room temperature and absorbed directly to silica gel. The 
product was isolated by FCC (first column, 1% TEA/Hexanes to 1% TEA in 25% 
EtOAc/Hexanes; second column 10-25% EtOAc/Hex) followed by crystallization to 
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yield a white cottony solid (335 mg, 0.91 mmol, 34%). 1H NMR (CD2Cl2): 7.76 (1H, d, J 
= 7.8 Hz); 7.70 (2H, dd, J = 8.1, 5.3 Hz); 7.62 (1H, d, J = 8.2 Hz); 7.40 (3H, dd, J = 8.1, 
6.8 Hz); 7.34 (1H, t, J = 8.1 Hz); 7.15 (2H, t, J = 8.8); 7.00 (2H, t, J = 8.8); 5.35 (s, 2H). 
13C NMR (CD2Cl2): 165.1, 164.4, 162.6, 161.9, 143.4, 136.8, 134.7, 134.6, 134.2, 134.1, 
124.6, 123.5, 120.5, 118.4, 117.5, 116.5, 116.3, 116.1, 115.9, 94.7, 84.4, 82.0, 78.5, 35.4. 
1H NMR (CDCl3): 7.81 (1H, d, J = 7.8 Hz); 7.65 (2H, dd, J = 8.5, 5.3 Hz); 7.58 (1H, d, J 
= 7.6 Hz); 7.40-7.33 (4H, m); 7.11 (2H, t, J = 8.6 Hz); 6.98 (2H, t, J = 8.7 Hz); 5.32 (2H, 
s).  13C NMR (CDCl3): 164.6, 164.0, 162.1, 161.5, 143.0, 136.6, 134.3, 134.2, 133.75, 
133.67, 124.28, 123.3, 120.4, 117.9, 117.1, 116.2, 116.0, 115.8, 115.5, 110.1, 94.6, 84.4, 
81.4, 78.1, 35.0. LRMS: (CI+): 369 (M++1). HRMS (CI+): calcd. 368.1125; found 
368.1123. IR (KBr pellet): 3059, 2942, 2217, 1600, 1518, 1508, 1490, 1449, 1432, 1391, 
1349, 1336, 1235, 1157, 837, 740, 530. EA: calcd: 78.25%C, 3.83 %H, 7.60 %N; found: 
78.00 %C, 3.74% H, 7.50% N.  
 
AZB 345. 2-p-Tolylethynyl-1-(3-p-tolylprop-2-ynyl)-1H-benzoimidazole. p-
Tolylpropynal (1.09g, 7.6 mmol, 2 eq) was dissolved into toluene (19 mL, 0.2 M). 1,2-
phenylenediamine (409 mg, 3.8 mmol, 1 eq) was added, and the solution was 
deoxygenated by bubbling with Ar. Formic acid was added (133 µL, 3.5 mmol, 0.93 eq), 
and the resulting dark orange mixture was refluxed for 3 d. After 3 d, the reaction mixture 
was cooled to room temperature and absorbed directly to silica gel. The product was 
isolated by FCC (first column, 1% TEA in Hexanes to 1% TEA in 25% EtOAc/Hexanes; 
second column 10-25% EtOAc/Hex) to give a white solid that was recrystallized from 
EtOAc/Hex to give a white cottony solid (327 mg, 0.91 mmol, 24%). 1H NMR (CDCl3): 
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δ 7.80 (1H, dd, J = 7.2, 1.3 Hz); 7.61 (1H, dd, J = 7.1, 1.3 Hz); 7.56 (2H, d, J = 8.0 Hz); 
7.35 (2H, dqd, J = 7.4, 7.2, 1.3 Hz); 7.29 (2H, d, J = 8.2 Hz); 7.22 (2H, dd, J = 7.8, 0.6 
Hz); 7.09 (2H, dd, J = 7.8, 0.6 Hz); 5.33 (2H, s); 2.40 (3H, s); 2.32 (3H, s). 13C NMR 
(CDCl3): δ  143.0, 140.3, 139.0, 137.0, 133.8, 132.1, 131.7, 129.4, 129.1, 124.1, 123.2, 
120.2, 118.8, 118.0, 110.3, 96.1, 85.6, 81.0, 77.8, 35.1, 21.7, 21.5. LRMS: (CI+): 361 
(M++1). HRMS (CI+): calcd. 360.1626; found 360.1623. IR (KBr pellet): 3025, 2943, 






1H-benzoimidazole. (4-Methoxy-phenyl)propynal (960 mg, 6.0 mmol, 2 eq) was 
dissolved into toluene (15 mL, 0.2 M). 1,2-phenylenediamine (324 mg, 3.0 mmol, 1 eq) 
was added, and the solution was deoxygenated by bubbling with Ar. Formic acid was 
added (120 µL, 2.8 mmol, 0.93 eq), and the resulting dark red mixture was refluxed for 3 
d. After 3 d, the reaction mixture was cooled to room temperature and absorbed directly 
to silica gel. The product was isolated by FCC (first column, 1% TEA in Hexanes to 1% 
TEA in 25% EtOAc/Hexanes; second column 10-25% EtOAc/Hex) to give an orange oil 
(282 mg, 0.72 mmol, 24%) that formed a glassy solid upon standing. An analytical 
sample was crystallized from EtOAc/Hex to give a pale orange crystalline solid. 
Characterization data (1H NMR, 13C NMR, LRMS, HRMS, IR) were in accordance with 





phenyl)-prop-2-ynyl]-1H-benzoimidazole. (4-Trifluoromethylphenyl)-propynal (0.811 
g, 4.09 mmol, 2 eq) was combined with 1,2-phenylenediamine (221 mg, 2.05 mmol, 1 
eq) in toluene (10.2 mL, 0.2 M with respect to 1,2-phenylenediamine). The resultant 
yellow solution was deoxygenated by bubbling with Ar, then formic acid (72 µL, 1.90 
mmol, 0.93 eq) and heated to reflux for 3 days. The mixture was adsorbed directly onto 
SiO2 and purified by flash column chromatography (1% TEA/Hexanes to 1% TEA in 
25% EtOAc/Hex) followed by crystallization from EtOAc/Hex to give a pale yellow 
needle-like solid (263 mg, 0.56 mmol, 28%). An additional amount of product was 
isolated from the mother liquor by column chromatography using the same eluent system 
as previously described (66 mg, 0.14 mmol, 6.9%). 1H NMR (CDCl3): 8.04 (2H, d, J = 
8.2 Hz); 7.68 (2H, d, J = 8.2 Hz); 7.55-7.48 (5H, m); 7.41 (1H, dd, J = 3.0 Hz); 7.29 (2H, 
dd, J = 3.0 Hz). 13C NMR (CDCl3): δ 173.4, 154.4, 141.4, 134.9, 132.1, 131.9, 126.5, 
125.3 (d, JC-F = 3), 123.4, 122.9, 114.4, 108.79, 84.2, 83.6, 78.1, 77.0, 33.2. LRMS (CI+): 
487 (M++H2O), 467 (M+-1). HRMS calcd for C26H15N2F6: 469.1139, found 469.1136. IR 





benzoimidazole. (3-Fluorophenyl)-propynal (0.531 g, 3.58 mmol, 2 eq) was combined 
with 1,2-phenylenediamine (193 mg, 1.79 mmol, 1 eq) in toluene (9  mL, 0.2 M with 
respect to 1,2-phenylenediamine). The resultant yellow solution was deoxygenated by 
bubbling with Ar, then formic acid (68 µL, 0.90 mmol, 0.93 eq) and heated to reflux for 3 
days. The mixture was adsorbed directly onto SiO2 and purified by flash column 
chromatography (1% TEA/Hexanes to 1% TEA in 25% EtOAc/Hex) followed by 
crystallization from EtOAc/Hex to give a pale yellow needle-like solid (181 mg, 0.49 
mmol, 27%). 1H NMR (CDCl3): 7.83-7.80 (1H, m); 7.60-7.57 (1H, m); 7.47-7.34 (m, 
6H); 7.28-7.22 (1H, m); 7.19-7.15 (m, 2H); 7.13-7.08 (1H, m); 7.03 (1H, tdd, J = 8.4, 
2,5, 1.2) 13C NMR (CDCl3): δ 162.7 (d, JC-F = 248 Hz), 143.1, 136.3, 133.7, 130.4, 130.3, 
130.0, 129.9, 128.0, 127.6, 124.5, 123.4, 122.7, 120.5, 119.0, 118.7, 118.5, 117.4, 1117.2, 
116.4, 116.2, 110.1, 105.0, 94.1, 84.3, 82.5, 79.0, 34.9. LRMS (CI+): 369 (M++1). HRMS 
(CI+) calcd for C24H14F2N2: 369.1203, found: 369.1204. IR (KBr): 3448, 3066, 2935, 




fluorophenyl)-prop-2-ynyl]-1-methyl-3H-benzimidazol-1-ium. The neutral 
benzimidazole (25 mg, 0.068 mmol, 1 eq) was dissolved in Et2O (450 µL) and DCE (680 
µL) (0.06 M final concentration, 3:2 DCE:Et2O). A solution of methyl triflate (12.3 µL, 
0.11 mmol, 1.6 eq) in Et2O (440 µL) was added dropwise, and the solution was warmed 
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to room temperature. The product formed as a pale yellow solid precipitate which was 
isolated by vacuum filtration, then recrystallized from DCE/Et2O to give a pale yellow, 
flaky solid (24.0 mg, 0.045 mmol, 66%). On larger scale, an analytical sample was 
obtained by performing a second recrystallization from DCE/Et2O then dissolving the 
product in DCM, performing a filtration using a syringe-tip 0.2 µM filter, and adding 
hexanes to precipitate the product in the -20 °C freezer. 1H NMR (CD3CN): δ 8.08-8.06 
(1H, m); 7.98 (2H, dd, J = 8.9, 5.5 Hz); 7.92-7.90 (1H, m); 7.84-7.80 (2H, m); 7.48 (2H, 
dd, J = 8.9, 5.4 Hz); 7.36 (2H, t, J = 8.9 Hz); 7.12 (2H, t, J = 8.9 Hz); 5.66 (2H, s); 4.18 
(s, 3H). LRMS (CI+): 383 (M+-OTf); 165. HRMS (CI+): calcd. 383.1360, found 383.1351. 




prop-2-ynyl]-3H-benzimidazol-1-ium.The neutral benzimidazole (25 mg, 0.069 mmol, 
1 eq) was dissolved in Et2O (460 µL) and DCE (684 µL) (0.06 M final concentration, 3:2 
DCE:Et2O). A solution of methyl triflate (12.6 µL, 0.11 mmol, 1.6 eq) in Et2O (440 µL) 
was added dropwise, and the solution was warmed to room temperature. The product 
formed as a white solid precipitate which was isolated by vacuum filtration, then 
recrystallized from DCE/Et2O to give a white, flaky solid (24 mg, 0.046 mmol, 67%). On 
larger scale, an analytical sample was obtained by performing a second recrystallization 
from DCE/Et2O then dissolving the product in DCM, performing a filtration using a 
syringe-tip 0.2 µM filter, and adding hexanes to precipitate the product in the -20 °C 
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freezer 1H NMR (CD3CN): δ 7.86-7.84 (1H, m); 7.69-7.67 (1H, m); 7.61-7.57 (4H, m); 
7.22 (2H, d, J = 7.9 Hz); 7.12 (2H, d, J = 7.9 Hz); 6.98 (2H, d, J = 7.9 Hz); 5.43 (2H, s); 
3.95 (3H, s); 2.26 (3H, s); 2.12 (3H, s). LRMS (CI+): 375 (M+-OTf). HRMS (CI+): calcd: 
375.1861. found: 375.1859. IR (KBr): 3031, 2972, 2947, 2214, 1602, 1554, 1511, 1483, 





methoxyphenyl)-prop-2-ynyl]-1-methyl-3H-benzimidazol-1-ium. The neutral 
benzimidazole (25 mg, 0.064 mmol, 1 eq) was dissolved in Et2O (430 µL) and DCE (640 
µL) (0.06 M final concentration, 3:2 DCE:Et2O). A solution of methyl triflate (11.5 µL, 
0.10 mmol, 1.6 eq) in Et2O (410 µL) was added dropwise, and the solution was warmed 
to room temperature. The product formed as an orange solid precipitate which was 
isolated by vacuum filtration, then recrystallized from DCE/Et2O to give a pale orange 
solid (10 mg, 0.019 mmol, 29%). An analytical sample was obtained by performing a 
second recrystallization from DCE/Et2O then dissolving the product in DCM, performing 
a filtration using a syringe-tip 0.2 µM filter, and adding hexanes to precipitate the product 
in the -20 °C freezer 1H NMR (CD3CN): δ 8.07-8.04 (1H, m); 7.88 (2H, d, J = 9.2 Hz); 
7.79-7.77 (1H, m); 7.38 (2H, d, J = 8.9 Hz); 7.13 (2H, d, J = 8.9); 6.90 (2H, d, J = 8.9 
Hz); 5.62 (2H, s); 4.15 (3H, s); 3.92 (3H, s); 3.79 (3H, s). 13C NMR could not be 
obtained, as rate of decomposition occurred on NMR timescale. LRMS (CI+): 407 (M+-
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OTf). HRMS (CI+): calcd: 407.1760, found: 407.1750. IR (KBr): 2968, 2212, 1603, 





ium. The neutral benzimidazole (150 mg, 0.32 mmol, 1 eq) was dissolved in Et2O (2.1 
mL) and DCE (3.2 mL) (0.06 M final concentration, 3:2 DCE:Et2O). A solution of 
methyl triflate (58 µL, 0.51 mmol, 1.6 eq) in Et2O (2.0 mL) was added dropwise, and the 
solution was warmed to room temperature. The product formed as an orange solid 
precipitate which was isolated by vacuum filtration, then recrystallized from DCE/Et2O to 
give a pale yellow solid (126.3 mg, 0.20 mmol, 62%). An analytical sample was obtained 
by performing a second recrystallization from DCE/Et2O then dissolving the product in 
DCM, performing a filtration using a syringe-tip 0.2 µM filter, and adding hexanes to 
precipitate the product in the -20 °C freezer (60 mg, 0.094 mmol, 29%). 1H NMR 
(MeCN): δ 8.11 (2H, d, J = 8.0 Hz); 8.04-8.01 (1H, m); 7.96-7.93 (1H, m); 7.83 (2H, d, J 
= 8.2 Hz); 7.80-7.77 (2H, m); 7.56 (2H, d, J = 8.0 Hz); 7.34 (2H, d, J = 8.0 Hz); 5.54 
(2H, s); 4.02 (3H, s). 13C NMR could not be obtained, as rate of decomposition occurred 
on NMR timescale. LRMS (CI+): 481 (M+-OTf-H2). HRMS calcd for C27H17F6N2+ 
483.1290, found 481.1342. IR (KBr): 3421, 2921, 1655, 1618, 1581, 1545, 1510, 1480, 





32P-γ-ATP (Ultratide Isoblue) was purchased from MP Biomedicals. T4 
polynucleotide kinase was purchased from either Invitrogen or New England Biolabs. 
Pre-mixed 5x polynucleotide kinase buffer from Invitrogen was used with both enzymes. 
Formamide loading buffer was a mixture of formamide (Aldrich) with 0.05 M ETDA (pH 
8 before mixing). For preparative gels, no dyes were added. For analytical gels, 0.25% by 
weight each bromophenol blue and xylene cyanol were added. φx174RF plasmids were 
obtained from Fermentas.  
3.7.2.2. General protocol for radiolabeling DNA 
In an 1.5 mL sterile Eppendorf tube, 1 µL DNA (40 µM in 1X TE buffer, 1 pmol) 
was combined with 6 µL 5x PNK buffer, 16 µL sterile H2O. To this mixture was added 6 
µL 32P-ATP and 1 unit (1 µL) T4-polynucleotide kinase. Samples were mixed gently, 
then incubated in a 37 °C water bath for 1 h. After 1 h, an additional 1 unit (1 µL) T4-
PNK was added, and the labeling reaction was incubated for 1 h further. After 2 h total 
incubation, the enzyme was inactivated by heating to 65 °C for 10 min, after which 
excess 32P-ATP was removed by purification via Bio-Rad P-6 micro bio-spin column 
(according to manufacturer insert).  
3.7.2.3. General protocol for DNA Purification 
DNA was concentrated to dryness under vacuum centrifugation then treated with 
70 µL 10% aqueous piperidine at 90 °C for 30 min. After piperidine/heat treatment, 
samples were again concentrated by vacuum centrifugation. Samples were diluted to 55 
µL using formamide loading buffer, then purified on a 20% denaturing acrylamide gel 
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(75 mm spacer thickness, 14 x17 inches). Electrophoresis was run at 1100-1200 V (to 
maintain a temperature of approx. 60 °C) in 1X TBE buffer for times varying with the 
size of the DNA. The 22-mer required 2.5 h to obtain good separation. Bands were 
visualized using X-ray film, cut out, and extracted with water overnight. The water 
containing the eluted DNA was concentrated by vacuum centrifugation to 100 µL, and 20 
uL 3M NaOAc (pH 5) was added, then 500 µL cold (-20 °C) EtOH was added. Samples 
were cooled to -20 °C for approx. 1 h, then pelleted by centrifuging at 15,000xg for 6 
min. The supernatant was removed by pipet, and the pelleted DNA was washed twice 
with 200 µL cold EtOH. The pellet was redissolved in 100 µL H2O and 20 µL 3M 
NaOAc (pH 5), then treated with 500 µL cold EtOH. The sample was cooled to -20 °C, 
for approx. 1 h, then the same procedure was followed to pellet the DNA. The pellet was 
rinsed with cold (-20 °C) 70% aqueous EtOH (2x 200 µL). The resuspension and 
pelleting process was repeated once more to ensure full removal of urea and salts.  
3.7.2.4. General protocol for DNA Annealing 
Radiolabeled DNA (combined from 4 labeling reactions) was diluted with water 
buffer to a volume of 38 µL in a 250 µL PCR tube. To this was added 5 µL 10X TE 
buffer (to make 1X final concentration), 5 µL 5 M NaCl (to make 0.5 M final 
concentration), and 2 µL of the complementary sequence (40 µM, 40 pmol. The oligomer 
was annealed according to the following temperature regime: Heated to 90 °C for 5 min, 
then cooled at a rate of 10 °C every 10 min, pausing at Tm. Annealing was analyzed by 
running a non-denaturing analytical gel, 20% acrylamide at 1200 V at 4 °C, exposing the 
gel to a phosphor screen, and using a phosphorimager to visualize the results.  
Maxam-Gilbert sequencing was performed according to literature.64 
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3.7.2.5. General protocol for DNA/drug incubations 
In a 1.5 mL Eppendorf tube was combined H2O, sodium phosphate buffer, DNA 
(50,000 cpm), and the AZB derivative in DMSO. Samples were incubated at 37 °C for 2 
h. Following incubation, the reaction mixture was extracted with 50 µL CHCl3, then 20 
µL 3M NaOAc (pH 5) and 500 µL cold EtOH (-20 °C) was added. Samples were cooled 
to -20 °C for approx. 1h, then pelleted by centrifuging at 15,000xg for 6 min. The pellet 
was rinsed with cold (-20 °C) 70% aqueous EtOH (2x 200 µL). Samples were then 
diluted with formamide loading buffer (formamide with 0.05 M EDTA, pH 8, 0.25% w/v 
xylene cyanol and 0.25% w/v bromophenol blue) and run on a 20% denaturing analytical 
acrylamide gel (20 mm spacer thickness, 14”x17”) at 2000 V for approx. 2.5 h. The gel 
was then dried for 60 min. in vacuo with heating to 90 ºC. Following overnight exposure 
to a phosphor screen, the gel was imaged using a Typhoon Trio phosphorimager (GE 
Healthcare). Quantitation was performed using ImageQuant TL 2005 from Amersham 
Biosciences. Lanes and bands were automatically detected, then manually resized. 
Background subtraction was “rolling ball” type, typically set to a radius size of 12. 
Images were manipulated using Abode Photoshop Elements 6.0 to crop, adjust contrast, 
and sharpen blurring. No processing was performed which would change the relative 
intensity of the bands, and processing was done following quantitation.  
Nicking assays were analyzed using 0.8% TAE-Agarose gel electrophoresis with 
5 µg/mL ethidium bromide (gel volume approx. 50 mL). Plasmids were diluted with 1/6 
volume of 6X DNA loading dye and the samples were electrophoresed for 30 minutes at 
100 V, at 300 mA. After electrophoresis, DNA was visualized using a UV illumination 
source. Quantitation was performed using ImageQuant TL 2005 from Amersham 
Biosciences. Lanes and bands were automatically detected, then manually resized. 
Background subtraction was “rolling ball” type, typically set to a radius size of 12. 
 179 
Images were manipulated using Abode Photoshop Elements 6.0 to crop, adjust contrast, 
and sharpen blurring. No processing was performed which would change the relative 
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4. UK-1 Analog Synthesis 
4.1. BACKGROUND 
Benzoxazole natural products have been shown to have promising biological activity.1-7 
This chapter will describe efforts towards synthesizing analogs of UK-1 using a palladium-
catalyzed biaryl coupling. First, background will be provided on the biological activity of some 
known anticancer benzoxazole natural products. Then, current methods to synthesize 2-
arylbenzoxazoles will be reviewed. The route to UK-1 analogs and its optimization will then be 
presented, and future structure-activity relationship studies will be described.  
4.1.1. Benzoxazole Natural Products 
Benzoxazole natural products are relatively uncommon and show novel biological 
properties, including potent cytotoxicity.  
 
 
Figure 4.1. Benzoxazole-containing natural products. 
Many of these benzoxazole natural products (Figure 4.1) have been isolated as part of a 
natural product isolation program focused on small molecule organic compounds produced in the 
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fermentation broth of streptomyces samples from diverse locations. All of the isolated 
bis(benzoxazoles) are connected from C4 of one ring to C2 of the second heterocycle. 
Bis(benzoxazole) AJI9561, isolated from fermentation of soil samples collected at Chibra, Japan, 
displays activity against Jurkat and P388 cells (0.88 and 1.63 µM, respectively).5 A33583 was 
isolated from a fermentation broth of streptomyces strain NRRL 12068. It was originally 
characterized as having antibiotic activity, but more recently, it was reported to have good 
antileishmanial (antiparasitic) activity. IC50 values against L. donovani, a common vector for 
antileishmaniasis, a parasitic infection, were 50 nM.7 The compound’s activity is not attributable 
to general cytotoxicity, because it has a much higher an IC50 against L6 cells (14 µM) than its 
antileishmanial effective dose.7  
Nataxazole, isolated in 2008, is isolated from streptomyces strain Tü 6176, a sample 
collected at Mata de Estrela, RN, Brazil.6 Its ED50 was measured in MCF7 (breast 
adenocarcinoma, 0.68 µg/mL), HepG2 (hepatocellular carcinoma, 0.068 µg/mL), and AGS 
(gastric adenocarcinoma, 0.4 µg/mL) cells.6 A cell cycle study showed accumulation of cells at S 
phase and reduced numbers at G2/M phase. UK-1 (vide supra) shows a similar pattern, implying 
that they operate by the same mechanism, and also that they are both topoisomerase II 
inhibitors.6  
Caboxamycin is a monobenzoxazole isolated from a marine strain of streptomyces 
collected in the Canary Basin (located near Morocco in the Atlantic Ocean) strain NTK 937.4 
Unlike many of the other streptomyces-produced benzoxazoles, Caboxamycin shows antibiotic 
activity against many strains of bacteria and yeast, summarized inTable 4.1.4 Cytotoxicity was 
measured for cell types AGS (7.5 µg/mL), Hep G2 (7.4 µg/mL), and MCF7 (7.3 µg/mL).4  
Table 4.1. Activity of Caboxamycin against various bacteria and yeasts 
Biological Caboxamycin EC50 (µM) Positive control (µM)1 
Bacillus subtilis 8 9 
Staphyloccoccus lentus 20 14 
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Candida glabrata 117 4 
Xanthomonas campestris 43 6 
Ralstonia solanacearum 176 75 
Staphylococcus epidermis 43 7 
1Positive Control for prokaryotes is chloramphenicol, for eukaryotes is cycloheximide 
UK-1 is a bis(benzoxazole) with anticancer activity but no antifungal or antibacterial 
activity.1-3,8 UK-1 was first isolated in 1993 from the mycelial cake of acetonimycete strain 517-
02.8 The acetonimycete strain was found in soil collected from the Sugimoto campus Osaka City 
University.8 The stock organism was fermented with a seed medium (100 mL) consisting of 1% 
glucose, 1% soluble starch, 0.6% wheat germ, 0.5% peptone, 0.3% yeast extract, 0.2% soybean 
meal, and 0.2% CaCO3 (pH 7.0 before stabilization).8 This mixture was incubated on a rotary 
shaker (220 rpm) at 30 °C for 48 h, after which a small amount (30 mL) of this fermentation was 
transferred into another 3 L of seed medium.8 After an additional 48 h of incubation at 30 °C 
with aeration at 3 L/min and agitation of 500 rpm, the mixture was added to 300 L of production 
medium consisting of 3% glucose, 0.5% malt extract, 0.5% yeast extract, and 0.2% CaCO3 and 
fermented for a final 48 h at 30 °C with agitation at 250 rpm.8 
Following incubation, the fermentation was filtered, and the solid, the mycelial cake, was 
extracted with acetone, which was subsequently concentrated and extracted with chloroform.8 
The resultant organic layer was concentrated, then the crude material was purified with silica gel 
chromatography (eluting with chloroform) and recrystallization from methanol to yield 550 mg 
pure UK-1.8 The structure was elucidated through a combination of 2-D NMR spectroscopy and 
independent fragment synthesis.2 Ueki and coworkers proposed a biosynthetic pathway that 
proceeds via condensation of 3-hydroxyanthranilic acid methyl ester onto 2-amino-3-
hydroxybenzaldehyde. The subsequent benzoxazole then undergoes a second condensation with 
salicylaldehyde to form UK-1 (Scheme 4.1).  
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At concentrations up to 100 µg/mL, UK-1 did not show any inhibitory activity against 
yeast, fungi, or bacteria (Gram-negative or Gram-positive).1-3,8 Interestingly, UK-1 did show 
cytotoxic activity.8 The effective dose to inhibit growth by 50% (ED50) was 1.17 for B16 cells, 
1.22 for HeLa cells, and 0.11 µg/mL for P388 cells (mouse leukemia).8 In a later report, UK-1 
showed an ED50 of 1.9 µg/mL against AGF cells, 0.65 against MCF7 cells, 0.085 against HepG2 
cells.6  
 
Scheme 4.1. Proposed Biosynthesis of UK-12 
4.1.2. Mode of Action 
Although, its mechanism of action is unknown, UK-1 is thought to inhibit topoisomerase 
II (TopoII).9 Topoisomerases regulate structure (topology) of DNA via series of cleavages and 
religations.9 TopoII, a member of the family of topoisomerases, causes double-stranded breaks in 
DNA.9 Compounds that interfere with topoisomerase activity typically cause cell death. 
Additionally, UK-1 is thought to chelate M2+ ions (Figure 4.2). UK-1 has a unique biological 
reactivity profile but suffers from poor solubility in aqueous media, which limits possibilities for 
drug development. The Kerwin group reported a minimum pharmacophore that is synthetically 
more accessible but retains similar cytotoxicity.10  
 
Figure 4.2. UK-1-metal ion complex 
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Figure 4.3. UK-1 (l), Demethyl UK-1 (center), and minimum pharmacophore (r). 
The Kerwin group became interested in UK-1 for its highly selective cytotoxicity. It is 
unusual for a compound that is cytotoxic to show little antibiotic or antifungal activity. They 
reported a total synthesis of UK-1 in 1997 (Scheme 4.2).11 This total synthesis begins with the 
methyl ester of 3-hydroxyanthranilic acid. This compound is acylated to form the corresponding 
amide with the acid chloride of 2-benzyloxybenzoic acid in good yield. The resulting amide is 
then subjected to neat thermolysis to form the benzoxazole ring via condensation, then base is 
used to saponify the methyl ester. The combined yield for these steps is moderate. The free acid 
can then be converted to the acid chloride and used to acylate a second 3-hydroxyanthranilic acid 
methyl ester, which proceeds in moderate yield. The second benzoxazole ring is then closed via 
an acid-catalyzed ring-closing in refluxing xylenes in quantitative yield. Overall, the synthesis 




Scheme 4.2. Total Synthesis of UK-111 
Although the total synthesis of UK-1 (Scheme 4.2) is short and takes advantage of the 
pseudosymmetery of the bis(benzoxazole) system, a new route which allows for higher 
functional group tolerance and later divergence is needed for an effective analog synthesis. In the 
case of the minimum pharmacophore, the benzoxazole ring is closed via a thermolysis requiring 
very high temperatures and has proved to be incompatible with several functional groups.10 Other 
groups have reported similar approaches to synthesis of analogous benzoxazole systems. Smith 
et al. reported a series of analogs lacking the methyl ester moiety to determine which functional 
groups were required for TopoII inhibition.9 They used traditional coupling chemistry to form 
the same amide from 3-hydroxyanthranilic acid methyl ester and 2-benzyloxybenzoic acid that 
Kerwin et al. used, followed by the same thermolysis.11 Following deprotection, a second amide 
coupling generates the open bis(benzoxazole) precursor, which is closed using catalytic 




Figure 4.4. Synthesis by Smith et al. of analogs of UK-1 lacking C4-methyl ester12 
Smith et al. also produced analogs lacking the 2ʹ′-hydroxyl group on the C2-position of 
the benzoxazole with or without the methyl ester.9 Using a similar route, involving ring-closing 
of amides onto phenols, they generated the desired bis(benzoxazoles).9 
 
 
Figure 4.5. Synthesis by Smith et al. of UK-1 analogs lacking 2ʹ′-hydroxyl group12 
Activity of the bis(benzoxazole) analogs at inhibiting human topoisomerase II was 
compared to UK-1. Deletion of either the o-hydroxyl or the methyl ester does not show a 
significant effect on topoII inhibition, but deletion of both groups leads to no inhibition at the 
highest concentrations assayed (80 µM). UK-1 shows an IC50 of 32 µM; deletion of the methyl 
ester leads to an IC50 of 20 µM, and deletion of the o-hydroxyl group gives an IC50 of 38 µM.9 
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Smith et al. propose that distance between the Lewis basic sites on the system is critical for 
activity.9 Computational studies on these analogs found that there appears to be a required 
geometry of Lewis basic sites for good activity against TopoII. The Lewis basic sites should 
form a triangle with sides equal to 2.875-3.045 Å on two sides and 4.524-4.727 Å on the third 
(Figure 4.6).9 This arrangement likely is required for effective metal ion binding. 
 
 
Figure 4.6. Model of Lewis basic sites on topoII inhibitors. 
The modeled distance range for a is 2.875-3.045 Å and b is 4.524-4.727 Å.12  
The heteroaromatic ring is not required to be a bis(benzoxazole). A bis(benzimidazole) 
analog synthesized by Kerwin et al. (Figure 4.7) showed 22.2 µM IC50 for A549 cells, similar to 
UK-1 (5.1 µM), and showed low µM activity for a range of cell lines.12 This structure also can 
form the requisite arrangement of Lewis basic sites.  
 
 
Figure 4.7. Bis(benzimidazole) UK1 analog reported by Kerwin et al.9 
 
4.1.4. Mono-Benzoxazole or -Benzimidazole UK-1 Analogs 
The Kerwin group, along with others,9,12 has been evaluating structure-activity 
relationships for UK-1 analogs. Because the bis(benzoxazole) scaffold is difficult to construct, a 
scaffold using single benzoxazole, benzimidazole, or benzothiazole was used. In 2001, the 
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Kerwin lab reported a minimum pharmacophore for UK-1 that retained the unusual selectivity of 
the parent compound. The compound reported was a mono-benzoxazole with a methyl ester at 
C4 and a 2-hydroxyphenyl at C2. The activity of this compound, TOP027, shown in Table 4.3, 
was in the low µM range.  
 
Scheme 4.3.Route to benzoxazole UK-1 analog TOP027 reported by Kerwin et al.10 
In a series of possible analogs, the analog TOP027 was shown to be the most cytotoxic 
without showing significant antibiotic activity. As expected, 2-(2-hydroxyphenyl)benzoxazole 
was inactive in all assays. Other compounds which did not offer three Lewis basic sites which 
could readily coordinate metal ions did not show efficacy at concentrations below 100 µM. For 
example, TOP003, TOP004, and TOP029 incorporate a benzyl group capping the phenol and 
do not show significant cytotoxicity (Table 4.3).  
 
Figure 4.8. Structures assayed to find a minimum pharmacophore 
Table 4.2. Cytotoxicity vs. antibacterial activity of minimum pharmacophores reported by 
Kerwin et al.10 
Analog S. Aureus IC50, S. Aureus (Meth-resistant) Cytotoxicity1 
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µM IC50, µM IC50, µM 
TOP027 NA NA 0.88-9.1 
TOP003 NA NA >100 
2-(2-hydroxyphenyl) 
benoxazole 
NA NA >100 
TOP033 NA NA >100 
TOP009 43 29 >100 
UK-1 NA NA 0.32-65 
TOP004 102 102 >100 
1 Range is an average from the following cell lines: MCF7, HL60, HT29, PC-3 after 72h. 2 NA = 
no activity 
In 2006, Chen and coworkers reported a series of benzoxazoles, benzimidazoles, and 
benzothiazoles (Figure 4.9).12 They investigated cytotoxicity of benzoxazoles where the 
carbomethoxy group was located at C7 instead of C4, effectively reversing the nitrogen and 
oxygen on the benzoxazole ring relative to the ester and phenol.12 This change proved to 
dramatically reduce the cytotoxicity of the compounds. Changing the heteroaromatic core but 
maintaining nitrogen at the 1-position did not cause significant differences in cytotoxicity of the 
compounds, although the benzothiazole was somewhat less cytotoxic than the benzimidazole or 
benzoxazoles. Again, maintaining the geometrical relationship between the three Lewis basic 
sites, the carbonyl at C4, the nitrogen of the benzoxazole or benzimidazole, and the free phenol, 
appears to provide the lowest IC50 values. 
 
Figure 4.9. Benzimidazole and benzothiazole analogs of UK-1 reported by Chen et al.12 
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Table 4.3. Cytotoxicity studies on analogs varying the heteroaromatic ring12 
IC50 against cell linea 
Compound 
A549b BFTC-905c RDd MES-SAe HeLaf 
N,O bis Me >100 >100 >100 >100 52.6 
N,O Me ester >100 54.7 >100 89.4 67.6 
N,O Me phenol >100 >100 >100 >100 >100 
TOP027 >100 49.6 58.5 >100 75.8 
OMe/OBn >100 89.2 Ndf 91.3 82.1 
Thiazole >100 87.3 39.1 76.7 81.6 
Benzimid/ Me ester 74.1 37.9 35.9 33.2 31.5 
Benzimid bis-OH 38.2 9.6 17.6 52.7 52.5 
aIC50 determined after 72 h. bHuman lung carcinoma cell line c Human bladder carcinoma 
transitional cell line d Human rhabdomyosarcoma cell line e Human uterine sarcoma line f Human 
epithelial carcinoma cell line f Not determined 
4.1.5. C4 Benzoxazole Polar Analogs 
In order to generate a library of compounds varied enough to acquire useful structure-
activity relationship (SAR) data, varying substituents at both C2 (Figure 4.10, R2, blue) and C4 
(Figure 4.10, R1, red) would provide the best possible combination. Previously, the Kerwin lab 
reported a series of C4 polar analogs and their biological information.13  
 
 
Figure 4.10. Positions to vary for SAR study 
Beginning with the free carboxylic acid at C4, a library of amides and esters were 
synthesized (Scheme 4.4). Deprotection of the benzyl group on the phenol provided the small 
library of polar analogs. Esters (TOP040 and TOP044) appeared to have low effective 
concentrations, regardless of size. TOP046, with a methyl amide showed comparable 
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cytotoxicity, but increasing the size of the amide appeared to raise IC50 values, meaning that 
these compounds were less efficacious (Table 4.4).  
	  
Scheme 4.4. C4 analogs of minimum pharmacophore13 
Table 4.4. Cytotoxicity data for C4 UK-1 minimum pharmacophore analogs.13 





1 TOP046 (R = NHMe) 10±8 11±1 
2 TOP040 (R = OEt) 15±5 40±10 
3 TOP050 (R = NHBu) 30±10 14±4 
4 TOP048 (R = NH(CH2)6OH) 31±7 39±17 
5 TOP043 (R = NH(CH2)2O(CH2)2OH) >50 41±17 
6 TOP044 (R = O(CH2CH2O)4OH) 13±2 11±1 
7 UK-1 1.4±0.9 2.0±0.5 
 
Metal binding of the C4 polar analogs was also assayed. There appeared to be a loose 
correlation between metal binding affinity; however, certain analogs did not follow the trend. 
The large ester (TOP044) and amide (TOP043) showed very tight metal binding, but relatively 
poor cytotoxicity compared to the other analogs (Table 4.5).  
Table 4.5. Metal binding of C4 polar analogs 
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Entry R Mg2+ (M-1) Cu2+ (M-1) 
1 TOP027 (R = OMe) 10 3.2 x 105 ND 
2 TOP046 (R = NHMe) 6±2 x 105 >3 x 107 
3 TOP040 (R = OEt) 1.5±0.4 x 105 >3 x 107 
4 TOP050 (R = NHBu) 1.1±0.2 x 104 >6 x 107 
5 TOP048 (R = NH(CH2)6OH) 2.4±0.4 x 104 >2 x 107 
6 TOP043 (R = NH(CH2)2O(CH2)2OH 3±1 x 105 >7 x 107 
7 TOP044 (R = O(CH2CH2O)4OH) 8±3 x 105 >7 x 107 
8 TOP00910 4.0 x 104 ND 
9 UK-1 5±1 x 105 >5 x 107 
1 ND = Not determined 
 
4.1.6. Methods of 2-Arylbenzoxazole Synthesis 
To complete a SAR study on the minimum pharmacophore and potentially improve the 
druglike properties of TOP027, a library of C2 aryl analogs was needed. A review of the 
literature shows some common trends. Sections are divided as follows: condensation reactions, 
oxidative couplings, closure onto aryl halides, multicomponent couplings, and biaryl couplings at 
C2.  
4.1.6.1. Condensation of aminoalcohols with carboxylic acid or carboxylic acid equivalents 
Condensation of an o-aminophenol with an aryl carboxylic acid is a classical route to 
benzoxazoles (Scheme 4.5). These reactions typically require high heat and catalytic acid to 
promote cyclization and dehydration. Although many varied conditions have been reported, 
TsOH is a commonly used acid.14 Other acid catalysis conditions include: boric acid 
(stoichiometric amounts used in conjunction with a Dean-Stark trap),15 polyphosphoric acid,16 
polyphosphate ester,17 acetic anhydride,18 and others. Milder reaction conditions can provide the 
product if the carboxylic acid is activated towards amide formation using reagents such as CDI,14 
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N,N-dimethyl chlorosulfitemethaniminium chloride (SOCl2/DMF),19 ionic liquid solvent,20 
microwave irradiation,21 or zeolite E4.22 Neat reactions containing Lawesson’s reagent have been 
subjected to microwave irradiation to give a range of 2-arylbenzoxazoles in yields ranging from 
71-90%.23  
 
Scheme 4.5. General scheme for C2-aryl benzoxazole from o-aminophenol and carboxylic acid. 
Another strategy is to use an acid chloride instead of a carboxylic acid (Scheme 4.6). This 
typically requires a basic additive to promote amide formation followed by a Lewis acidic 
additive to improve the cyclization and dehydration to the benzoxazole.14 Recently, there have 
been several reports of using microwave irradiation as an alternative to the Lewis basic and 
acidic additives.24 Reactions run in the microwave using dioxane as solvent and a slight excess of 




Scheme 4.6. Combination of acid chloride with o-aminophenol. 
 
Scheme 4.7. Benzoxazole synthesis from trifluoromethyl ketone and o-aminophenol. 
Also, instead of a carboxylic acid, a trihalomethylarene can undergo the same conversion 
when heated with o-aminophenol in the presence of catalytic polyphosphoric acid and heat 
(Scheme 4.7).25 Yields of this variant, however, are extremely variable, ranging from 35-98% 
depending on the substrate.25 
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Although trifluoromethylketones are not the same oxidation state as carboxylic acids, 
they too will form benzoxazoles with o-aminophenol.26 The initial reflux in toluene under acid 
catalysis yields the trifluoromethyl imine, which, upon treatment with LiHMDS, can undergo 
nucleophilic attack by the appendant phenolate, which collapses to give the benzoxazole 
product.26 
4.1.6.2. Oxidative coupling of aryl aldehydes with aminoalcohols 
 
 
Scheme 4.8. 2-Aryl benzoxazole formation using o-aminophenol and aryl aldehyde 
Many mild oxidants can mediate the cyclization between o-aminoalcohols and an 
aromatic aldehyde, including I2,27 PCC (on silica),28 thianthrene cation radical,29 DDQ,30 MnO2,  
Hypervalent iodine reagents can be used as oxidants,31 including solid-supported hypervalent 
iodine.32 One interesting variant is a radical reaction catalyzed by 4-
methoxytetramethylpiperidine N-oxide (4-methoxy-TEMPO) using aerobic conditions (so that 
O2 is the stoichiometric oxidant).33 Yields are good for a variety of aromatic aldehydes, with no 
obvious electronic effects, but the reaction may require refluxing xylenes as the solvent for good 
yields. 
4.1.6.3. Oxidative coupling of benzyl alzohols with aminoalcohols 
 
 
Scheme 4.9. Synthesis of 2-aryl benzoxazoles using a benzylic alcohol in presence of an oxidant 
Using an alcohol instead of an aldehyde has also been reported by Wilfred and Taylor 
(Scheme 4.9).34 The authors propose that the oxidant, MnO2 in this case, oxidizes the alcohol to 
an aldehyde, which then forms an N,O-acetal.34 This N,O-acetal can then undergo a second 
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oxidation to the benzoxazole. The reported yield using benzyl alcohol and 2.5 eq. o-aminophenol 
in refluxing toluene with 15 equivalents of activated MnO2 was 73%.34 
 
 
Scheme 4.10. Triphenylphosphine-carbon tetrachloride mediated coupling of aminoalcohol to 
carboxylic acid35 
One method which avoids high temperatures and harsh conditions involved activation of 
a carboxylic with an aminoalcohol in the presence of triphenylphosphine and carbon 
tetrachloride (Scheme 4.10).35 Protection of amines or hydroxyl groups on the aromatic ring of 
the carboxylic acid was unnecessary when aliphatic aminoalcohols were used.35 This method has 
not been reported for coupling of aromatic carboxylic acids with aromatic amino alcohols. Yields 
ranged from 52-74%, depending on the substituents.35 A variant of this process is reported with 
aromatic carboxylic acids involves activation of the carboxylic acid by polymer-supported 
triphenylphosphine and Cl3CCN under microwave irradiation.36 Microwave heating (to 150 °C) 
is required to close the intermediate amide into the benzoxazole.36 Yields for this benzoxazole 
formation range from 79-97%, with lowered yields observed when an electron-poor group (i.e. 
carboethoxy ester or nitro) is appended to the benzoxazole ring.36 
4.1.6.4. Ring-closing onto aryl halides 
 
Scheme 4.11. Benzoxazole formation using copper (I) catalysis to combine 1,2-dihalobenzene 
and aromatic amide 
Glorius et al. report a benzoxazole synthesis that reverses the sense of electrophilicity and 
nucleophilicity traditionally used to construct benzoxazoles.37 In this case, the coupling proceeds 
 202 
between a 1,2-dihalobenzene and an aromatic amide.37 Electron-poor amides appear to give 
slightly higher yields, but all transformations reported proceed in yields ranging from 67-86%. 
The preformed 2-halo aryl amide will cyclize efficiently under similar conditions (Scheme 
4.12).38,39 One such transformation uses CuI with 1,10-phenanthroline as a ligand in presence of 
cesium carbonate in refluxing 1,2-dimethoxyethane.39 Microwave heating speeds conversion.40 
This cyclization of the intermediate 2-halo aryl amide also works in water as a solvent, but the 
required temperature remains 120 °C, necessitating use of a sealed tube.41 In addition to Cu(I) 
catalysts, Fe(III) with a diketonate ligand has also been used.42 This transformation also requires 
elevated temperature (120 °C in DMF) over extended reaction periods.42 
 
Scheme 4.12. O-Arylation to close benzoxazole ring 
4.1.6.5. Multicomponent Couplings 
 
Scheme 4.13. Pd-catalyzed CO insertion to form benzoxazole ring 
o-Aminophenol can undergo a multicomponent coupling with CO and an aryl iodide in 
presence of catalytic palladium to generate the intermediate o-amidophenol, which can then be 
closed under the standard conditions using heat and p-toluenesulfonic acid.43 This transfomation 
provides the final benzoxazoles in 74-97% overall yield.43 Heteroaromatic aryl iodides 
participate in this transormation, including 2-iodothiophene and 2-bromopyridine.43 
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4.1.6.6. Couplings at C2 
 
Scheme 4.14. Coupling at C2 of unsubstituted benzoxazole.44 
In 2004, Ellman et al. reported a coupling on benzoxazoles and benzimidazoles that 
proceeds via Rh-catalyzed N-heterocyclic carbene formation at the C2 position of the 
heteroaromatic ring (Scheme 4.14, top).44 Rhodium (I) in presence of tricyclohexylphosphine and 
triethylamine generates the N-heterocyclic carbene. The metal center then undergoes oxidative 
addition by the aryl iodide, followed by reductive elimination to generate the coupled product. 
Yields were lowest with electron poor aryl halides.44 When 1-bromo-4-fluorobenzene is used 
instead of bromobenzene, the yield decreases from 79% to 30%.44  
Palladium catalysis also allows direct substitution at C2 on the benzoxazole system 
(Scheme 4.14, bottom). A report in 2009 by You et al. does not require CuBr or ligand, using 
catalytic pivalic acid instead (Scheme 4.14, center).45 Catalytic palladium and pivalic acid in 
presence of stiochiometric base (potassium triphosphate) at elevated temperatures in DMF 




Scheme 4.15. Modified Suzuki coupling at C2 of benzoxazole.46 
Recently, Liebeskind et al. reported a modified Suzuki coupling at C2 of benzoxazoles 
(Scheme 4.15).46 This coupling is one of the mildest reported to synthesize benzoxazoles. 46 The 
copper thiophene-2-carboxylate (CuTC) is proposed to both complex the palladium to facilitate 
oxidative addition and to activate the boronic acid so that it undergoes efficient transmetallation 
to the palladium. 46 In the original publication, both the free, primary amide and dimethyl amide 
could undergo coupling with no difference in yield. 46 
4.2. PROPOSED RESEARCH 
We wanted to find a route suitable for the rapid assembly of UK-1 analogs, both the 
bis(benzoxazole) and the monobenzoxazole minimum pharmacophore (TOP027). Ideally, a 
wide variety of building blocks would be available to introduce functionality in a systematic 
manner. We hoped to develop a route that would be very modular, introducing points of 
difference late in the synthesis using inexpensive starting materials and developing robust, 
scalable reactions. Also, because we were interested in installing functionalized aryl groups, it 
was important to try to avoid high temperatures and strong acids. For our initial library, we 
selected compounds that might distort the arrangement of Lewis basic sites to probe what the 
requirements are for cytotoxicity. If metal binding is critical, the 2-amino substrate TOP071 
should show good activity. The series of 3- and 4-substituted aromatic rings will show what 
steric constraints are tolerated, and whether the metal-binding can occur at a slightly longer 
distance between Lewis bases than previously suggested.9 TOP074, which has a 2-pyridyl 
substituent, would shorten the geometry, and the bound metal would form a five-membered ring 
rather than a six-membered ring. 
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4.2.1. Proposed C2 Analog Series 
 
 
Figure 4.11. Proposed C2 analogs 
There are two unique challenges associated with synthesizing these analogs. Although 
there are many reported methods to generate benzoxazoles, many perform poorly when the o-
aminophenol includes an electron-withdrawing substituent. The nucleophilicity of the amine is 
greatly diminished. Additionally, the required intermediate 3-hydroxyanthranilic acid methyl 
ester is subject to oxidation, and isolation is often difficult. Although it is commercially 
available, it is expensive. Previous work in the Kerwin lab used the commercially available 3-
methoxy-2-nitrobenzoic acid to synthesize the intermediate 2-hydroxyanthranilic acid methyl 
ester. Our first retrosynthetic analysis took an approach that would allow introduction of 
differences at both C2 and C7. The route was highly modular and avoided the use of the 3-
hydroxyanthranilic acid methyl ester (Scheme 4.16). The carboxymethyl group could be installed 
by carbonylation of the aryl halide in methanol using palladium catalysis. This would allow 
installation of a variety of esters or even aryl groups. To assemble the benzoxazole ring, we 
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chose to use the method reported by Glorius et al.37 to close the amide onto the aryl halide. This 
method then allows use of a variety of aromatic acid chlorides, which can either be purchased 
directly or synthesized from the corresponding acid.  
 
 
Scheme 4.16. Retrosynthetic analysis of minimum pharmacophore analogs. 
4.3. SYNTHESIS 
4.3.1. Copper (I) Catalyzed Ring Closing 
This proposed route would allow improved access to a variety of UK-1 analogs to 
generate detailed SAR data, which could lead to improved pharmacological properties as an 
anticancer agent. We began by synthesizing the amide from 2,6 dibromoaniline. Anilines are less 
nucleophilic than aliphatic amines, and this aniline is extremely hindered because of the flanking 
bromines, which made this reaction more demanding than a standard amide formation. The 
reaction was optimized by screening a variety of conditions (Table 4.6). We found that using 
oxalyl chloride key to obtaining good yields of the amide. The resulting crude product from the 
optimized conditions (Table 4.6, Entry 11) was clean when analyzed using 1H NMR and TLC. 
The procedure was amenable to scale-up to multigram scale. 
 
Scheme 4.17. Amide formation from benzyloxysalicylic acid and 2,6-dibromoaniline 
Table 4.6. Amide formation optimization 
Entry Formation of Amide formation Concentration Temperature Percent Yield 
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Acid Chloride (M) (°C) 
1 SOCl2 
Pyr (1.2 eq) in 
DCM 
0.2 0→21 0 
2 SOCl2 
Pyr (1.2 eq) in 
DCM→toluene 
0.2 21→110 0 
3 SOCl2 NaH in THF:DMF 0.2 21 0 
4 SOCl2 Toluene 0.2 110 
22% 
deprotecteda 
5 SOCl2 neat neat 130 
11%; 5 % 
deprotected 
6 SOCl2 Neat (2 eq amine) neat 120; 90 min. 0 
7 SOCl2 DMF 1M 120 0 
8 SOCl2 THF 1M Δx 0 
9 (COCl)2 DMF (2 eq amine) 10M 130 
28%, 13% 
deprotected 
10 (COCl)2 DMF 7M rt 
56%, 13% 
deprotected 
11 (COCl)2 DMF 7M 50 63% 
12 (COCl)2 DMF 7M 95 
54%, 6% 
deprotected 
a Average of two trials 
With the amide in hand, we attempted the copper(I)-catalyzed ring closing using 
conditions similar to those reported by Glorius et al.37 Copper iodide was used as the copper 
sourse, with N,N’-dimethylethylenediamine (N,N’-dmeda) as ligand, two equivalents potassium 
carbonate, and refluxing toluene. Conditions were optimized by changing the ligand, solvent and 
temperature (Table 4.7). Elevated temperatures were required. 1,10-phenanthroline was preferred 
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because doxygenation was easier with a solid than a liquid ligand. Coordinating solvents 
performed best in this system. We speculate that this is because they complete with product 
benzoxazole to coordinate the catalyst and improve turnover. Finally, conditions similar to those 
reported by Batey et al.39 were found to successfully cyclize the amide (Table 4.7, Entry 9). Our 
cyclization worked nicely even at 5 mol% catalyst loading, giving a crude product that was clean 
as judged by 1H NMR and TLC in 82% yield.  
 
 
Scheme 4.18. Optimization of Cu(I)-catalyzed benzoxazole ring closing. 
Table 4.7. Optimization of Cu(I)-catalyzed ring-closing 
Entry 






1 5 N,N’-dmeda toluene 110 RSMa only 
2 20 N,N’-dmeda toluene 110 45%c 
3 30 N,N’-dmeda toluene 110 26% c 
4 20 N,N’-dmeda toluene 130d 44% c 
5 20 1,2-phenylenediamine toluene 130 45% c 
6 20 1,10-phenanthroline toluene 130 44% c 
7 20 1,10-phenanthroline DCE 130 36% c 
8 20 1,10-phenanthroline DMSO 130 66% 
9 20 1,10-phenanthroline DME 130 83% 
10 5 1,10-phenanthroline DME 130 82% 
aRSM = recovered starting material b Ligand loading was always 2 eq. with respect to CuI. cRSM also isolated. 
dSealed tube 
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With optimized conditions in hand, we attempted the carbonyl insertion. A similar 
process for electronically challenging substrates was recently reported by Albaneze-Walker et 
al.47 After 1 h, we observed a 10% conversion. We were encouraged to see that the reaction gave 
10% conversion to the ester after 1 h. However, the conversion required high temperature and 
pressure.  
 
Scheme 4.19. CO insertion onto 4-bromobenzoxazole 
After establishing that this was a feasible route to C2-aryl analogs, we began to 
synthesize some related amides using other aryl acid chlorides. To our great disappointment, the 
conditions optimized for the acid chloride of 2-benzyloxybenzoic acid were not generalizable for 
other acid chlorides (Scheme 4.20). Initial attempts at optimization were unsuccessful.  
 
Scheme 4.20. Amide formation with varied acid chlorides. 
We realized that this route, which introduced the structural diversity at the first step, 
might not be the best way to generate our library. If the first step for each partner required 
optimization, this did not meet the requirement for easy synthesis of many analogs. Also, the 
forcing conditions (high pressure, high temperature) for both the benzoxazole ring closing and 
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the carbonylation could become problematic for some library elements with more sensitive 
functionalities. Finally, the 2,6-dibromoaniline is costly, $10 per gram. We decided to explore 
alternative routes to our library that would introduce diversity late in the synthesis, use mild 
conditions to preserve sensitive functionality, and be cost-effective. 
4.3.2. Thiobenzoxazole-Derived Coupling Partner 
An alternative to the copper-catalyzed benzoxazole ring formation was a biaryl coupling 
at C2 of the benzoxazole. These couplings were reported by Liebeskind to proceed under lower 
temperature than any of the alternative benzoxazole ring closures.46 We envisioned a route where 
diversity of the library was introduced at the final step, allowing rapid generation of analogs. 
Although this route does use the 3-hydroxyanthranilic acid methyl ester, this compound has been 
used before with success.  
 
 
Scheme 4.21. Revised retrosynthetic analysis 
Forming the 3-hydroxyanthranilic methyl ester followed previously published procedure 
and proceeded smoothly (Scheme 4.22).48 Using the very inexpensive m-cresol as the starting 
material afforded multigram quantities of the desired carboxylic acid. Electrophilic aromatic 
substitution using sulfonic acid as a blocking group generates TOP057 in moderate yield. 
Formation of the sodium phenolate salt under aqueous conditions, followed by concentration to 
driness and reflux in dimethylsulfate generates the methyl ether TOP058 in good yield. Benzylic 
oxidation using potassium permnganate gives TOP050, which is commercially available but 




Scheme 4.22. Synthesis of 3-methoxy-2-nitrobenzoic acid. 
We then turned our attention to the synthesis of the 3-hydroxyanthranilic acid methyl 
ester (Scheme 4.23). Hydrogenation proceeded smoothly and in high yield. Conditions 
previously reported for the deprotection included isolation of the free base using sodium acetate 
to neutralize the hydrogen bromide salt. We found that the neutralization could be omitted and 
the salt directly subjected to Fisher esterification without any loss in yield. We hoped to use the 
hydrochloric acid salt of the anthranilic acid to proceed, as the salt appears to be stable to 
oxidation at room temperature, whereas the free base is relatively unstable, decomposing even at 
low temperatures.  
 
 
Scheme 4.23. Synthesis of the HCl salt of 3-hydroxy anthranilic acid methyl ester. 
The use of carbon disulfide in the presence of aqueous base to generate the 
thiobenzoxazole was originally reported as an Organic Syntheses procedure for forming 2-
mercaptobenzimidazole, but the authors note that by replacing the 1,2-phenylene diamine with o-
aminophenol, they were able to isolate the mercaptobenzoxazole in 80% yield (Scheme 4.24).49 
We were concerned that the aqueous base might also hydrolyze the methyl ester. This 
transformation did yield the desired product, but it was difficult to purify, and yields were poor.  
 
Scheme 4.24. Formation of thiobenzoxazole via aqueous, basic carbon disulfide49 
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An alternative procedure that was likely to be more compatible with the methyl ester was 
one reported by Fielder and Collins using phosgene to form 7-carbomethoxybenzoxazoline-2-
one (Scheme 4.25).50 It seemed reasonable to try to analogous reaction using thiophosgene. We 
speculated that we could use the HCl salt of the 3-hydroxyanthranilic acid methyl ester if we 
used one extra equivalent of base.  
 
 
Scheme 4.25. Phosgene addition to 3-hydroxyanthranilic acid methyl ester 
Either reaction did produce the desired product; however, the use of thiophosgene gave 
higher yields, and purification was more facile. Some dimer formation to the thiourea was 
observed, but it was minimized by using dilute (20 mM) reaction conditions (Scheme 4.26). 
Additionally, this method proved to be tolerant of deprotonation of the ammonium salt in situ, 
which limited decomposition of the 3-hydroxyanthranilic acid methyl ester. The coupling partner 
was synthesized using 2-chloroacetamide to alkylate the sulfur. 
 
Scheme 4.26. Synthesis of coupling partner. 
The coupling partner, which could generate analogs of the minimum pharmacophore was 
generated in eight steps with 9% overall yield.10,48 The coupling reaction was then optimized 
using phenylboronic acid (Scheme 4.27). Liebeskind et al. note that they observed no difference 
between the primary amide and the dimethyl amide in their couplings.46 However, in this case, 
no coupling product could be obtained with the free amide (Table 4.8). The only observed 





























Scheme 4.27. Optimization of Coupling Reaction 










1 1 (2-furyl)3P 4 0.05 110 4%RSM 
2 2 (2-furyl)3P 8 0.05 110 38%RSM 
3 4 (2-furyl)3P 16 0.05 110 49% RSM 
4 4 (2-furyl)3P 16 0.1 110 65% RSM 
5 4 (2-furyl)3P 16 0.2 80 
39% RSM,  
trace TOP076 
6 4 (Ph)3P 16 0.2 80 
12% RSM,  
16% TOP076 
7 4 (o-tolyl)3P 16 0.2 80 
6% RSM,  
11% TOP076 
8 4 (o-tolyl)3P 16 0.2 110 78% TOP076 
 
We then attempted the same coupling with the dimethylamide TOP054 (Table 4.9). 
Luckily, these couplings did give some of the desired coupling product. To determine the origin 
of the undesired byproduct, control reactions were performed, omitting reagents systematically. 
It was found that the formation of the byproduct requires both the catalyst/ligand complex and 
the boronic acid. Thinking that perhaps the boronic acid was responsible for proteolysis, we tried 
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using transmetallating agents that are aprotic, including a borate ester and a potassium 
trifluoroborate salt (Table 4.9, Entries 6 and 7). None of these cross-couplings were successful. 
We decided to turn our attention to synthesizing some of our analog library to see whether the 
yield improved with electronic substituent effects. 
Table 4.9. Optimization of Liebeskind coupling for R = Mea 






1 PhB(OH)2 (1.1) 1.3 0.05 
38% TOP066 (46% - RSM); 
18% RSM, 71% 3 
2 PhB(OH)2 (1.1) 1.3 0.025 
24% TOP066 (50% - RSM), 
38% RSM, 64% 
TOP076+TOP063 
3 PhB(OH)2 (1.1) 2.2 0.05 22% TOP066, 44% TOP063 
4 PhB(OH)2 (2.2) 1.1 0.05 37% TOP066, 34% TOP063 
5 PhB(OH)2 (2.2) 2.2 0.05 48% TOP066, 19% TOP063 
6 PhBF3K (1.1) 1.3 0.05 RSM 
7 PhBF3K (1.1) 0 0.05 RSM 
8 PhB(OC(CH3)2)2 (1.1) 1.3 0.05 RSM, C 
a Standard conditions: 1 mol% Pd2dba3, 4 mol% (2-furyl)3P, 110 °C, 16 h 
 
The couplings proceeded well (Scheme 4.28). Significant amounts of the byproduct were 
produced, but in cases where the desired coupling product did not include a phenol, basic 
extraction efficiently removed the byproduct. In the phenolic cases, the byproduct could be 
















TOP066 Ar = Ph, 47%
TOP067 Ar = 3-HOPh, 59%
TOP068 Ar = 4-HOPh, 50%
TOP069 Ar = 2-NO2Ph, 46%
TOP070 Ar = 3-NO2Ph, 59%
TOP075 Ar = 2-FPh, 31%
TOP073 Ar = 4-pyr, no pdt
TOP054
 
Scheme 4.28. Couplings to assemble library of C2-aryl benzoxazoles 
Yields were moderate in most cases. The 2- and 3-nitro compounds serve as precursors to 
the amines TOP071 and TOP072. Reductions using hydrogenation are currently ongoing. The 
coupling with 4-pyridylboronic acid was disappointing, giving only the byproduct discussed 
previously following isolation. There does not appear to be a strong electronic effect of yield of 
these coupling reactions, as the 3-hydroxyphenylboronic acid and 3-nitrophenylboronic acid give 
identical yields of their respective products.  
4.3.3. Attempted Extension of Thiobenzoxazole Route to Synthesis of UK-1 
We realized that the 7-bromobenzoxazole generated from the copper (I) catalyzed ring 
closing might provide access to UK-1 itself if it would be converted to the corresponding boronic 
acid.  
 
Scheme 4.29. Proposed route to UK-1. 
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We realized that it was possible to adapt this route to synthesize UK-1 (Scheme 4.29). 
With the halide at C7 of the benzoxazole, it might be possible to generate a boronic acid. No 
benzoxazoles of this structure have been reported in the literature, although C2 boronic acids of 
benzoxazoles are known. Unfortunately, attempt at metal-halogen exchange were unsuccessful. 
Initially, the aryl halide was combined with n-butyllithium at -78 °C in 0.4 M THF. 
Unfortunately, using either triisopropylborate or methyl chloroformate to quench the reaction did 
not generate the desired trapping products. Quenching aliquots with D2O showed that while the 
starting material was consumed after 5 min. at -78 °C, deuterium incorporation at C4 of the 
benzoxazole ring was not observed. Mass spectrometric analysis of the reaction mixture showed 
loss of the benzyloxy group. Adding the triisopropylborate as an in situ quench did not improve 
the results. Diluting the reaction mixture for the metal-halogen exchange to 1 mM in THF 
showed no D-incorporation by mass spectrometry after 30 min., but these reactions also did not 
show any loss of the benzyl group. Explorations in this area are ongoing.  
4.4. CONCLUSIONS 
We have developed a facile route to a library of C2-aryl benzoxazoles. Use of this route 
to assemble UK-1 or bis(benzoxazole) analogs does not appear promising, but optimization is 
incomplete. The route to the C2-aryl analogs is inexpensive and operationally simple. Also, 
because it relies on boronic acids, there are many commercially available possibilities for library 
synthesis. It appears to be highly functional group-tolerant and avoids the harsh conditions (acid 
and heating) typically required to form benzoxazoles. Synthesis of a full library is ongoing.  
4.5. FUTURE WORK 
These C2-aryl analogs will be assayed for their metal dependent DNA binding properties, 
as well as their cytotoxicity. It is hoped that this information about the function of the 2-
hydroxyphenyl group at C2 will allow synthesis of highly soluble and potent UK-1 analogs that 
can serve as antineoplastic agents. 
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4.6. EXPERIMENTAL SECTION 
General Notes 
THF, 1,2-dimethoxyethane, and dioxane were distilled over sodium/benzophenone, and 
CH2Cl2, 1,2-dichloroethane, and toluene were distilled from CaH2 immediately prior to use. All 
reactions were run in argon-flushed round bottom flasks that had been dried, either in a 110 °C 
oven or by flame under vacuum, under an argon atmosphere. Solvent ratios are expressed as % 
by volume. Flash chromatography (FCC) was performed according to the method of Still.51 
NMR was performed using a VARIAN Mercury spectrometer. 1H NMR was run at 400 MHz; 
13C NMR was run at 100 MHz with broadband proton decoupling unless otherwise specified. 
Solvent chemical shifts are reported in ppm (δ) and referenced to solvent.52 IR was obtained on a 
Nicolet IR100 FT-IR spectrometer. Melting points were obtained in open capillary tubes on a 
Büchi Melting Pont B-540 and are uncorrected. 
 
 
TOP 053. 2-Thioxo-2,3-dihydrobenzoxazole-4-carboxylic acid methyl ester. The 
hydrochloride salt of 3-hydroxyanthranilic acid methyl ester (3.05 g, 15 mmol, 1 eq) was 
suspended in dry DCM (100 mL) and cooled in an ice-water bath to 0 °C. To this solution was 
added dry triethylamine (5.23 mL, 37.5 mmol, 2.5 eq). An addition funnel was charged with 
thiophosgene (1.26 mL, 16.5 mmol, 1.1 eq) in DCM (50 mL), and this solution was added 
dropwise at 0 °C to the aminoalcohol. The solution was allowed to warm to room temperature 
overnight. After 16 h, the mixture was poured onto satd NH4Cl (100 mL). The aqueous layer was 
extracted with DCM (2x50 mL). The combined organic layers were dried (Na2SO4), and conc. 
The product was adsorbed to silica and purified via FCC using a gradient of hexanes-50% 
EtOAc/Hex. The product was isolated as an orange solid (1.90 g, 9 mmol, 61%). This sample 
was recrystallized to remove any dimeric product (which co-elutes) to give the product as a pale 
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yellow solid (1.15 g, 34%). 1H NMR (CDCl3): δ 10.42 (1H, br s); 7.82 (1H, dd, J = 8.0, 0.9 Hz); 
7.49 (1H, d, J = 8.2 Hz); 7.28 (1H, t, J = 8.2 Hz); 4.01 (3H, s). 13C NMR (CDCl3): δ 180.8, 
165.1, 149.1, 131.9, 129.5, 125.7, 123.6, 114.3, 112.6, 52.8. LRMS (CI+): 210 (M++1), 178 (M+-
S). HRMS (CI+): calcd. for C9H7NO3S 210.0225, found 210.0221. IR (thin film, DCM): 2919, 
1688, 1491, 1421, 1368, 1308, 1259, 1178, 1126, 1012, 929 cm-1. mp 197.5-198.3 °C. 
 
TOP 061. 2-Carbamoylmethylsulfanylbenzoxazole-4-carboxylic acid methyl ester. 
TOP053 (830 mg, 4.0 mmol, 1 eq) was dissolved in dry THF (8 mL, 0.5 M) with stirring. To 
this was added dry triethylamine (1.22 mL, 8.7 mmol, 2.2 eq) followed by 2-chloroacetamide 
(390 mg, 4.2 mmol, 1.05 eq). The reaction was stirred at room temperature overnight. In the 
morning, the reaction was partitioned between chloroform (30 mL) and satd NH4Cl (30 mL). The 
aqueous layer was washed with CHCl3 (3 x 30 mL) until no product remained (as judged by 
TLC). The combined organic layers were washed with satd NH4Cl (30 mL), water (30 mL), and 
brine (30 mL), dried (Na2SO4), and concentrated. The product was adsorbed to silica prior to 
column chromatography. The column was eluted with a gradient system, beginning at 50% 
EtOAc/Hex (100 mL), increasing to 75% EtOAc/Hex (100 mL), 100% EtOAc (100 mL), 5% 
MeOH/EtOAc, (100 mL) and 10% MeOH/EtOAc (100 mL). The product was isolated as a light 
orange solid (771 mg, 2.9 mmol, 77%), which was recrystallized before use in the coupling 
reactions from EtOAc/Hex. 1H NMR (CDCl3): δ 8.07 (1H, br s); 7.97 (1H, dd, J = 7.9, 1.1 Hz); 
7.66 (1H, dd, J = 8.2, 1.0 Hz); 7.35 (1H, t, J = 7.9 Hz); 5.66 (1H, br s); 3.98 (3H, s); 3.92 (2H, s). 
1H NMR (d6-DMSO):  7.91 (1H, d, J = 8.2 Hz); 7.84 (1H, d, J = 7.0 Hz), 7.82 (1H, br s); 7.41 
(1H, t, J = 8.0 Hz); 7.38 (1H, br s); 4.16 (2H, s); 3.32 (3H, s). 13C NMR (CDCl3): δ 170.3, 167.7, 
165.1, 152.8, 140.7, 126.8, 123.8, 120.2, 114.5, 52.3, 34.8. LRMS (CI+): 267 (M++1). HRMS 
(CI+): calcd. for C11H11N2O4S 267.0440, found: 267.0445. IR (KBr pellet): 3388, 3196, 1704, 
1661, 1500, 1425, 1301, 1236, 1137, 763 cm-1. mp: 163.8-165 °C.  
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TOP 054. 2-Dimethylcarbamoylmethylsulfanylbenzoxazole-4-carboxylic acid methyl 
ester. TOP053 (311 mg, 1.5 mmol, 1 eq) was dissolved in dry THF (3 mL, 0.5 M) with stirring. 
To this was added dry triethylamine (456 µL, 3.3 mmol, 2.2 eq) followed by N,N-dimethyl-2-
chloroacetamide (161 µL, 1.6 mmol, 1.05 eq). The reaction was stirred at room temperature 
overnight. The reaction was partitioned between chloroform (30 mL) and satd NH4Cl (30 mL). 
The aqueous layer was washed with CHCl3 (3 x 30 mL) until no product remained (as judged by 
TLC). The combined organic layers were washed with satd NH4Cl (30 mL), water (30 mL), and 
brine (30 mL), dried (Na2SO4), and concentrated. The product was adsorbed to silica prior to 
column chromatography. The column was eluted with a gradient system, beginning at 50% 
EtOAc/Hex (100 mL), increasing to 75% EtOAc/Hex (100 mL), 100% EtOAc (100 mL), 5% 
MeOH/EtOAc, (100 mL) and 10% MeOH/EtOAc (100 mL). The product was isolated as a light 
orange solid (337 mg, 1.1 mmol, 77%), which was recrystallized before use in the coupling 
reactions from EtOAc/Hex. 1H NMR (CDCl3): δ 7.90 (1H, dd, J = 7.9, 1.0); 7.59 (1H, d, J = 8.2); 
7.26 (1H, t, J = 8.1); 4.42 (2H, s); 3.96 (3H, s); 3.20 (3H, s); 2.99 (3H, s). 13C NMR (CDCl3): δ 
167.1, 166.5, 165.4, 152.5, 141.4, 126.5, 123.2, 120.2, 113.0, 52.2, 37.7, 36.4, 35.9. LRMS (CI+): 
295 (M++1). HRMS (CI+): calcd. for C13H14N2O4S 295.0753, found 295.0753. IR (KBr pellet): 
3456, 1721, 1640, 1488, 1423, 1278, 1197, 1123, 750 cm-1. mp 121.9-123.9 °C. 
 
TOP063. Methyl 2-formamido-3-hydroxybenzoate. TOP054 (50 mg, 0.17 mmol, 1 eq) 
was combined with phenylboronic acid (45.2 mg, 0.37 mmol, 2.2 eq) in a 7 mL capacity thick-
walled tube. The tube was flushed with Ar, and dioxane (2.4 mL) was added. Pd2dba3, (0.7 mg, 
0.0016 mmol, 1 mol%) and trifurylphosphine (1.4 mg, 0.0014 mmol, 4 mol%) were added as a 
solution in dioxane (1 mL, final rxn. conc. 0.05 M). The tube was sealed, and the reaction was 
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heated to 110 °C for 16 h. After 16 h, the reaction was cooled and partitioned between ether (20 
mL) and water (15 mL). The aqueous layer was extracted with ether (2x15 mL), and the 
combined organic layers were washed with satd NaCl (20 mL), dried (MgSO4), and conc. The 
reaction mixture was absorbed to silica and FCC (SiO2) in a gradient 10% EtOAc/Hex→25% 
EtOAc/Hex. Fractions were allowed to evaporate overnight to improve recovery, as the product 
is not easily seen by TLC. The product was isolated as a white solid (22.7 mg, 0.12 mmol, 71%). 
An analytical sample was recrystallized from EtOAc/Hex. 1H NMR (400 MHz, d6-DMSO): δ 
11.80 (1H, br s); 7.63 (1H, d, J = 8.2); 7.52 (1H, d, J = 8.2); 7.18 (1H, t, J = 8.1); 3.87 (3H, s). 
13C (100 MHz, d6-DMSO): δ 164.4, 154.3, 143.9, 131.2, 124.2, 121.5, 113.9, 113.4, 52.1. LRMS 
(CI+): 194 (100%, M+), 162 (M+-OCH3). mp = 226.8-227.4 °C.  
General procedure for Liebeskind coupling reactions: 
TOP054 (50 mg, 0.17 mmol, 1 eq) was combined with the appropriate arylboronic acid 
(0.37 mmol, 2.2 eq) and CuTC (71.2 mg, 0.27 mmol, 2.2 eq) in a 7 mL capacity thick-walled 
tube. The tub was flushed with Ar, and dioxane (2.4 mL) was added. Pd2dba3, (0.7 mg, 0.0016 
mmol, 1 mol%) and trifurylphosphine (1.4 mg, 0.0014 mmol, 4 mol%) were added as a solution 
in dioxane (1 mL, final rxn. conc. 0.05 M). The tube was sealed, and the reaction was heated to 
110 °C for 16 h. After 16 h, the reaction was cooled and partitioned between ether (20 mL) and 
satd NaCl (15 mL). The aqueous layer was extracted with ether (2x15 mL), and the combined 
organic layers were washed twice with 15 mL of 2 M NaOH (except TOP067 and TOP068, for 
which this step was omitted) with satd NaCl (20 mL), dried (MgSO4), and conc. The reaction 
mixture was absorbed to silica and FCC (SiO2) in an appropriate mixture of EtOAc/Hex.  
 
TOP066. 2-Phenylbenzoxazole-4-carboxylic acid methyl ester.53 FCC in 10% 
EtOAc/Hex. Fractions were allowed to evaporate overnight to improve recovery, as the product 
is not easily seen by TLC. The product was isolated as a white solid (20.7 mg, 0.08 mmol, 48%). 
An analytical sample was recrystallized from EtOAc/Hex. 1H NMR (400 MHz, CDCl3): δ 8.33 
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(2H, dd, J = 7.7, 1.7); 8.01 (1H, dd, J = 7.8, 1.0); 7.75 (1H, dd, J = 8.1, 0.9); 7.54-7.48 (3H, m); 
7.38 (1H, t, J = 8.0) 4.05 (3H, s). 13C NMR (100 MHz, CDCl3): δ 165.7, 164.6, 151.3, 141.6, 
132.0, 128.8, 128.1, 126.9, 126.4, 124.3, 121.9, 114.8, 52.4. LRMS (CI+): 254 (M++1). HRMS 
(CI+): calcd for C15H11NO3: 254.0817, found 254.0811. mp 75-80 °C. (lit.53 78-81 °C) 
 
TOP067. 2-(3-Hydroxyphenyl)-benzoxazole-4-carboxlic acid methyl ester. FCC in 
Hexanes→25% EtOAc/Hex yielded the product as a white solid (27 mg, 0.10 mmol, 59%). 1H 
NMR (CDCl3): δ 8.03 (1H, dd, J = 7.8, 1.0); 7.89 (1H, s); 7.84 (1H, d, J = 7.8); 7.77 (1H, dd, J = 
8.0, 1.0); 7.42 (1H, t, J = 7.7); 7.37 (1H, t, J = 7.9); 7.05 (1H, dd, J = 8.0, 1.7); 6.64 (1H, br s); 
4.03 (3H, s). 13C NMR (d6-acetone): δ 166.0, 164.8, 158.8, 152.3, 142.3, 131.2, 128.8, 127.5, 
125.5, 123.4, 120.2, 119.9, 115.7, 115.1, 52.3. LRMS (CI+): 270 (M++1), 238. HRMS calcd. for 
C15H11NO4, 270.0766 found 270.0762. IR (KBr): 3215, 1781, 1722, 1687, 1635, 1464, 1431, 
1320, 1261, 1130, 952, 748, 737 cm-1. mp 177.8-178.9 °C. 
 
TOP 068. 2-(4-Hydroxyphenyl)-benzoxazole-4-carboxlic acid methyl ester. FCC 
(Hexanes→25% EtOAc/Hex) yielded the product as a white solid (22.7 mg, 0.084 mmol, 50%). 
1H NMR (CDCl3): δ 8.24 (2H, d, J = 8.8); 8.01 (1H, dd, J = 7.8, 1.0); 7.75 (1H, dd, J = 8.0, 1.0); 
7.44 (1H, s); 7.38 (1H, t, J = 8.0); 7.15 (1H, t, J = 8.0); 7.02 (2H, d, J = 8.8); 4.05 (3H, s). 13C 
NMR(d6-acetone): δ 166.2, 165.3, 162.1, 152.3, 142.7, 130.7, 127.3, 124.8, 122.8, 118.9, 116.9, 
115.3, 52.2. LRMS (CI+): 270 (M++1), 185. HRMS (CI+): calcd. for C15H11NO4 270.0766, found 
270.0766. IR (KBr): 3352, 1709, 1610, 1597, 1424, 1297, 1269, 1240, 1227, 1197, 1170, 1145, 
1053, 848, 757 cm-1. mp (decomp) 211.7-213.9 °C. 
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KeTOP069. 2-(2-Nitrophenyl)-benzoxazole-4-carboxylic acid methyl ester.7 FCC 
(25% EtOAc/Hex) yielded the product as a white solid (23.3 mg, 0.078 mmol, 46%). 1H NMR 
(CDCl3): δ 9.14 (1H, m), 8.69 (1H, dd, J = 7.8, 1.2 Hz); 8.42-8.39 (1H, m); 8.07 (1H, dd, J = 7.8, 
1.0 Hz); 7.83 (1H, dd, J = 8.1, 0.9); 7.74 (1H, t, J = 8.0); 4.07 (3H, s). 13C NMR (CDCl3): 
δ 165.5, 162.1, 151.4, 148.6, 141.2, 133.7, 130.1, 128.3, 127.5, 126.3, 125.4, 122.9, 122.6, 115.2, 
52.6. LRMS (CI+): 299 (M++1), 269 (M+-OCH3). HRMS (CI+) calcd. for C15H10N2O5: 299.0668, 
found: 299.0666. IR (KBr): 1726, 1532, 1430, 1354, 1289, 1240, 1195, 1146, 1024, 759, 747, 
710 cm-1. mp 165.3-166.7 °C. 
 
KeTOP070. 2-(3-Nitrophenyl)-benzoxazole-4-carboxylic acid methyl ester. FCC 
(Hexanes-25% EtOAc/Hex) yielded the product as a white solid (29.8 mg, 0.10 mmol, 59%). 1H 
NMR (CDCl3): δ 9.13 (1H, t, J = 1.8); 8.68 (1H, ddd, J = 7.8, 1.2, 0.8); 8.40 (1H, ddd, J = 8.2, 
2.3, 1.2); 8.06 (1H, dd, J = 7.8, 1.0); 7.82 (1H, dd, J = 8.1, 1.1); 7.74 (1H, t, J = 8.0); 7.48 (1H, t, 
J = 7.9); 4.07 (3H, s). 13C NMR (CDCl3): δ 165.4, 162.0, 151.4, 148.6, 141.2, 133.7, 130.1, 
128.3, 127.5, 126.3, 125.4, 122.9, 122.6, 115.2, 52.6. LRMS (CI+): 299 (M++1). HRMS (CI+): 
calcd for C15H10N2O5: 299.0668, found: 299.0670. IR(KBr): 1782, 1735, 1713, 1686,  1655, 
1560, 1542, 1509, 1476, 1459, 1421, 1354, 1321, 1299, 1283, 1191, 1064, 794, 748, 710 cm-1. 






TOP075. 2-(2-fluorophenyl)-benzoxazole-4-carboxylic acid methyl ester. FCC (10% 
EtOAc/Hex) yielded the product as a white solid (14.2 mg, 0.052 mmol, 31%). 1H NMR 
(CDCl3): δ 8.36 (1H, td, J = 7.6, 1.8); 8.06 (1H, d, J = 7.8, 1.0); 7.82 (1H, dd, J = 8.1, 0.9); 7.55 
(1H, dddd, J = 12.4, 7.3, 4.9, 0.8); 7.45 (1H, t, J = 8.0); 7.32 (1H, td, J = 7.8, 1.2); 7.26 (1H, ddd, 
J = 11.0, 8.4, 1.0); 4.07 (3H, s). 13C NMR (CDCl3): δ 165.1, 161.4 (J = 4.6), 160.2 (JC-F = 259.8 
Hz); 151.31, 151.29, 141.0, 133.7 (JC-F = 8.5 Hz); 131.2, 127.2, 124.5 (JC-F = 3.9 Hz), 122.2, 
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116.0 (JC-F = 21.5 Hz), 115.1, 115.0 (JC-F = 10.8), 52.5. LRMS (CI+): 272 (M++1). HRMS (CI+) 
calcd for C15H10FNO3: 272.0271, found 272.0723. IR (KBr): 2952, 1716, 1655, 1543, 1317, 
1294, 1243, 1223, 1174, 1140, 1111, 1073, 1027, 758 cm-1. mp 90.0-90.4 °C.  
 
 
TOP 062. 2-Benzyloxy-N-(2,6-dibromophenyl)-benzamide. 2-Benzyloxysalicylic acid 
(2.90g, 12.7 mmol, 1 eq) was dissolved in DCM (24.4 mL, 0.52 M) and cooled to 0 °C in an ice-
water bath. Oxalyl chloride (1.31 mL, 15.3 mmol, 1.2 eq) was added dropwise and the reaction 
was warmed to room temperature. After gas evolution ceased, 1 drop DMF was added. After 1 h 
at room temperature, the reaction was concentrated by rotary evaporation to an off-white solid. 
The solid was dissolved in DMF (1.82 mL, 7 M), and 2,6-dibromoaniline (3.16 g, 12.7 mmol, 1 
eq) was added. The mixture was warmed to 50 °C overnight. A white solid formed after approx. 
30 min. After 16 h at 50 °C, the reaction was partitioned between Et2O (50 mL) and water (50 
mL). The aqueous layer was washed 2x with Et2O (30 mL), and the combined organic layers 
were washed with satd NaCl (50 mL) and dried (MgSO4). Concentration in vacuo yielded a 
white crystalline solid that was clean by 1H NMR and TLC. An analytical sample was 
crystallized from EtOAc/Hex to give a white solid (4.18 g, 9.11 mmol, 72%). 1H NMR (CDCl3, 
400 MHz): δ 9.58 (1H, s); 8.34 (1H, dd, J = 7.8, 1.1); 7.57 (2H, dd, J = 8.1, 0.6); 7.51-7.49 (3H, 
m); 7.38 (3H, m); 7.14 (2H, q, J = 8.0); 7.00 (1H, t, J = 8.0) 5.33 (s, 2H). 13C NMR (CDCl3, 100 
MHz): δ 163.1, 156.9, 135.4, 135.3, 133.5, 133.0, 132.1, 129.0, 128.9, 128.7, 127.9, 123.6, 
121.7, 121.0, 112.9, 71.5. LRMS (ESI+): 483.87. HRMS (ESI+): calcd: 459.9541, found 





TOP064. 2-(2-Benzyloxyphenyl)-4-bromobenzoxazole. Amide TOP062 (100 mg, 0.22 
mmol, 1 eq) was combined with copper(I) iodide (2 mg, 0.01 mmol, 5 mol%), 1,10-
phenanthroline (3.9 mg, 0.02 mmol, 10 mol%), and potassium carbonate (60 mg, 0.44 mmol, 2 
eq) were combined in a sealed tube and flushed with Ar. DME was added (670 µL, 0.33 M) was 
added, and the tube was sealed and heated to 130 °C overnight. After 16 h, the reaction was 
cooled to room temperature and partitioned between Et2O (10 mL) and water (20 mL). The 
aqueous layer was washed 2x with Et2O (20 mL), and the combined organic extracts were 
washed with satd NaCl (20 mL), and dried (MgSO4). The product was a white crystalline solid 
(68 mg, 0.18 mmol, 82%) which was clean as judged by TLC and 1H NMR. An analytical 
sample was recrystallized from EtOAc/Hex. 1H NMR (400 MHz, CDCl3): δ 8.26 (1H, d, J = 
7.5); 7.77 (2H, d, J = 7.2); 7.60-7.52 (3H, m); 7.47 (2H, t, J = 7.0); 7.37 (1H, t, J = 7.0); 7.30-
7.34 (1H, m); 7.20-7.12 (2H, m); 5.33 (2H, s). 13C NMR (100 MHz, CDCl3): δ 162.2, 157.6, 
150.5, 141.6, 136.6, 133.1, 131.5, 128.5, 127.6, 127.5, 126.7, 125.7, 121.0, 116.1, 113.5, 112.7, 
109.5, 70.4. LRMS (CI+): 380, 382 (M++1), 290, 292 (M+-OBn). HRMS (CI+): calcd. for 
C20H14BrNO2 379.0208, found 379.0204.  IR (KBr): 3056, 1612, 1580, 1547, 1497, 1473, 1455, 
1444, 1418, 1382, 1293, 1269, 1178, 1167, 1012, 847, 776, 735, 696, 464 cm-1. mp 98.4-100.9 
°C.  
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Scanned 1H and 13C NMR spectra 
 
 
 Figure A.1. MIS086 1H NMR 
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 Figure A.2. MIS086 13C NMR 
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 Figure A.3. MIS087 1H NMR 
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 Figure A.4. MIS087 13C NMR 
 232 
 
 Figure A.5. Isomyosmine 1H NMR 
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 Figure A.6. 13C NMR of isomyosmine 
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 Figure A.7. 1H NMR of NNN-5ʹ′-OAc 
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 Figure A.8. 13C NMR of NNN-5ʹ′-OAc 
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 Figure A.9. 1H NMR of MIS089. 
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 Figure A.10. 13C NMR of MIS089 
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 Figure A.11. 1H NMR of MIS096 
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 Figure A.12. 13C NMR of MIS096 
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 Figure A.13. 1H NMR of MIS097 
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 Figure A.14. 13C NMR of MIS097 
 242 
X-ray Crystallography data 
X-ray Experimental for C16H26N2O3S:  Crystals grew as colorless prisms by slow evaporation 
from DCM.  The data crystal was cut from a cluster of crystals and had approximate dimensions; 
0.13 x 0.12 x 0.10 mm.  The data were collected on a Nonius Kappa CCD diffractometer using a 
graphite monochromator with MoKα radiation (λ = 0.71073Å).  A total of 323 frames of data 
were collected using ω-scans with a scan range of 2° and a counting time of 134 seconds per 
frame.  The data were collected at 153 K using an Oxford Cryostream low temperature device.  
Details of crystal data, data collection and structure refinement are listed in Table 1.  Data 
reduction were performed using DENZO-SMN.1  The structure was solved by direct methods 
using SIR972 and refined by full-matrix least-squares on F2 with anisotropic displacement 
parameters for the non-H atoms using SHELXL-97.3  The hydrogen atoms on carbon were 
calculated in ideal positions with isotropic displacement parameters set to 1.2xUeq of the 
attached atom (1.5xUeq for methyl hydrogen atoms).  The hydrogen atoms on thioamide 
nitrogen atoms, N1 and N1a, were observed in a ΔF map and refined with isotropic displacement 
parameters.  The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + 
(0.0498*P)2 + (0.4537*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.126, with R(F) equal to 
0.0487 and a goodness of fit, S, = 1.01.  Definitions used for calculating R(F), Rw(F2) and the 
goodness of fit, S, are given below.4  The data were checked for secondary extinction effects but 
no correction was necessary.  Neutral atom scattering factors and values used to calculate the 
linear absorption coefficient are from the International Tables for X-ray Crystallography (1992).5  
All figures were generated using SHELXTL/PC.6  Tables of positional and thermal parameters, 
bond lengths and angles, torsion angles, and H-bonding interactions are located in tables 1 





Figure A.15. View of molecule 1 of MIS087 showing the atom labeling scheme.  Displacement 




Figure A.16. View of molecule 2 of MIS087 showing the atom labeling scheme.  Displacement 




Figure A.17. View of the fit by least-squares of selected atoms of molecule 1 (dashed lines) onto 





Figure A.18. Unit cell packing figure for MIS087.  The view is approximately down the b axis.  
Dashed lines are indicative of H-bond interactions (Table 7).  Molecules 2 are shown in 
wireframe form while molecules 1 are in ball-and-stick display format. 
Table A.1. Crystal data and structure refinement for 1. 
Empirical formula  C16 H26 N2 O3 S 
Formula weight  326.45 
Temperature  153(2) K 
Wavelength  0.71069 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.9862(5) Å α= 103.933(2)°. 
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 b = 10.0925(5) Å β= 91.236(2)°. 
 c = 17.6731(10) Å γ = 92.306(2)°. 
Volume 1726.49(16) Å3 
Z 4 
Density (calculated) 1.256 Mg/m3 
Absorption coefficient 0.201 mm-1 
F(000) 704 
Crystal size 0.13 x 0.12 x 0.10 mm 
Theta range for data collection 2.04 to 27.50°. 
Index ranges -12<=h<=12, -10<=k<=13, -22<=l<=22 
Reflections collected 13579 
Independent reflections 7892 [R(int) = 0.0315] 
Completeness to theta = 27.50° 99.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7892 / 0 / 411 
Goodness-of-fit on F2 1.007 
Final R indices [I>2sigma(I)] R1 = 0.0487, wR2 = 0.1040 
R indices (all data) R1 = 0.1010, wR2 = 0.1257 
Largest diff. peak and hole 0.673 and -0.326 e.Å-3 
 
Table A.2. Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x103) for 1.  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
S1A 8659(1) 3405(1) 5400(1) 26(1) 
O1A 9508(1) 2218(2) 5383(1) 34(1) 
O2A 5440(1) 5279(1) 3186(1) 31(1) 
O3A 5688(1) 3574(1) 2048(1) 30(1) 
N1A 7030(2) 2919(2) 5347(1) 24(1) 
N2A 3530(2) -208(2) 4172(1) 29(1) 
C1A 6468(2) 2380(2) 4539(1) 22(1) 
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C2A 5085(2) 1737(2) 4587(1) 20(1) 
C3A 4732(2) 428(2) 4161(1) 24(1) 
C4A 2613(2) 503(2) 4624(1) 30(1) 
C5A 2857(2) 1820(2) 5063(1) 32(1) 
C6A 4111(2) 2449(2) 5052(1) 27(1) 
C7A 6407(2) 3549(2) 4126(1) 26(1) 
C8A 5969(2) 3045(2) 3271(1) 26(1) 
C9A 6142(2) 4127(2) 2824(1) 27(1) 
C10A 5615(2) 6348(2) 2784(1) 34(1) 
C11A 5140(2) 5843(2) 1943(1) 38(1) 
C12A 5847(2) 4558(2) 1588(1) 39(1) 
C13A 8740(2) 4413(2) 6416(1) 33(1) 
C14A 8242(2) 3544(3) 6955(1) 47(1) 
C15A 7925(3) 5670(3) 6461(2) 62(1) 
C16A 10230(2) 4810(2) 6575(1) 43(1) 
S1 6459(1) 1475(1) -384(1) 24(1) 
O1 5645(1) 2679(1) -392(1) 31(1) 
O2 8405(1) -283(1) 1925(1) 31(1) 
O3 9320(1) 1438(2) 2951(1) 34(1) 
N1 8108(2) 1911(2) -387(1) 22(1) 
N2 11506(2) 5225(2) 819(1) 29(1) 
C1 8694(2) 2492(2) 413(1) 21(1) 
C2 10033(2) 3215(2) 364(1) 21(1) 
C3 10333(2) 4527(2) 814(1) 25(1) 
C4 12450(2) 4586(2) 357(1) 30(1) 
C5 12256(2) 3279(2) -113(1) 31(1) 
C6 11028(2) 2587(2) -116(1) 27(1) 
C7 8841(2) 1342(2) 838(1) 23(1) 
C8 9011(2) 1901(2) 1715(1) 27(1) 
C9 9339(2) 833(2) 2146(1) 25(1) 
C10 8726(2) -1335(2) 2309(1) 39(1) 
C11 8761(2) -779(2) 3182(1) 42(1) 
C12 9687(2) 483(2) 3395(1) 40(1) 
C13 6282(2) 342(2) -1366(1) 28(1) 
C14 6938(2) -987(2) -1328(2) 44(1) 
C15 4767(2) 98(2) -1513(1) 39(1) 
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C16 6904(2) 1011(2) -1967(1) 36(1) 
_____________________________________________________________________________  
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Table A.3. Bond lengths [Å] and angles [°] for MIS087. 
______________________________________________________________________  
S1A-O1A  1.4907(15) 
S1A-N1A  1.6744(17) 
S1A-C13A  1.836(2) 
O2A-C9A  1.407(2) 
O2A-C10A  1.435(2) 
O3A-C9A  1.408(2) 
O3A-C12A  1.432(2) 
N1A-C1A  1.489(2) 
N1A-H1NA  0.81(2) 
N2A-C3A  1.342(2) 
N2A-C4A  1.342(3) 
C1A-C2A  1.515(3) 
C1A-C7A  1.532(3) 
C1A-H1A  1.00 
C2A-C3A  1.381(3) 
C2A-C6A  1.394(3) 
C3A-H3A  0.95 
C4A-C5A  1.377(3) 
C4A-H4A  0.95 
C5A-C6A  1.384(3) 
C5A-H5A  0.95 
C6A-H6A  0.95 
C7A-C8A  1.521(3) 
C7A-H7A1  0.99 
C7A-H7A2  0.99 
C8A-C9A  1.502(3) 
C8A-H8A1  0.99 
C8A-H8A2  0.99 
C9A-H9A  1.00 
C10A-C11A  1.509(3) 
C10A-H10A  0.99 
C10A-H10B  0.99 
C11A-C12A  1.508(3) 
C11A-H11A  0.99 
C11A-H11B  0.99 
C12A-H12A  0.99 
C12A-H12B  0.99 
C13A-C14A  1.520(3) 
C13A-C15A  1.521(3) 
C13A-C16A  1.528(3) 
C14A-H14A  0.98 
C14A-H14B  0.98 
C14A-H14C  0.98 
C15A-H15A  0.98 
C15A-H15B  0.98 
C15A-H15C  0.98 
C16A-H16A  0.98 
C16A-H16B  0.98 
C16A-H16C  0.98 
S1-O1  1.4910(14) 
S1-N1  1.6884(16) 
S1-C13  1.835(2) 
O2-C9  1.406(2) 
O2-C10  1.433(2) 
O3-C9  1.407(2) 
O3-C12  1.435(2) 
N1-C1  1.492(2) 
N1-H1N  0.82(2) 
N2-C3  1.341(2) 
N2-C4  1.341(3) 
C1-C2  1.512(3) 
C1-C7  1.536(2) 
C1-H1  1.00 
C2-C3  1.388(3) 
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C2-C6  1.391(3) 
C3-H3  0.95 
C4-C5  1.383(3) 
C4-H4  0.95 
C5-C6  1.386(3) 
C5-H5  0.95 
C6-H6  0.95 
C7-C8  1.520(3) 
C7-H7A  0.99 
C7-H7B  0.99 
C8-C9  1.504(3) 
C8-H8A  0.99 
C8-H8B  0.99 
C9-H9  1.00 
C10-C11  1.509(3) 
C10-H10C  0.99 
C10-H10D  0.99 
C11-C12  1.510(3) 
C11-H11C  0.99 
C11-H11D  0.99 
C12-H12C  0.99 
C12-H12D  0.99 
C13-C16  1.520(3) 
C13-C15  1.529(3) 
C13-C14  1.531(3) 
C14-H14D  0.98 
C14-H14E  0.98 
C14-H14F  0.98 
C15-H15D  0.98 
C15-H15E  0.98 
C15-H15F  0.98 
C16-H16D  0.98 
C16-H16E  0.98 



























































































































































































Table A.4. Anisotropic displacement parameters  (Å2x 103) for MIS087.   
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S1A 21(1)  33(1) 25(1)  7(1) -1(1)  -7(1) 
O1A 23(1)  37(1) 35(1)  -3(1) 0(1)  2(1) 
O2A 38(1)  28(1) 27(1)  7(1) 5(1)  3(1) 
O3A 41(1)  29(1) 19(1)  4(1) -3(1)  5(1) 
N1A 22(1)  29(1) 22(1)  9(1) -2(1)  -8(1) 
N2A 30(1)  30(1) 27(1)  9(1) -7(1)  -11(1) 
C1A 23(1)  23(1) 20(1)  4(1) -2(1)  -3(1) 
C2A 20(1)  21(1) 20(1)  8(1) -3(1)  -2(1) 
C3A 25(1)  26(1) 21(1)  5(1) -2(1)  -2(1) 
C4A 22(1)  39(1) 32(1)  17(1) -6(1)  -8(1) 
C5A 24(1)  41(1) 36(1)  16(1) 3(1)  4(1) 
C6A 28(1)  22(1) 30(1)  5(1) -1(1)  1(1) 
C7A 28(1)  26(1) 23(1)  6(1) -3(1)  -6(1) 
C8A 27(1)  25(1) 23(1)  4(1) -2(1)  -1(1) 
C9A 30(1)  30(1) 21(1)  5(1) -1(1)  2(1) 
C10A 45(1)  26(1) 34(1)  11(1) 2(1)  1(1) 
C11A 43(1)  38(1) 35(1)  14(1) 4(1)  12(1) 
C12A 53(2)  45(2) 24(1)  13(1) 4(1)  13(1) 
C13A 25(1)  32(1) 34(1)  -8(1) -4(1)  -2(1) 
C14A 33(1)  78(2) 24(1)  1(1) 2(1)  -4(1) 
C15A 38(2)  37(2) 94(2)  -16(2) -13(1)  7(1) 
C16A 24(1)  43(2) 50(2)  -10(1) -9(1)  -4(1) 
S1 20(1)  30(1) 23(1)  7(1) -1(1)  -5(1) 
O1 24(1)  31(1) 34(1)  0(1) 1(1)  2(1) 
O2 31(1)  32(1) 34(1)  14(1) -3(1)  -4(1) 
O3 45(1)  37(1) 20(1)  6(1) -2(1)  6(1) 
N1 20(1)  28(1) 20(1)  8(1) -2(1)  -7(1) 
N2 31(1)  27(1) 29(1)  8(1) -7(1)  -7(1) 
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C1 21(1)  23(1) 19(1)  3(1) 0(1)  1(1) 
C2 22(1)  21(1) 21(1)  8(1) -5(1)  -1(1) 
C3 27(1)  26(1) 22(1)  7(1) -2(1)  -2(1) 
C4 23(1)  35(1) 36(1)  17(1) -7(1)  -7(1) 
C5 24(1)  33(1) 37(1)  13(1) 5(1)  3(1) 
C6 26(1)  22(1) 31(1)  5(1) 1(1)  0(1) 
C7 24(1)  21(1) 23(1)  5(1) -1(1)  -3(1) 
C8 33(1)  26(1) 22(1)  5(1) 1(1)  0(1) 
C9 25(1)  29(1) 22(1)  6(1) 1(1)  1(1) 
C10 46(1)  36(1) 40(1)  20(1) 5(1)  2(1) 
C11 46(2)  49(2) 39(1)  24(1) 14(1)  18(1) 
C12 48(2)  54(2) 23(1)  14(1) -1(1)  16(1) 
C13 22(1)  27(1) 29(1)  0(1) -6(1)  -1(1) 
C14 37(1)  31(1) 60(2)  3(1) -6(1)  3(1) 
C15 29(1)  39(1) 42(1)  -5(1) -10(1)  -2(1) 




Table A.5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 1. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H1A 7060 1668 4246 26 
H3A 5388 -57 3837 29 
H4A 1752 77 4643 36 
H5A 2174 2290 5370 38 
H6A 4305 3352 5357 32 
H7A1 5770 4219 4394 31 
H7A2 7303 4021 4163 31 
H8A1 6500 2255 3028 31 
H8A2 5014 2726 3237 31 
H9A 7117 4399 2827 32 
H10A 6574 6650 2808 41 
H10B 5099 7141 3040 41 
H11A 4158 5649 1913 45 
H11B 5344 6549 1654 45 
H12A 5478 4161 1054 47 
H12B 6814 4786 1552 47 
H14A 8688 2674 6837 71 
H14B 7271 3369 6876 71 
H14C 8448 4029 7498 71 
H15A 8052 6286 6981 93 
H15B 6973 5391 6364 93 
H15C 8226 6144 6067 93 
H16A 10540 5336 6207 65 
H16B 10739 3982 6510 65 
H16C 10367 5368 7110 65 
H1 8074 3170 709 25 
H3 9657 4963 1142 30 
H4 13293 5054 353 36 
 258 
H5 12954 2862 -430 37 
H6 10867 1695 -442 32 
H7A 8037 713 722 27 
H7B 9630 814 642 27 
H8A 9736 2626 1823 33 
H8B 8172 2325 1917 33 
H9 10258 513 2010 30 
H10C 9610 -1689 2142 46 
H10D 8046 -2100 2160 46 
H11C 9084 -1478 3442 50 
H11D 7848 -548 3360 50 
H12C 9634 914 3959 48 
H12D 10623 226 3288 48 
H14D 6483 -1394 -947 66 
H14E 7886 -790 -1170 66 
H14F 6866 -1626 -1843 66 
H15D 4588 -566 -2013 59 
H15E 4365 962 -1527 59 
H15F 4379 -258 -1093 59 
H16D 6678 450 -2492 54 
H16E 7880 1093 -1885 54 
H16F 6554 1922 -1912 54 
H1N 8250(20) 2460(20) -657(12) 26(6) 














































































Table A.7. Hydrogen bonds for MIS087  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N1-H1N...N2#1 0.82(2) 2.43(2) 3.173(2) 151.4(19) 
 N1A-H1NA...N2A#2 0.81(2) 2.33(2) 3.088(2) 155(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Scanned 1H and 13C NMR spectra 
 
 Figure A2.1. 1H NMR of AZB344 
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 Figure A2.4. 13C NMR of AZB345 
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 Figure A2.5. 1H NMR of AZB347 
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 Figure A2.6. 1H NMR of AZB348 
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 Figure A2.7. 1H NMR of AZB349 
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 Figure A2.8. 1H NMR of AZB379 
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 Figure A2.12.  1H NMR of AZB381 
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 Figure A2.13. 13C NMR of AZB381 
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 Figure A2.14. 1H NMR of AZB384 
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APPENDIX III 
Scanned 1H and 13 C NMR spectra 
 
 Figure A3.1. 1H NMR of TOP053  
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 Figure A3.2. 13C NMR of TOP053 
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 Figure A3.3. 1H NMR of TOP054 
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 Figure A3.4. 13C NMR of TOP054 
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 Figure A3.5. 1H NMR of TOP061 
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 Figure A3.6. 13C NMR of TOP061 
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 Figure A3.7. 1H NMR of TOP062 
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 Figure A3.8. 13C NMR of TOP062 
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 Figure A3.9. 1H NMR of TOP063 
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 Figure A3.10. 13C NMR of TOP063 
 287 
 
 Figure A3.11. 1H NMR of TOP064 
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 Figure A3.12. 13C NMR of TOP064 
 289 
 
 Figure A3.13. 1H NMR of TOP066 
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 Figure A3.14. 13C NMR of TOP066 
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 Figure A3.15. 1H NMR of TOP067 
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 Figure A3.16. 13C NMR of TOP067 
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 Figure A3.17. 1H NMR of TOP068 
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 Figure A3.19. 13C NMR of TOP068 
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 Figure A3.20. 1H NMR of TOP069 
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 Figure A3.21. 13C NMR of TOP069 
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 Figure A3.22. 1H NMR of TOP070 
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 Figure A3.23. 13C NMR of TOP070 
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 Figure A3.24. 1H NMR of TOP075 
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